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Protein glycosylation is one of the critical post-translational modifications (PTMs) and 
practically engaged with a wide range of physiological and biological processes. Glycosylation is 
the most dynamic post-translational modification and an individual's glycome changes overcome 
the genetic factors and get affected by environmental factors which eventually reflect his 
lifestyle, physiological conditions and wellbeing. The flow study, we attempted to add this 
information to comprehend the glycoprotein biomarker identified with inhibitor advancement 
and connected the glycosylation related changes to the biochemical pathway of inhibitor 
development against rFVIII in HA population. We performed the study with mice and human 
models. Plasma and IgG N-glycome examination is one of the important methodologies to 
identify the biomarker related to numerous conditions.  The N-glycome pattern also varies in 
response to the treatment. The treatment-related modifications also reaffirm the observations 
noted in the progression of the disease.  
Similarly, the glycosylation can be a useful strategy to modify the protein-based drugs to 
enhance its mode of action. The variant of AAV can be a potential capsid engineering technique 
to alter the tropism and improve the gene delivery range of host cell range for engineering a 
better gene delivery system. The small amount of and glycan variants are difficult to detect in a 
complex biological mixture, which may require various enrichment strategies, and sample 
preparations help to enhance the detection sensitivity in mass spectrometry. Due to the with the 
development of state-of-the-art mass spectrometry (MS) technology, we tried to identify N-
glycan biomarkers related to inhibitor development in HA. Also, we decided to study the 
response of the patient after emicizumab. Additionally, we identified N-glycosylation in rAAV-
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1 CHAPTER 1: INTRODUCTION TO THE GLYCOSYLATION, ITS 
IMPORTANCE AND MS BASED TOOL FOR ANALYSIS 
1.1 Introduction 
Glycosylation is one of the most common PTMs of proteins that maintaining many biological 
functions in the body and regulate the health and disease condition.1 In humans, it is 
estimated that 50% of proteins are glycosylated.2 Physiological changes like aging, 
pregnancy, malignant metastasis, disease progression, inflammatory responses, metabolic 
changes, bacterial and viral infections can alter the microenvironment in the cell.3,4,5,6. Hence, 
glycan profile changes can be a prognostic or diagnostic biomarker for many physiological 
conditions.7 The altered glycosylation pattern can also alter the binding specificity of the 
glycan with other molecules and eventually change their biological functions. Even though 
the importance of glycosylation is known, the inability to characterize the structural details of 
the attached glycoforms to correlate their biological activity was not apparent for many years. 
Glycosylation is not a template-driven procedure, as we see in protein DNA or RNA 
synthesis.8 The glycosylation process requires a panel of enzymes. The main two enzymes 
which have a direct role in the structural design of glycoforms are glycosyltransferases and 
glycosidases.9 The enzymes responsible for sugar nucleotide synthesis also passively 
participate in the process.10 There are many factors, including the expression level of 
enzymes and proteins participate in the glycosylation pathways, metabolic changes, 
availability of sugar nucleotides, that affect the overall glycosylation pattern of the protein.11 
 The enzymatic machines are required to regulate the glycan structure. The exoglycosidases 
and glycosyltransferases are residing at the membranes of ER and Golgi. The nascent protein 
gets exposed to this enzyme panel; during the post/ co-translational process and encounter a 
competitive modification.12 The protein can exit any time during the process of glycosylation, 
and, it is not possible to have a uniform /completed glycoform during the event. Hence the 
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resulting protein can be a heterogeneous mixture that contains glycoforms, vary in their 
structure, composition, linkage, and spatial arrangement. Glycosylation is typically divided 
into N-linked glycosylation and O-linked glycosylation. The N-linked glycosylation is 
happening at the Asn residue, where the glycan is covalently linked to the N atom of the Asn 
residue. The precursor structure for N-linked glycan synthesis is a Glc3Man9GlcNAc2 
glycoform which gets added at ER to the Asn-residue of the consensus sequence and 
followed by the cleavage of glucose residues to form Man9GlcNAc2 .The mannosidase 
enzyme cleave this structure to form Man8.13,14At this stage the protein is taken to Golgi and 
it can remain as high mannose or they get further treated with mannosidase or added by 
different sugars sequentially from GlcNAc, Galactose and N-Acetyl neuraminic acid. The N-
glycan structure usually has a typical ‘pentacore’ structure, which contains two N-
Acetylglucosamine (GlcNAc) and three mannose (Man) residues in a biantennary form. The 
‘pentacore’ can be extended and modified at the nonreducing terminal with different 
monosaccharide residues to form various structures with a variety of linkages.15 Based on the 
composition, the N-glycan is divided into three groups: complex, hybrid, and high mannose. 
If the extension of the pentacore mannose happening with varying sugar units, including 
GlcNAc, galactose (Gal), and N-Acetylneuraminic acid (Neu5Ac) at both the antennae, the 
resulting structure is called complex sugars. They can also extend only with mannose, which 
is called a high mannose structure. If the core structure is extended in one antenna with 
different sugars and another antenna with only mannose, then the structure is called hybrid. 
The structures can bare fucose at innermost GlcNAc residue by Alpha1-6 linkage is called 
core fucosylation.16Each of these sugars and their percentage has a significant role in the 
biological system. The peptide backbone contains a consensus motif N-X-S/T, where X can 
be any amino acid except for proline.17An additional N-glycosylation sequence N-X-C was 
discovered first in bacteria is also occasionally found in mammalian proteins.18,19Similarly, 
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the O-linked glycosylation is occurring through the covalent linkage between the O atom of 
serine (Ser, S) or threonine (Thr, T) to the glycan structure.20 For O-linked glycosylation, as 
shown by a typical O-glycopeptide in figure 1.1, an O-GalNAc (N-Acetylglucosamine) 
glycan is conjugated with Ser/Thr in the peptide backbone without a consensus motif.  O-
linked glycosylation is much simpler structures but does not have a single biosynthetic 
pathway as in N-glycan. There are several kinds of O-glycans found in nature. The main ones 
are α linked O-GlcNAc, α linked O-GalNAc, β-linked O-xylose, α -linked O-mannose, α/ β 
O-glucose/ galactose, and α linked O-fucose. Due to the high biological significances, 
glycobiologists widely studied  O-GalNAc and O-GlcNAc type of O-glycan.21 There are 
mainly eight types of O-GalNAc glycan cores with diverse structures, but they all share the 
uniform monosaccharide residue GalNAc at the reducing end of the sugar chain.22  
 
Figure 1.1-specific glycan heterogeneity 
The N-glycosylation sites are labeled with red dots, and O-glycosylation sites are labeled with green dots. 
The potential site-specific N-glycosylation variations (at left) and O-glycosylation variations (at right) are 
illustrated with their micro and macro heterogeneity. 
 
A few other glycosylations are also seen in nature. C-type glycosylation is where a mannose 
is added to carbon on a tryptophan side chain.23 Glypiation features the GPI anchor that links 
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proteins to lipids through glycan linkages.24Phosphoglycans linked to phosphoserine through 
the phosphate group.25Very rarely, S-linked glycosylation, also seen in nature, refers to the 
linkage of glycan to the cysteine through its S-atom.26 
1.2 Glycoprotein biomarker 
In each glycoprotein, there can be multiple glycosylation sites, including N and O-
glycosylation. The macro heterogeneity refers to the variability of occupancy of the glycan at 
each location. The structure of occupied glycan may also vary in each site, which refers to 
their microheterogeneity.27 Both factors must be efficiently monitored.  N- and O-linked 
glycans play an essential role in varieties of cellular processes, including modulating protein 
folding, regulating cell-cell interaction, cell-pathogen interaction, and receptor binding and 
signalling. 
The difference in the expression of glycoprotein and their micro and macro heterogeneity can 
be directly correlated to some disease progression or physiological sate hence can be 
considered as a biomarker. There are numerous clinically approved bio markers identified 
with malignant growth, which are glycoproteins. For example, upregulation of the AFP28–30 is 
a glycan biomarker of liver cancer, and CEA31 is considered as a biomarker for colon cancer, 
CA125 is a ovarian cancer32 biomarker, and PSA is well-known biomarker for prostate 
cancer.33 Plasma protein glycan alteration can be also a biomarker of different disease 
conditions. For example, increased multi-antennary glycans with fucose residues in plasma 
are the diagnostic biomarker of hepatic cancer.34 Similarly decreased core-fucosylated 
glycans, increased hybrid and multi-branched structures, decreased monoantennary, 
galactose, bisecting type or core fucose structures in plasma glycosylation is a diagnostic a 
pattern of disease progression in gastric cancer.35Whereas increased core fucosylation of 
plasma protein is a potential diagnostic biomarker of pancreatic cancer.36Increased plasma 
sialylation, high branched structures, high-mannosylation or outer-arm fucosylation and 
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decreased biantennary core-fucosylated glycans  structures are the diagnostic biomarker of 
breast cancer37. 
1.3 Antibody biomarker 
Antibody or immunoglobulin is one of the basic functional proteins in the body, 
which is essential to secure the body against outside substances, generally called antigens. At 
the point when an antigen enters the body, the immune system will get initiated to recognize 
and eliminate them through a series of biochemical responses, which is known as immune 
responses. The most essential part of immune activation is the generation of antibody specific 
to the foreign antigen by B-lymphocytes. The naïve B- lymphocyte go through the process of 
clonal selection  and clonal expansion to produce high-binding affinity antigen which can 
specifically bind and attach to that type of antigen.38 There are many glycoprotein serves as a 
biomarker in the body, that upregulate in response to the physiological changes. IgG is one of 
the dominant glycoprotein in the plasma.  The IgG structures have conserved glycosylation 
site at CH2 domain and variable region   which has a profound impact on their function.39 
The glycosylation of human IgG1is a good example to illustrate how glycosylation 
change influences protein function. IgG1 is a well-studied serum glycoprotein and contains 
only one N-glycosylation site at ‘Asn 297’ of the Fc region. Antibody glycosylation is one of 
the best study model for correlating the change in glycosylation with the protein function. 
The absence of core fucosylation of IgG1 glycosylation will result in a dramatically enhanced 
binding of Fc to FcγRIIIa (Fc gamma receptor IIIa), promoting antibody-dependent cellular 
cytotoxicity (ADCC).40 The addition of Neu5Ac at the terminal end of the glycans will 
inhibit FcγRIIIa ligation and increase FcγRIIIb expression, showing an anti-inflammatory 
effect.40 With a decreasing degree of galactosylation, the inflammation effect will be 
promoted. Also, bisecting GlcNAc correlates with deceased core fucosylation and enhances 
ADCC.40   
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Depending on the variability in each sub type the Fc glycosylation is varying in 
number for example, IgG1 glycosylation site at N-180 (also sometime referred as N-297) 
corresponds to N176 of IgG2, N-227 of IgG3, and N-177 of IgG4.  Regardless of the IgG 
subtype, the conserved glycosylation is generally known as CH2-84.4.41 Different IgG 
subtypes have different FcR affinity. The antibody glycosylation also can decide the Fc 
receptor binding there by regulation of its effector functions including phagocytosis, antigen 
presentation, ADCC, CDC and cytokine release.42,43 The FcRs are the on and off switch of 
antibody effector functions. FcγRI, FcγRII, and FcγRIII are the three major classes of FcRs in 
human. The receptors are of two major types as inhibitory (FcγRIIB) and activating (FcγRI, 
FcγRIIA, and FcγRIIIA)44. FcγRI generally binds to the monomeric IgG where as other FcRs 
binds to the  multimeric antigen antibody complex with the specificity of subtypes.44 
Decreased galactosylation and increased core fucosylation is an indication of 
proinflammatory response in the immune system. 
1.4 Glycan in virus entry to the cell. 
Virus entry to the host system require specific binding capacity of virus to the host 
cell receptors termed as tropism. The structural sialylation is the one type which commonly 
exemplifies with different linkages will also influence cell-pathogen interaction. As a 
terminal monosaccharide residue, Neu5Ac is usually linked to Gal via α2,3-linkage or α2,6-
linkage. The infection of viruses starts with the specific binding with host cells. For example, 
the binding of influenza A virus needs sialylated glycans as receptors on the surface of host 
cells. Different types of influenza A viruses have different binding specificities. Avian 
influenza A viruses preferentially bind to respiratory epithelial cells that contain α2,3-linked 
Neu5Ac moieties, while human viruses selectively bind to α2,6-linked Neu5Ac moieties.45 
Also, for enterovirus and arbovirus, they only recognize α2,3-linked Neu5Ac moieties of the 
host cells.46–49 . Similarly, the host cells also carry many glycan receptors which can 
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specifically attach to the surface viral glycan during its entry. Many of the viruses including 
human  pathogenic viruses, , bind to this host cell glycan receptors during their entry.50 The 
specific glycans on the cell surface such as glycosaminoglycans, heparin sulphate sialic acid 
or galactose can serve as a receptor in virus entry to the cell. Hence the specific glycan act as 
a key for virus attachment and entry to the cells and there by decide the pathogenicity, 
transmissibility or cell tropism of the virus. 
1.5 Gene therapy viral vectors 
       Gene therapy is therapeutic modification, introduction or removal of a genetic material to 
treat a genetic disorder or a disease.51 Central point of gene therapy is the efficient delivery of 
DNA or RNA to the host cells. Vectors are the “molecular cargos” used to deliver the genes. 
There is no universal vector used for treating all diseases. The viral vectors are designed to 
deliver the nucleic acid in applications to gene therapy is one of the most encouraging 
approach in in recent years because of their immunosurveillance of the infected host system. 
The normal retrovirus52, adenovirus53, herpes simplex virus54 and adeno-associated virus 
(AAV) are scientifically modified to fit for gene therapy use. AAV is an important principle 
gene therapy vector especially to transfer antisense RNA  and ribozyme genes in pre-clinical 
cancer models.55AAVs can be used to treat some diseases, such as LPL deficiency56, LCA 
(eye)57and hemophilia A.58 
1.6 Importance of glycosylation analysis 
The analysis of glycoprotein can be challenging due to several reasons. Primarily, the 
abundance of glycoproteins in a complex mixture can be relatively low. Due to the high 
complexity of the process and structure, it is hard to understand the glycosylation sequences, 
structural conformation, the isomeric pattern of monosaccharide building blocks, 
distinguishing their type from the same mass pattern, type of modifications, and percentage 
of changes using a single analytical strategy. The analytical complexities increase as the 
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complexity of glycosylation increases.59 Mass spectrometry is the pivotal technique that is 
used to understand the details of these complexities using the combination of different 
methodologies. The 4S features of mass spectrometry like sensitivity, specificity, 
stoichiometry, and speed, make the technique compatible with characterizing the challenging 
features of glycoprotein.20,60–64However, the complete characterization requires extensive 
sample processing and multi-level analysis, including released glycan analysis, glycopeptide 
analysis(bottom-up), and glycoprotein analysis(top-down analysis), as we explained 
elaborately in  figure1.2. The glycoproteins/glycopeptides are less efficiently ionized in 
comparison to the non-glycosylated version. Hence their detection is hindered in the presence 
of non-glycosylated peptides/proteins and must be enriched before the analysis to overcome 
this issue. The main challenge in glycosylation analysis under mass spectrometry is related to 
their structural similarity. Unlike amino acids, the different monosaccharides can have the 
same masses and highly similar structures.  Hence structural elucidation is highly 
challenging.  
The commonly employed technique for a detailed analysis of glycosylation study is a 
bottom-up technique. Wherein an endoprotease like trypsin is used to digest the protein to get 
a peptide pool, and glycopeptides are further enriched from this mixture.  The tandem mass 
spectrometry is used to get structural details of glycopeptide. The analysis of glycopeptide 
tandem mass spectra is comparatively hard to comprehend. Here we get a mixture of 
fragment masses that contain both amino acid and oligosaccharide sequence information. The 
lack of entirely dependable software makes this analysis still complicated. However, recently 
developed software like pGlyco,65,66 massytools,67GlycopepID,68 Proteome Discoverer 
(Thermo Scientific, MA, USA), Glycomaster DB,69 Byonics (Protein Metrics, CA, USA), 
GlycopepEvaluator70 and  Glycoproteome Analyzer (GPA)71 could solve this issue to an 
extent with a high speed mapping of glycopeptide and false discovery rate of  ≤ 1%. The 
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software is also referred to the specific enzyme existence in the organism, and already 
published structures related to an organism therefore species level filtration can also be 
possible. All these techniques are selectively used in different aspects of our studies in the 
biomarker discovery and rAAV glycosylation detection. 
 
Figure 1.2:Site-specific glycan heterogeneity 
A schematic overview of glycoprotein characterization using mass- spectrometry. a) glycocentric analysis where 
chemically/enzymatically released glycan get purified, derivatized/labeled separated and analyzed. b) 
glycopeptide analysis including denaturation of purified glycoproteins, trypsin digestion, enrichment and 
separation. c) Intact glycoprotein protein analysis after purification from complex sample. 
 
The fundamental drawback of the bottom-up approach is the loss of information during 
the extensive purification, enrichment, and MS fragmentation. However, it is essential to fill 
the knowledge gap in each level that can be bridged with the intact glycoprotein, glycopeptide, 
and glycomics level information obtained by mass spectrometry.72 
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1.7 Glycocentric analysis 
The glycocentric analysis is generally focused on the structural elucidation of released 
glycan in detail, including composition linkage and isomeric pattern of the attached oligo 
saccharide, their monosaccharide modification, overall distribution, and relative abundance in 
the sample. The analysis includes glycan release from a complex glycoprotein mixture by 
enzymatic or chemical method. Their purification, labeling, enrichment and analysis. The 
detailed workflow is illustrated in figure1. 3. 
 
Figure 1.3:The schematic representation of release glycan analysis by MALDI-MS. 
The MS1 spectra showed different glycoforms identified from the sample. MS2 spectra showed the 
structural analysis of H3N4F1 sugar by tandem mass spectrometry. The structures are assigned with the help of 
Glycoworkbench software. 
 
1.7.1 Glycan release  
N-glycans are usually released from glycoproteins or glycopeptides by PNGase F73 
before analysis. The conventional method takes a longer time with overnight incubation 
period and laborious clean-up protocol. Recently Waters and Prozyme introduced an N-
glycan analysis kit protocol in which they claim a rapid release of less than 10mins.Waters 
introduced a surfactant called RapiGest (Waters, Milford, US) which is used to denature 
protein molecule at higher temperature (~95ºC for 2 mins). RapiGest aided protein 
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denaturation makes the N-glycans accessible to rapid PNGase F (GlycoWorks, Rapid 
PNGase F, Waters) and helps to efficiently deglycosylate the protein at 50ºC with less than 
10mins of incubation. Song et al. in 2016 developed a rapid chemical method to release N 
and O-glycans rapidly from different glycoproteins called oxidative release of natural glycan 
(ORNG)74 by NaClO. The method is a simple and efficient approach for releasing glycans 
from glycoproteins and glycosphingolipids in a cost-effective manner. The O-glycan release 
includes β-elimination,75–77 classical hydrazinolysis78, O-Glycome reporter/amplification 
(CORA)79 are also used as general release of O-glycan. Here we use the conventional 
PNGase F mediated N-glycan release. Enrichment of free glycoforms is normally 
accomplished by solid-phase extraction (SPE) with C18 cartridges or non-porous graphitized 
(non-PGC) carbon columns.80 
1.7.2 Labeling methods of released glycan  
Unlike peptides, glycans are having unique physicochemical properties including 
highly polar nature with poor UV absorption. They also lack a fluorophore or chromophores 
in their structure. These unique properties make them less ionizable in mass spectrometry as 
well as poorly detectable in UV or fluorescent-based standard detectors in their nascent form. 
Unlike nucleic acids, there are no ways to amplify glycan as we use PCR for DNA/RNA. 
Hence it is essential to label them before MS analysis to overcome the weak ionization nature 
also make them compatible with UV or fluorescent detectors by coupling with suitable tags. 
Therefore, different labeling strategies have been employed worldwide, based on the 
researcher’s convenience and analytical methods employed. The most used methods are 
permethylation, reductive amination, hydrazide labeling, and Michael addition. The 
ambiguity due to the diversity in methods used by different labs is the main disadvantage 
when it comes to comparing the data between each lab. However, in our lab, we have applied 
the two widely used labeling methods in different experiments. Additionally, we developed a 
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novel labeling technique for carbohydrate labeling which is compatible with the existing 
method in a rapid and easy way.81 The method is also described in detailed in section 1.7.2.2. 
 
Figure 1.4 Commonly used glycan labeling reagent and their mechanism. 
Reductive amination is formed by a stable bond formation between the reducing terminal of 
sugar (1). Hydrazino formation (2) is also formed at the reducing terminal like 2-hydrazino quinoline 
or 2-hydrazino pyramidine through hydrazine bond. The third strategy is permethylation where every 
single hydrophilic groups, get methylated. 
 
 
1.7.2.1 Reductive amination 
Reductive amination is one among the most powerful methods for labeling the 
released glycan at their reducing end. The glycans with reducing end react with the primary 
amine or Schiff’s base-containing labeling agent like 2-amino benzamide or 2-amino benzoic 
acid  to form an unstable imine which get reduced by a reductant like sodium cyano 
borohydride to form stable secondary amine, ( figure1.4(1)).82 2 -amino benzamide (2-AB) 
and 2-amino benzoic acid (2-AA) labeling is not only enhances the ionization in mass 
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spectrometry but it gives the fluorescent absorbance to the glycan which can uses HPLC-FD 
based separation and analysis. 2-aminopyridine (PA), and 2-aminonaphthalence trisulfonic 
acid((ANTS) and 1-aminopyrene-3,6,8-trisulfonic acid (APTS) also used for the same 
purpose.83 The reagents like1-phenyl-3-methyl-5-pyrazolone (PMP) can also use in alkaline 
conditions, for labeling glycan at the reducing end. The method is known as Michael 
addition.84 The labeled glycan can be purified by L/L extraction or SPE based purification. 
1.7.2.2 Hydrazone formation 
The labeling through reductive amination is efficient but time-consuming due to the 
extensive desalting process before MALDI analysis. In our lab, we introduced two novel 
reagents;2-hydrazino quinoline and 2-hydrazino pyrimidine for labeling the glycan through 
Schiff's base formation, which effectively enhances the signal intensity in MALDI without an 
extensive sample cleanup procedure. Both the reagents containing an electron-withdrawing 
group 2- pyridine(or quinoline,2HQ), or 2-pyrimidine (N-heterocycle, 2-HPM) can derivatize 
oligosaccharides at their reducing end through a stable Schiff's base within 15 min, and the 
derivatization can provide their better ionization in  MALDI. Additionally, 2 HQ and 2-HPM 
can act as co-matrix or matrix, which enhances the signal intensity of the oligosaccharides in 
MALDI, and hence the tedious purification and desalting steps before MALDI can be 
avoided. We have detailed the tagging mechanism in the published literature. For 2-HPM 
mediated labeling, methanol with 10% glacial acetic acid and 10mg/ml reagent at 60-70 
degrees for 10mins is the ideal labeling conditions.85 
Each time we have used the ten picomoles of standards DP5 or dextrin. The method 
optimization was performed by varying the reaction media, type of solvent, reaction 
temperature, the concentration of reagent. The optimum temperature of the reaction was 37- 
60-degree celsius temperatures. The 2-HQ mediated labeling is further optimized with 
varying reaction media. The reaction media was formulated with 10% DMF and 10% glacial 
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acetic acid in ACN, and the reaction time was 60 minutes to 70 minutes, which is higher than 
2-HPM. Each point of method optimization one parameter kept varied, and others kept 
constant. Derivatization rate was calculated by dividing the peak intensity of 2-HQ-
derivatized DP5 by peak intensities of both underivatized and 2-HQ-derivatized DP5. The 
reactions were conducted in triplicate, and the average values and standard deviations were 
determined for each condition.  The additional property of 2- HQ is its fluorescence. This can 
be utilized for HPLC -FD based glycan analysis as we used in the reductive amination 
method with 2AA or 2 AB. Since it is a novel method, the optimum fluorescent condition 
was set with fluorometry, and the λex was observed to be optimum at 280nm and λem at 
335nm (The graph is shown in Appendix A F2). The fluorescent property was compared with 
conventional 2-AB by labeling one nanomole of dextrin, and injected 500picomoles in each 
reaction and compared their results. We have received the same fluorescent response by both 
the runs; hence, it is an efficient fluorescent label (Appendix A F1). The additional advantage 
of 2-HQ is that it can be ionized well in MALDI and quiet stable at tandem mass 
spectrometry. The details are shown in Appendix A F4. The 2-HQ can be used as a matrix 
also. The HQ labeled glycan can ionize in MALDI-MS without mixing with convention DHB 
mixing (Shown in Appendix A F5). Hence our inhouse developed method can also be used as 
an efficient and alternative labeling strategy. 
1.7.2.3 Permethylation 
Permethylation is widely used in mass spectrometry-based glycan analysis for 
enhancing the ionization potential of glycan. Hence the method is routinely performed for 
released glycan prior to the MALDI-MS analysis. It has number of advantages including 1) it 
is known to enhance the intensity of the glycans than the underivatized oligosaccharides.2) 
stabilize the liable sialic acid in the glycan moieties.3) The sialylated glycoforms are less 
efficiently ionized in mass spectrometry in ‘pos’ mode. By this method, all reactive glycan 
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hydrogen group like -OH, -NH and -COOH, in the glycan structures get converted to the 
methyl group- -OCH3, -COOCH3 and -NCH3-respectively. The charge related issues in 
mass spectrometry also get resolved by this method.4) better determination of the linkages 
and branching of different glycosidic linkages in the structure 5) conversion of hydrophilic 
glycoforms to hydrophobic structures which allows C18 based separation and better 
ionization and flying in the gaseous phase86.Also, permethylation based MALDI-analysis 
offer a faster profiling than the HPLC /UPLC based techniques. Figure 1.4(3) showed the 
mechanism in which the simple glycan dissolved in DMSO get reacted to methyl iodide 
(CH3I), catalyzed by methyl-sulfinyl carbanion prepared by the NaOH in DMSO. The bases 
can also vary from NaOH to KOH or LiOH to form, the carbanion reagent for the reaction.87 
The permethylated hydrophobic glycans get enhanced in their ionization, which can increase 
the detection sensitivity of glycans in MS, including both ESI-MS and MALDI-MS.88 The 
analysis is carried out in positive mode, and ions are formed in M+Na+ form. Conventional 
permethylation can introduce an excess of salt in the mixture, which usually can purify using 
liquid extraction with chloroform or DCM and water.  
Extraction is utilized to remove salts generated during permethylation.  The method is 
effectively used in relative quantification and various glycan-based biomarker discovery.89 
The method is highly suitable for detection and tandem based mass spectrometric analysis 
due to its high signal responses. Nevertheless, it is limited for detailed analysis like linkage 
specific sialic acid analysis. The specific modifications can overcome the limitation of 
permethylation and bring up this method more suitable for the analysis and quantitation of 
certain sugars. The anhydrous condition and using carboxylic acid activator EDC, with the 
catalyst HOBt carboxylic acid get activated and binds to the adjacent OH group of galactoses 
to undergo a lactone formation and hence unable to label with dimethylamine. If the glycan is 
treated with dimethylamine in the presence of EDC and HOBt, the alpha 2,6 sialic acid gets 
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labeled with dimethylamine and gets modified.90 Hence both the linkages make a 13Da 
difference. The mechanism is detailed in figure 1.5. The standard purification method is 







Figure 1.5:The linkage specific permethylation of alpha 2,3 and alpha 2,6 sialic acid. 
The alpha 2,6 linked sialic acid get activated and linked to dimethylamine made 13Da increase linkage 
specific analysis. 
 
1.8 Glycopeptide analysis 
The glycopeptide analysis is much more informative in comparison to glycocentric 
related to the functional aspect. In the glycopeptide analysis, we can get the site-specific 
information about the glycosylation, which allows understanding their functional aspect 
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related to the specific proteins. The complex proteins are isolated from the biological samples 
and denatured followed by endoprotease (generally trypsin) digestion to generate the peptide 
mixture. Since the natural abundance of glycoproteins is very low in the mixture, it is 





Figure 1.6 Bottom-up approach for glycoprotein analysis. 
The workflow details the steps involved in the process and spectra showed the 





1.8.1 Glycopeptide enrichment 
The natural abundance of glycoproteins is generally very low, and if the sample is a 
complex mixture, the sensitivity of the analysis goes down in mass spectrometry. A practical 
approach to enrich glycopeptides is essential prior to mass spectrometry-based analysis. 
There are multiple strategies developed to enrich the glycopeptides, including 
chromatographic separation, biological affinity-based capturing, chemical-based capturing, 
enzymatic labeling, and metabolic labeling are the widely used enrichment strategies. Due to 
the highly polar -OH, COOH, and NH groups on the glycan structure, it makes it efficiently 
separable using hydrophilic interaction liquid chromatography (HILIC). The main adsorption 
force is  H-bonding for HILIC based separation.91 The method can also use for the 
enrichment of glycopeptides.92,93 The HILIC medium is usually Silica, cellulose, or 
sepharose.92,91,94The functional group attached to the basic medium can also be used for 
HILIC enrichment. The common functional groups are amide95, maltose96, diol97, and 
cyclodextrin98 are efficiently used for HILIC based glycopeptide enrichment. The modified 
technique like zwitterionic HILIC (ZIC-HILIC)91,99 and weak anion exchange-based 
electrostatic repulsion hydrophilic interaction chromatography (ERLIC)100,101 also used for 
the glycopeptide enrichment. Specific glycan binding proteins like lectins are used for 
enriching a sugar-based protein and peptides.102–104Chelation interaction chromatography 
used for enriching the glycopeptide based on their charge.105,106,107 Metabolic labeling 
mediated specific sugar enrichment is also an alternative glycopeptide enrichment method 
used mass spec-based glycoprotein analysis.108 
1.8.2 Glycosite detection    
The analysis of intact glycopeptide is also challenging due to their complexities. 
However, the detection of N-glycosylation site on the peptide is relatively simple by specific-
labeling method. The PNGase F enzyme is generally used to release the N- glycosylation from 
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the protein. The enzyme can cleave the Asn-linked glycan by hydrolysis thereby causing a 
deamidation of Asn to Asp. Thus the deglycosylation can cause an addition of 0.9858 Da to 
the peptide at the glycosite73 and the difference can be picked up by HR-MS. However, the 
deamidation of Asn residue at higher pH (more than 8) is also a possible modification (4-9%)  
during the trypsin digestion. Hence the  procedure may lead to a false discovery of 
glycosylation site.109 However, the process can be modified to label the N-glycosylation site 
when we carry out the reaction in the presence of 18O-water.110 The labeling by H2
18O can lead 
to a mass shift of  2.9883 Da, which can be discriminated from the normal deamidation111 as 
shown in figure 1.7. 
 
Figure 1.7: The common glycosite labeling mechanism 
A) PNGase F mediated site-specific labeling of N-glycopeptide by 18O-water. The partial cleavage of the glycan 
to leave innermost ‘Asn’ to the site for glycopeptide labeling 
 
The alternating methodology for site specific labeling is possible by partially cleaving N-
glycan to generate a fixed modification with GlcNAc on the N-glycosite. (Figure 1.7 B). 
Different Endoglycosidases like Endo H can be used to for this purpose. It breaks down the 
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glycoside bond between the innermost GlcNAc which binds to the ‘Asn’ and the glycan 
core112, thus it can be distinguished with mass spectrometry by the addition of ‘GlcNAc’ 
mass to the peptide. The method can also be achieved chemically by acidolysis. The 
differential strength between amide and glycosidic bond can be used for the differential 
cleavage. The innermost GlcNAc is linked to the peptide by amide bond whereas all other 
sugars are linked together by glycosidic bond. Hence the relatively strong amide bond does 
not cleave by this method whereas glycosidic bonds get cleaves off. Microwave energy is 
also used to enhance the process.113  
1.8.3 Mass spectrometry techniques for glycan analysis 
The advanced mass spectrometry-based techniques with high sensitivity and 
compatibility are widely used to break down the complexities of the glycoprotein analysis. 
Mass spectrometry mainly consists of four parts which includes an ionization chamber to 
induce the molecular ions in gas phase, analyzer to sort the ions formed by means of time or 
space, detector to detect the resulting ions data analysis and a Data processor/digitizer. 
 Electron ionization/ electron bombard ionization causes the loss of electron in the 
glycan molecule which eventually help to fragment. The EI was the primordial technique to 
understand the monosaccharide composition of the sugar. The combination with GC/MS was 
efficient to analyze the sugar molecule. However, larger molecule like N-linked glycans are 
difficult to vaporize into the gas phase due to their high polar nature which has to be 
converted to permethylated glycoforms and also applied to analyze the monosaccharide 
analysis of the glycan after acid hydrolysis and derivatization.114 Fast atom bombardment 
(FAB)was the first efficient conventional technique with gentle ionization technique to 
analyze negatively charged as well as neutral glycan molecule without insource 
fragmentation.114However the technique had low sensitivity and high background masses 
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from the matrix, which inhibit the efficient analysis of  glycan from the mixture. The 
technique soon replaced by MALDI and ESI.  
1.8.3.1 MALDI 
The MALDI and ESI are the most efficient ionization techniques for analyzing the 
glycan molecules to date. MALDI has the advantage of gentle ionization method which keeps 
the oligosaccharide structure intact and ionization efficiency remains constant regardless of 
the size of the oligosaccharide.114 For MALDI analysis, the glycan sample is mixed with the 
matrix typically as the low molecular aromatic acids like 2,5 dihydroxy benzoic acid (2,5 
DHB) and allowed to co-crystallize on a MALDI-plate. The plate is then introduced into the 
machine for analysis. The sample spots are irradiated using a UV-laser. The matrix absorbs 
the energy from the laser and then transfers a small amount of energy to the analyte molecule 
makes them ionize??. The main disadvantage of the technique is poor sensitivity due to low 
ionization efficiency of carbohydrates. Some sugars like sialylated sugars are thermal labile 
and may degrade during the analysis. Hence, the mass obtained by MALDI- analysis alone 
may not be enough for identifying the structure of sugars. Normally we must confirm the 
identity parallel by complementary analytical techniques. The sample derivatization like 
permethylation can stabilize the sialic acid linkage and overcome the disadvantage mentioned 
above.  The MALDI-is commonly interfaced with the time of flight (TOF) or TOF/TOF 
analyzer for fragmentation analysis. 
1.8.3.2 ESI 
Electron spray ionization is a gentle method of ionization that keeps oligosaccharides 
intact. Commonly ESI is coupled with the separation technique like HPLC, ion mobility or 
CE prior to the mass spec detection. The spectra are formed by spraying the glycan in liquid 
phase through a narrow orifice under the influence of a strong electric field(1-3kv).Difference 
in the potential applied between the tip of the needle and capillary is coupled with very high 
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temperatures, that causes finely charged droplets. The inert gas used to vaporize the solvent 
as they are aspirated into mass spectrometry. Both positive and negative charged ions can be 
produced by this method and multiply charged ions are commonly observed. Depending on 
the solvent used, their additives and source conditions there can be different adducts and type 
of ions can be formed. However, the ionization efficiency decreases as the glycan masses 
increases which makes the relative quantitation difficult by this method. Hence the spectra 
are much complicated than the MALDI-profile. The glycopeptide analysis was efficiently 
performed by ESI-MS 
1.8.3.3 Mass analyzers 
The ion separation in the early stage was performed with magnetic field sector 
instrument. The instruments are huge and limited to certain mass ranges, however, could 
produce accuracy in the mass measurements. Fourier-transfer ion cyclotron resonance 
(FTICR) uses a high magnetic field along with the alternating voltage to trap the ions with 
high resolution. In quadrupole mass analyzers, the ions are separated using a low potential 
and passes through centroid rods using alternating and static voltages. The linear ion trap 
instruments confine the ions by applying voltage at the end of rods. Paul trap is a type of 
quadrupole ion trap consists of two hyperbolic electrodes with their foci facing each other 
opposite side of a hyperbolic ring electrodes. The oscillation (RF) and static current(DC) 
traps the ions between the three electrodes.115 Orbitrap analyzer provide high resolution by 
confining the ions by oscillating them around the central rod.116 The Orbitrap also use FT 
based technique to trap the ions. However, the trapping is performed electrostatically (as 
opposed to magnetically) and the frequency oscillations are measured along the long axis of 
the trapping cell.117 The ions are trapped in radial direction between the inner and outer 
electrodes by applying a DC voltage applied. 
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1.8.3.4 Structural analysis of carbohydrates by mass spectrometry 
The compositional analysis of carbohydrates is possible by analyzing the molecular 
weight with the component mass. The method is useful for the purity determination or 
primary detection of the known compounds. The high-resolution mass spectrometry-based 
glycosylation analysis with tandem mass analyzers creates fragments from the peptides and 
glycans simultaneously. There are many fragmentation methods in MS-based glycopeptides 
analyses. The common ones are collision-induced dissociation (CID)118, electron -transfer 
dissociation(ETD)119 and high-energy C-trap dissociation (HCD)120. CID is compatible with 
many commercial instruments with various analyzers, including ion-trap 121 ,Q-TOF122, triple 
quadrupole123, TOF-TOF, and other hybrid MS.124The CID based fragmentation generally 
create B and Y ions125as shown in figure 1.8B. Since the glycosidic bonds are liable than the 
amide bond, hence rarely produce enough b and y ions at normalized collision energy 
(NCE)as shown in figure 1.8A. The insufficient b and y ion generation in CID is overcome 
by using stepped energy collision in Q-TOF and TOF- TOF instruments. The other 
disadvantage of CID based method is the low molecular cutoff in CID (<300 Da) used in the 
detection. The advanced mass spectrometry like orbitrap instrument also used an advanced 
CID fragmentation method named HCD where the fragmentation takes place at collision cell 
instead of ion trap as in CID. It is a beam typed CID  with the detection of fragment ions 
coupled with orbitrap analyzer.126 HCD based fragmentation is performed with high energy 
than the conventional CID method to allow multiple fragmentation pathways.127 HCD 
produce a higher number of oxonium ions from the glycan part than the ‘b’ and ‘y’ ion from 
the peptide part. The usage of SCE-HCD can improve the quality of MS2 Spectra in 
glycopeptide analysis,65 also permits low mass fragmentation detection without any low 
molecular cut-off mass. The orbitrap based analyzer improves the quality of the MS/MS 
spectra.127The ETD  fragmentation is widely used to detect multiply charged glycopeptide by 
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cleaving between the N–Cα bond to produce c- and z-ions128 (figure 1.8A) and localize the 
glycosylation site.129 The glycan portion remain intact without fragmentation and widely used 
to fragment multiply charged long glycopeptides.130 In our study the glycopeptide analysis 
were performed by HCD and glycosite analysis were performed by CID method using 
orbitrap Elite Velos hybrid high resolution mass spectrometer. Whereas the glycocentric 
analysis were performed using MALDI-TOF-TOF-MS.  
 
Figure 1.8:Fragmentation pattern of glycopeptide in mass spectrometry 
A The fragmentation pattern in peptide and illustration of possible fragment ions. B) The possible 
fragment ions from glycan moieties. 
 
1.8.4 Fragmentation pattern of glycoforms 
 The structural details of carbohydrates by obtained by tandem mass spectrometry 
based on the CID fragmentation. The fragmentation pattern of the sugar labeled through 
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reducing terminal (reductive amination, hydrazine formation) generates B and Y ions in CID, 
and it is easy to interpret the monosaccharide residue by calculating the fragment ions using 
the formula Molecular weight-18 Da. The same type of breakage can occur any anomeric site 
on the other side of ‘O’ atom to form C and Z ions. Higher energy fragmentation can also 
create the cross-linked fragmentation and resulting A and X ions (Figure 1.8b). Each of these 
ions can be utilized for predicting sequence of the monosaccharide linkages and detecting the 
site-specific modifications. Monosaccharide stereochemistry and anomeric confirmations 
cannot be elucidated by interpretation of MS/MS data alone. To elucidate the accuracy higher 
status of tandem based analysis is required in conjunction with the standards and databases. 
The de novo structural elucidation of carbohydrate involves breaking oligosaccharides to 
overlapping segments of disaccharides. The data is acquired by successive rounds of CID. In 
this process sample is injected to the mass spectrometer to produce parent ions. The parent 
ions undergo fragmentation to produced disaccharides which matches to the fragmentation 
pattern in the databases. By comparing the disaccharide fragmentation with the standard 
sugar and their linkages the structures can be predicted by this method.131 Overlapping 
disaccharides are piece packed together to predict the parent ion structure. Permethylation 
and per acetylation is widely used to increase the ionization efficiency of the glycoforms. 
Similarly, to the native structural ions, permethylated glycan also causes a unique signature 
for each monosaccharide residue, and their fragmentation is also unique at each terminus. 
Because of the experimental procedure and use of sodium hydroxide the theoretical mass of 
the permethylated sugar ions will always be in the sodiated form.132 Hence the mass is 




The fragmentation pattern of permethylated N-glycoform133 is listed in Tglable1.1 
with the example of G2fS2(H5N4A2F1/54201) 




The combination of all these techniques are used to identify, characterize and correlate the 
glycosylation pattern of different biological samples in our study. The Glycoworkbench 
software is used to predict the structure and fragmentation process. 
1.9 Purpose of the study 
As an essential post-translational modification, glycosylation can regulate the 
biological activities in the cell and body. The glycosylation can regulate the signaling 
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pathways, pathogenesis17, disease progression134 and immunogenicity135 in biological system. 
Hence the health of an individual is widely dependent on perfection in the glycosylation 
process. The comprehensive analysis of glycosylation is essential to understand the perfection 
of glycosylation and their dynamic modification and aberration related to disease progression. 
In chapter 2, we are trying to understand the glycosylation related biomarker discovery of 
hemophilia A patients with inhibitor development and their profile variation in comparison 
with negative inhibitor hemophilia A patients. Immunoglobulin glycosylation regulates the 
effector functions and can be an indicator of the immune health of an individual. In this 
study, the plasma glycosylation profiling of inhibitor developed patients is widely studied for 
comprehending the root of inhibitor development. With the help of mass spectrometry 
techniques, we tried to understand the differences in glycoprotein expression of the patient 
plasma, their site-specific glycosylation differences, and the overall glycan profile of the 
plasma and antibody isolated from the plasma is monitored. Inhibitor positive and negative 
samples are compared after treating with emicizumab, a bispecific antibody used to treat for 
hemophilia A. Mass spectrometry-based glycan difference analysis has wide scope of 
analysis in biomarker discovery as well as personalized medicine development. The 
glycosylation variations can be linked with multi ‘omics’ studies-proteomics, genomics, 
transcriptomics epigenomics, lipidomic and metabolomics.  We tried to understand the 
plasma glycosylation pattern change with the inhibitor development and after treating with 
emicizumab. Here we explain the conducted study related to inhibitor development in the 
mouse model to compare the glycosylation variation with humans. We also studied the 
plasma glycosylation pattern of HA mice from three different strains- BALB/c, BL-6, and 




The third chapter discusses the glycosylation analysis on a gene-therapy vector rAAV. 
Adeno associated virus (AAV) is a gene delivery tool, which has been approved as a gene 
therapy vector for combating genetic diseases. AAV capsid proteins are the major 
components that determine the tissue specificity, immunogenicity, and in vivo transduction 
performance of the vector. The glycosylation can be examined for AAV8 neutralization; 
altered receptor binding improved cell ingression and tropism in a mixture of various tissues.  
In this study, the AAV2, 8serotypes are monitored for the capsid glycosylation profile was 
systemically analyzed by peptide mass fingerprinting utilizing high-resolution mass 







2 CHAPTER 2: BIOMARKER DISCOVERY IN HEMOPHILIA A INHIBITOR 
DEVELOPED PATIENTS 
2.1 Abstract 
Hemophilia A inhibitor development is a life-threatening challenge in the field of health 
care. The inhibitor development may relate to the immunological recognition or progression 
contrasts in the population. Glycan plays an essential job in the immune functions of the body, 
and their dynamic changes can be related to the disease progression, which implies to the 
immunological conditions of the body. Regardless of this fact, the intricate connection between 
the dynamic elements of glycosylation during inhibitor advancement is not studied well. In the 
present examination with the advanced mass spectrometry-based technology with a specific 
sample preparation strategy for glycan analysis, we researched the plasma and antibody 
glycosylation differences in various phases of inhibitor advancement in contrast with the 
inhibitor negative HA male patients. The results can be correlated with various immunological 
assays to comprehend the roles of glycosylation changes, during the inhibitor improvement and 
how it is reacting to the emicizumab treatment.  
2.2 Introduction 
          Hemophilia is a congenital bleeding disorder caused by a deficiency of blood 
clotting Factors VIII, IX, and XI. The absence of FVIII causes hemophilia A(HA) and 
deficiency in factors IX, and XI leads to HB and HC, respectively.136 The FVIII gene is residing 
on the X chromosome.137 HA is mainly affecting the males with a prevalence of 1:5000 in the 
United Staes.138The most commonly occurring, hemophilia types are A and B. Hemophilia A 
occurs 85% of the total hemophilia population139 followed by HB. Both have an X-linked 
recessive mode of inheritance. Whereas hemophilia C, which is less regular among all and has 
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an autosomal mode of inheritance.140 The female patients with congenital hemophilia generally 
act as a carrier as the males are affected by their maternal X chromosome.  
The deficiency in clotting factors is occurring by a genetic mutation in corresponding 
genes. F8 and F9 genes are more susceptible to genetic modification, and 1/3 of the cause is a 
spontaneous mutation without any family history.141 Considering the measure of Factor VIII 
activity in the blood of HA patients, the severity of the condition is categorized into severe (<1 
IU/mL), moderate (<5 IU/mL), and gentle (5-40 IU/mL). In the all, out HA population, around 
60% showed severe Hemophilia, and 15% showed moderate, and the staying 25 % showed 
mild forms.138 People with hemophilia A must depend on lifelong treatment strategies and 
medication to maintain health quality.  
The main symptoms of HA include joint bleeding, muscle hematoma, and soft tissue 
bleeding.142 Patients with hemophilia show prolonged bleeding when a cut or injury happens, 
internal bleeding for unknown reasons, muscle, joint and tissue damages, and other sequelae 
of bleeding. Mild conditions can have a less complicated life until they encounter severe cut, 
wound, surgery, or trauma. In some cases, the conditions of bleeding can lead to morbidity and 
mortality. The advancement of modern medicine and treatment strategies could save many 
such situations and improve the patients' health quality. As of now, the backbone of treatment 
is the replacement of FVIII with plasma derived or recombinant FVIII concentrates on 
accomplishing hemostasis. FVIII activity blood or plasma transfusion can transmit many 
infections and spread of diseases, including HIV and Hepatitis B. Hence modern medicine 
depends on recombinant FVIII in treating the patients. 
2.2.1 Factor VIII structure 
Human coagulation factor VIII (FVIII) is a critical cofactor in the coagulation pathway. 
Human factor VIII is one of the largest coagulation factors with 2332 amino acids containing 
a single chain with MW of 293kDa comprises of six domains- A1, A2, A3, B, C1, and C2. In 
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the activated stage, it undergoes processing to form a heavy chain consists of A1, A2, and B 
with 200kDa and Light chain consists of A3, C1, and C2  with a molecular weight of 80kDa 
linked by metal ions.143 Factor VIII is a nonenzymatic cofactor for the enzymes-
prothrombinase and tenase-in the intrinsic pathway of blood coagulation.  FVIII also increases 
the catalytic activity of activated FIX to activate the FX in the presence of calcium ions and 
phospholipids. Hence the absence of variations of FVIII may cause a severe bleeding disorder 
called HA.143  ‘A’ domain, in turn, consists of A1, A2, and A3 domains, consists of 336, 337  
and 329 amino acids, respectively. The two main epitopes of ‘A’ domain reside in A2, which 
it binds to FIX a. The A1 domain contains an FX binding site. R-336 of A1 and R-562 of A2 
is the binding site of activated protein C binding site, which inhibits coagulation.144–148 The 
functions of the B domain are not entirely elusive.149 The modified rFVIII has B domain 
deleted, and with the heavy chain of 90,000 MW, and a light chain of 80,000 MW, likewise, 
end up being similarly functional as the full-length FVIII.150 C domains are C1 and C2 consists 
of 153 and 160 amino acids, respectively .C2 domain has phospholipid linkage site, addition 
to that C2 also connected to C1 and A1 domains.C2 domain also contains thrombin and factor 
Xa domain binding sites.C1 does not have a direct impact on FVIII activity. However, the 
researchers suggest that it can influence on C2 domain to von Willebrand factor linkage 
strengthening.151 
2.2.1  The Inhibitor development  
Replacement therapy with rFVIII is successful in HA treatment, except if a patient 
builds up an alloantibody (inhibitor) against the exogenous FVIII. 152 The studies by 
Scandella D with inhibitor developed patients’ plasma has used immunoprecipitation assays 
for epitope mapping indicated that mainly (around 70%) anti FVIII antibodies are binding to 
various sites of A2 as well as the C2 domains of the Factor VIII proteins.148 The results of 
neutralization assays indicate that there is a third critical inhibitor epitope within the light 
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chain outside C2. Anti-A2 antibodies prevent normal function of the factor X ase complex of 
the intrinsic pathway of blood coagulation. Anti-C2 antibodies prevent the binding of FVIII 
to phospholipid and to von Willebrand factor, both of which are important for normal FVIII 
function.148Around 25-30% of patients develop high-titer, neutralizing anti-factor VIII 
(FVIII) antibodies, which binds to the functional domains of FVIII and inhibit their action 
(inhibitors),causes a significant snag in HA treatment.153 The epitope mapping studies also 
proved that there are multiple antibodies, bind to various active domains of FVIII collectively 
called as inhibitors. The essential process of FVIII immunology is based on the T 
helper cell-dependent pathway (TH cells), in which B-cells segregate into B memory 
cells and FVIII antibody-secreting plasma cells. Briefly, the FVIII antigens are recognized by 
the antigen-presenting cells and degrade the FVIII proteins into peptides, and the antigens are 
displayed on their MHC II for recognition by CD4+ TCR and ultimately leading to the TH 
cell activation and inhibitor production. The real mechanism and cause of inhibitor 
development of some HA cohort are still not precise. 
The studies with patients, who develop inhibitors proved the incomplete or complete 
absence of the adequacy of replacement therapy.153 The studies with patients, who develop 
inhibitors proved the incomplete or complete absence of the adequacy of replacement 
therapy.154 The inhibitors are classified based on their titer or the historic titer based on the 
FVIII exposure.155 The inhibitors are high responding if the titer is >5BU/mL and low 
responding if the titer is <5BU/mL in patients’ blood.156–158 Inhibitor development is not only 
limited to congenital hemophilia patients. Sometimes, individuals with no history of 
hemophilia or genetic conditions can also develop unexpected bleeding disorder caused by 
the autoimmune response of their body against the FVIII. This condition is called acquired 
hemophilia. Hence patients with Factor VIII deficiency along with inhibitor development 
have variable severity make it challenging to select the adequate treatment strategy. All the 
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above treatments are highly expensive. The treatment with the monoclonal antibody drug, 
emicizumab, is widely used as a novel treatment strategy since it can mimic functional 
aspects of the FVIII in the body. The FVIII coagulation cascade interacts with FIX to activate 
FX. Emicizumab is a bispecific, genetically engineered monoclonal antibody that can bind to 
both FIX and FX. Hence it can overcome the FVIII deficiency by bridging FIX and FX to 
complete the hemostasis. It is essential to unwind the mechanism of inhibitor development 
for the betterment of strategizing the therapeutic measures. The FVIII coagulation cascade 
interacts with FIX to activate FX. Emicizumab is a bispecific, genetically engineered 
monoclonal antibody that can bind to both FIX and FX. Hence it can overcome the FVIII 
deficiency by bridging FIX and FX to complete the hemostasis. It is essential to unwind the 
mechanism of inhibitor development for the betterment of maneuvering the therapeutic 
measures. 
2.2.2 Glycan as a biomarker 
The studies revealed  that in humans, around 20%-50% of proteins are 
glycosylated.159 Approximately1-2% of the genome is assigned to produce the glycosylation 
machinery protein components in various cells.160 Even though the glycosylation process 
occurs in the endoplasmic reticulum and Golgi apparatus, the process of nucleotide-sugar 
donor-synthesis generally happens inside the cytosol except for CMP-sialic acid, which is 
synthesized inside the nucleus.161,162 Different factors can regulate the structural 
determination of glycan in glycoproteins. The main factors are the  expression level of 
glycosyltransferases, glycosidases, and other regulatory proteins and their availabilities.163,164  
The second factor is the substrate availability and the competition between several 
glycosyltransferases and glycan acceptors for the same substrate 160. The third factor is the 
transportation of essential enzymes and nucleotide sugars to the endoplasmic reticulum and 
Golgi apparatus. The fourth factor is the protein quaternary structure and folding 164,165 , and 
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the fifth factor is the microenvironmental variations in the like oxygen supply and pH .166 The 
protein glycosylation varies in the multilevel of life – cellular, tissue, individual, and species 
level. Even though they match at the protein level, the glycan species may change, which 
inurn alter their function. Since the glycan play an interconnection between the cells and 
molecules, the differences in the micro and macro heterogeneity of the proteins may relate to 
the health and disease of the individual. They also vary according to the physiological 
changes like aging4, pregnancy5, malignant metastasis6, disease progression, inflammatory 
responses, metabolic changes, bacterial and viral infections that caused alteration of the 
microenvironment in the cell.3 Hence, glycan profile changes can be a prognostic or 
diagnostic biomarker for many physiological conditions.7 The altered glycosylation pattern 
can also alter the binding specificity of the cells or proteins with other molecules and 
eventually change their biological functions. There are many plasma proteins like AFP167, 
PSA33 , and CA12531 also be related to certain cancers which is detailed in section1.1. 
Plasma antibody glycosylation is also a very good indicator of many disease conditions and 
immune ageing.168,169 The structural and functional importance of immunoglobulin and 
glycosylation is detailed under section 2.2.3 
 
It is realized that improper protein glycosylation may modify the cellular trafficking 
and flag , proteins for degradation instead of secretion. Aberrant glycoforms may bring about 
protein misfolding because of missing oligosaccharide markers, prompting less stable, non-
utilitarian protein adaptations. Subsequently, the host cell glycosylation condition won't just 
affect  FVIII glycosylation, yet additionally impact its resistant framework on inhibitor 
development. Hence we tried to understand the glycosylation variation in inhibitor developed 
patients over regular HA patients. Since glycosylation is a dynamic modification, we also 
wanted to study the glycosylation pattern changes of N-glycome of plasma and antibody with 
inhibitor development and in response to emicizumab treatment. The standard strategies of 
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glycoprotein analysis are illustrated in figure 1.1. Glycosylation is the both species and tissue 
specific. The tissue specific glycosylation may required for their functional specification. 
Plasma is a mixture of various secretary protein produced by different tissues. Hence 
analysing plasma N-glycome gives overall differences in the glycosylation differences 
between the individuals during disease progression.170 Where as IgG glycosylation can tell 
about the B-cell specific glycosylation modification during the disease progression. 
2.2.3 IgG glycosylation 
                       Immunoglobulins are the most significant and thoroughly  comprehended 
glycoproteins of our adaptive immune system.164 In the normal functioning of the antibody 
involves recognition of the foreign pathogens and allergens by initiating a series of 
biochemical reactions (immunological reactions) to eliminate them from the body. 
Nevertheless, in rare cases, the immune system can  be focused against the individual's own 
epitopes which may lead to an  autoimmune disease.171 Their production types and existence 
vary among the individuals based on their acquired immunity. All immunoglobulins are 
glycoproteins and the existence of glycan , their structure and interaction between the glycan 
and amino acids can regulate their effector function.118 Immunoglobulins are primarily 
divided into 5 different types as Ig G, M, A, E and D. The heavy chain isoforms are of five 
types as γ, μ, α, ε, and δ. The light chains can be of two different isoforms as κ and λ.118 IgG 
is the most abundant immunoglobulin in the body which itself divided into four types as 
IgG1, G2, G3 and G4. All the IgG’s have a conserved N-glycosylation site generally termed 
as Asn-297 at their heavy chain, Fc region of the CH2 domain.171 The conserved N-glycans 
are very important for the IgG to bind its Fc γ receptors and regulate their effector 
functions.171 For example, the capping of Fc-N-glycoform with alpha 2,6 sialic acid can 
impair the antibody binding to its Fc-receptor, and thus leading them to the anti-inflammatory 
response.172 The anti-inflammatory property will sustain if it contains the glycoforms 
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terminated with galactose.172 Also, the increased terminal galactosylation can enhance the 
complement C1q binding and thereby increases the CDC.173 Whereas the same antibody 
containing a shorter N-glycan terminated with GlcNAc residue leads to the binding of 
FCγRIIIa receptors which get  enhanced with  non-fucosylation and  proinflammatory 
response.172 Fucosylation is generally known as a 'safety switch' for ADCC in IgG.172 As the 
glycosylation is directly regulating the antibody effector functions, it may act as a linking 
between innate and adaptive immune response; the topic is a point of discussion in the 
specified field of  study.174 
IgG glycome is a biomarker for various pathological and physiological state of an 
individual. The IgG glycome show the highest microheterogeneity among other plasma 
proteins.175 The IgG related glycoform variation is a biomarker in many diseases. The de-
galactosylated N-glycan is a common biomarker related to primary osteoarthritis, RA172 
,ulcerative colitis, Crohn’s disease and  some malignancies.176 However some physiological 
changes during the disease condition reverse the glycosylation pattern. For example it is 
proved that during pregnancy, RA woman showed higher galactosylation than in the pre-
pregnant condition.177 Also, it is noted that the IgG glycosylation changes in response to 
antigen encountering like vaccination.165 
2.2.4 The IgG subtype expression in different immunological conditions 
 
The expression of each IgG subtypes is also related to the antigen it encounters at the 
time of clonal selection. IgG1 is highly expressed against soluble protein antigen as it 
contains the highest percentage in plasma.  IgG1 deficiency can cause 
hypogammaglobulinemia, and its lack of other protein can also be related to certain 
infections.178 IgG2 subtype is generally expressed against the bacterial polysaccharide, blood 
group antigen, and other carbohydrate antigens, and their absence can be related to the 
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deficiency of anti-carbohydrate antibody in the blood.179 IgG3 is a proinflammatory antibody, 
as it is expressed first in the course of infections .179,180Some allergic reactions can be an 
inducer of IgG1 and 4 (Figure 2.2).  
 
Figure 2.1The IgG site-specific glycan and their functional influence of its effector function 
          IgG4 is upregulated as an immune response against the long term exposure of an 
antigen , against some allergens181 or in response to some parasite infections181. IgG4 can be 
dominantly expressed  against the long term expression of therapeutic proteins including       
FVIII and FIX.182–184The different IgG subtypes have different affinity for the FcRs in the 
cells.185 Furthermore, the equivalent FcR can be connected to various signaling molecules 
when connected by various cell types varies in their  immunological functions.180 Decreased 
N-linked galactosylation and sialylation of IgG known to decrease the CDC activity , and this 
is a biomarker in many autoimmune disease like in RA.186The immune response balance is 
occurred through the action of different activating FcRs and inhibitory FcRs .The effect of 





Figure 2.2 IgG subtyping and their traits of inflammatory response 
The CH2.84.2 conserved glycopeptide sequence (glycosite is highlighted in red) is slightly different in 
all the subtypes (shown in blue). The general percentage of distribution from total IgG in normal 
conditions are given in bracket. The specificities of their antigenic 
 
2.2.5 Mouse plasma glycan biomarker  
The mouse models are widely used for biomarker discovery and drug discovery due 
to their easiness of life support at lab environments in a controlled way with a short life 
cycle.187,188 Mouse models are widely used for protein specific biomarker discovery in 
various diseases.189 Even though the glycosylation has some species-specific differences 
between human and mice model the disease specific aberrations can be monitored much 
efficiently with mice models.189 
Hence to make a controlled lab atmosphere the glycosylation differences with respect to 
hemophilia A is to monitor the glycosylation differences with inhibitor development with 
more related lab grown murine system.173  There are species-related differences between 
human and mouse models in their immunology190 and glycosylation. Nevertheless, the 
humanized murine models are widely used to study the antibody effector functions.191 There 
are three main IgG subtypes detected in mice that are divided as IgG1, IgG 2b, and IgG 3. In 
addition to that IgG 2a/2c is also been seen related to a specific strain. The site-specific 
glycosylation is widely studied for various effector functionalities. 
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2.3 Scope of the current study 
Glycomics and glycoproteomics based biomarkers are widely explored relating to the 
field of disease progression in the recent past. It is reported that the MS-based analysis for 
glycomics studies are reliable as they used globally and compared between the different labs 
and  endorsed by A multi-institutional assessment of glycomics methodologies coordinated 
by the Human Disease Glycomics/Proteome Initiative (HGPI) and Human Proteome 
Organization (HUPO)86 The disease progression in individuals is majorly influenced by their 
genetic background and the environmental effect mainly caused by their habits of life. In 
2012, U.S national academy has declared that glycans are directly involved in the 
pathophysiology of every major diseases and Extra information from Glycosciences will be 
expected to understand the objectives of personalized medication and to exploit significant 
interest in human genome and proteome research and its effect on human wellbeing.170 
Glycans and glycoproteins are already reported as the essential molecules in health and 
disease.164In our lab, we are trying to understand the mechanism of inhibitor development by 
studying glycosylation differences in factor VIII as a potential cause of immunogenic 
response in the inhibitor developed patients. As we realize that the inhibitor development is 
occurring just among specific individuals, we needed to comprehend the distinctions of their 
immune system and protein expression. Numerous studies impressively fortify that the 
knowledge of glycomics flavors and sometime overturned the traditional understanding of 
protein functions. The in depth  studies are conducted in cancer and autoimmune diseases.9,177 
Here we tried to explore the glycosylation differences among plasma protein in congenital 
HA patients without inhibitor development and the HA patient with inhibitor development 
using mass spectrometry based glycan analyses. The changes in the expression level of 
glycoprotein, especially the immunoglobulin subtypes and the modification of their 
glycosylation, may lead to an indicator regarding the unique mechanism of inhibitor 
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development. We also planned to study the treatment specific glycan alteration with 
emicizumab treatment, hence we can discriminate the healthy and proinflammatory specific 
glycan pattern. Incorrect glycoforms may result in protein misfolding due to altered 
oligosaccharide markers, leading to less-stable, non-functional or mal functional  protein 
conformations. Therefore, the host cellular glycosylation environment may influence its 
immune system on inhibitor formation. Since the glycosylation is dynamic the treatment 
strategies may improve the glycosylation pattern ,hence reverse the healthy pattern of 
glycosylation. Both the cases are important to understand the underlying pathways of 
inhibitor mechanism. Mass spectrometry based glycocentric and glycopeptide analysis help 
us to understand the  overall N-glycome variation between HA , inhibitor developed and 
control population . It also tell us about the micro and macro heterogeneity related to 
Inhibitor development through bottom- up analysis of glycoproteins. Additionally mass 
spectrometry based relative quantitation can tell us about the inhibitor specific upregulation 
of any glycoproteins in the sample. The variations can be compared with other biological 
assays like cytokine analysis and eventually help us to correlate with the immunological 
alterations relating to glycosylation changes. 
Hence, the comprehensive analysis of the glycosylation pattern of human antibody 
and plasma can give us an indication of the type of effector function of the immune system 
and intensity of inflammation. The biological role of glycoproteins is mainly regulated by the 
type of glycan attached to the glycosylation sites. The micro and macro heterogeneity of 
glycosylation can relate to the genetic and environmental variability within the cells. The 
glycoprotein expression level can also vary in response to specific physiological conditions. 
We anticipate that the microenvironment of inhibitor developed patient plasma changes due 
to the difference in the immune response against FVIII. The site-specific antibody 
glycosylation of antibody classes and subclasses are also determining the type of antigen it 
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encountered by their immune system (figure 2.2). All the trials are replicated in the HA mice 
models from 3 different strains. The observations are correlated with human studies.  
In summary, we tried to understand the glycosylation variation in inhibitor developed 
patients with regular HA patients. The human study was extended with mass spectrometry 
related plasma glycosylation changes with emicizumab treatment. All these steps with 
organized analysis can provide concrete evidence for the facts of inhibitor development. 
2.4 The experimental design 
  In this experiment, we decided to understand the glycosylation pattern of inhibitor 
developed patients and the typical HA patient without inhibitor development. The released 
glycan analysis of plasma protein can provide the details of glycosylation structure, linkage, 
and overall distribution. We investigated the glycosylation differences from total plasma and 
antibody isolated from the different HA patients with inhibitor development and compared 
them with HA, inhibitor negative cases within similar age group. The investigation was 
performed in three different stages. The first stage was for primary screening. For the initial 
discovery, we investigated healthy individuals without HA considering the variability in 
ethnicity, age, and blood group differences to understand the possible causes of variabilities. 
All the individuals considered for the study were male. We parallelly examined the HA 
patients with and without inhibitor advancement. In the subsequent stage, we inspected a 
patient's plasma at his pre-and post-treatment with emicizumab. The patient was inhibitor 
positive, and the two stages of treatments were compared with a control plasma without 
inhibitor development but within the same group. We expanded our study for comprehensive 
analysis at glycocentric and glycopeptide level. In the third stage, we increased the number of 
individuals within the same age group with and without inhibitor development and studied 
their glycosylation pattern change after the emicizumab treatment. We additionally analyzed 
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control samples without Inhibitor development to prove the effect of emicizumab 
glycosylation in overall profile. 
 
Figure 2.3: experimental plan for analytical cohort selection.  
a) Inhibitor developed individual from same age group at emicizumab pre-treatment stage. b) 
‘a’ at emicizumab post-treatment. c) Control HA patient without inhibitor development d) ‘c’ at 
emicizumab post-treatment e) BL-6, BALB/c and SV-129 strains before treatment with rFVIII and 
inhibitor development f) e) BL-6, BALB/c and SV-129 strains after treatment with rFVIII and inhibitor 
development 
 
For the detailed study of antibody and plasma glycosylation profile, we enriched the 
antibody from the plasma, which detailed in figure2.3. We have performed a glycosylation 
analysis of plasma and antibody independently to distinguish alpha 2,3 and alpha 2,6 sialic acid 
linkage analysis. The two-step permethylation will be supplementary analysis for the one-step 
process, which also gives additional information about the sialic acid linkage. The site-specific 
glycosylation analysis is performed at the glycopeptide level using glycopeptide mapping by 
HR-MS. Site-specific glycosylation differences, protein related glycoforms variation, glycan 
structure elucidation with glycopeptide sequences and the site of glycosylation can be the 
additionally obtained from the glycopeptide analysis. 
We additionally analyzed the N-glycome pattern differences in HA male mice before 
and after FVIII injection and inhibitor development. We analyzed three different strains -
SV129, BALB/c, and BL-6 CD.45.1- of lab mice to confirm the glycosylation alteration during 
inhibitor development in the mice. The HA mice plasma was collected in the 11th week for the 
baseline analysis. After that, the mice were treated with rFVIII and allowed to develop the 
inhibitor. In the 15th week, after inhibitor development, the plasma was collected again, and 
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their glycomics and glycoproteomics patterns were analyzed and the study can supplement the 
observations we get it in human samples hence prove the chances of glycan biomarker related 
to inhibitor development. As a background analysis, we also compared the HA mice sample, 
and wildtype mice sample with BL-6 stain to confirm no variation in their plasma glycome 
during the HA condition. 
2.5 Materials and methods 
Plasma from a HA patient drawn before and after emicizumab treatment and inhibitor values 
(citrated) obtained from Washington Center for Bleeding Disorders at Bloodworks Northwest. 
The hemophilic mouse plasma was obtained from Seattle children’s hospital(citrated). The 
glycan standard 4 4 0 0 1 were produced in-house. Super clean™ ENVI-Carb™ SPE Tube 
(Millipore/ sigma), Thermo Scientific™ HyperSep™ C18 Cartridges , magnetic stand, and 
Pierce™ Protein A/G Magnetic Beads ( Thermo Scientific, MA, US), Formic acid (FA), 
Human serum, Trifluoracetic (TFA) (LC-MS grade) acid and super-DHB matrix for MALDI-
MS (≥99.0%) were purchased from Sigma-Aldrich (ST. Louis, MO, USA). Tris-HCl buffer 
was purchased from US Biological (Swampscott, MA, USA). 10X TBS was purchased  from 
Bio-Rad. HPLC grade acetonitrile (ACN) and methanol were purchased from J. T. Baker® 
Chemicals (Avantor Performance Materials, Inc. Center Valley, PA, USA). Deionized water 
was produced using a Milli-Q A 10 system from Millipore (Bedford, MA, USA). Microcon-
30kDa Centrifugal Filter units (YM-30, 0.5 mL) with Ultracel® low-binding regenerated 
cellulose membrane was purchased from Millipore. BEH Amide Column, 130Å, 5 µm was 
purchased from Waters Corporation (MI, USA). Other materials, including sodium dodecyl 
sulfate (SDS), urea (UA), ammonium bicarbonate (ABC; NH4HCO3), sodium hydroxide 
beads (NaOH, 20-40 mesh, 97%), iodomethane ICH3 (≥99.0%), dimethyl sulfoxide (DMSO, 
anhydrous, ≥99.9%), dichloromethane (DCM, HPLC grade), and ammonium hydroxide 
solution (NH4OH, 30%), dimethylamine solution (2 M in methanol), dimethyl sulfoxide 
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(DMSO),1-hydroxybenzotriazole (HOBt) hydrate,1-ethyl-3-(3-(dimethyl amino)propyl)-
carbodiimide (EDC), Tween 20 detergent and BSA were purchased from Sigma-Aldrich (ST. 
Louis, MO, USA). 1.5 mL and 2 mL microcentrifuge tubes purchased from Eppendorf, 
PNGase F were purchased from purchased from New England BioLabs (Ipswich, MA), 2-
Iodoacetamide (IAA) and Dithiothreitol (DTT) was obtained from Alfa Aesar (Ward Hill, 
MA). N glycosidase F (PNGase F) was purchased from New England BioLabs (Ipswich, MA). 
Sequencing grade porcine trypsin was purchased from Promega (Madison, WI). LC-MS grade 
quality acetonitrile (ACN), formic acid (FA), and water were purchased from Thermo Fisher 
Scientific, Inc. (Waltham, MA). 
2.5.1  Antibody enrichment 
The IgG enrichment of plasma protein was performed by the manufactures protocol 
with minute modifications. Approximately 20µl of blood plasma is diluted with 480µl of 
binding buffer (1 X TBS contains 0.1%tween 20 and 0.1% BSA). Approximately 150µl of 
protein A/G beads were taken in a separate 1.5mL microfuge tube. The beads were washed 
with 150µl of binding buffer and gently mixed and collected on the magnetic stand. The 
supernatant was discarded. The beads were equilibrated with 1ml of binding buffer and 
repeated the previous step.  
 
Figure 2.4 The schematic representation of antibody enrichment from plasma using Protein A/G magnetic 
beads 
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 The diluted plasma sample was added to the prewashed tube and incubate at room 
temperature for 1hr with slow mixing. The beads were collected using the magnetic stand and 
washed with binding buffer without BSA. To the collected beads, add 150µl of elution buffer 
and followed by 10mins incubation without mixing. The beads were collected again and the 
supernatant containing IgG was neutralized using 15µl of 1M tris buffer pH 8.0. 5µl of 
enriched antibody and 0.3 µl of human plasma was separated on the reducing gel (10% SDS). 
The gels were stained after the separation using Coomassie stain. We repeated the analysis 
with mouse stains following the same protocol. 
2.5.2 Released N- glycan analysis of plasma and antibody 
2.5.2.1 N-glycan release and purification 
For the release of N-glycan, around 6µl of plasma (mice or human) and the enriched 
antibody from 10µl of the plasma (human) were taken separately. The volume was reduced 
below 10µl and then diluted it further with the denaturation buffer and boiled the mixture at 
90 °C for 10 min. After cooling it down, 1µl of 10% of NP-40 and 1µl of PNGase F (500U) 
were added to the mixture using manufactures protocol with minute modification in the 
incubation time upto16 hrs.  The enzymatically released N-glycans obtained from plasma and 
antibody were purified using a connected cartridges system where envicarb on bottom and 
C18-6ml on top. The cartridges were pre-conditioned with 5 mL of acetonitrile 
(ACN)containing 0.01% TFA followed by 3ml of 25% ACN in 0.1% TFA and finally with 
6ml of 5% ACN with 0.1%TFA water. The sample was diluted with 5% ACN in 0.1% TFA 
water and, passed through the cartridge system and washed it again with additional 6ml of 
5% ACN in 0.1% TFA water. The C18 cartridge was removed at this stage and the separated 
glycans were bounded to envicarb cartridge. The enriched glycans were eluted out with 6ml 
of 25%ACN in 0.1. % TFA water. The purified glycans were aliquoted into two vials and 
dried for the following derivatization. 
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2.5.2.2 Glycan permethylation (one step method) 
The base for permethylation is prepared by mixing around 350µl of 50% NaOH in 
DMSO and transferred into a screw-capped glass tube before quickly adding 700 μL 
anhydrous methanol. The mixture was vortexed well and 4ml of anhydrous DMSO was 
added to the tube. The mixture was vortexed well and centrifuged at 2000rpm for 1 min. The 
supernatant was discarded and 4mL of fresh DMSO was added again to the NaOH gel to 
dissolve the base. The base was washed with DMSO (3×4mL) and finally dissolved with 2ml 
of fresh DMSO to use as a reaction base for permethylation. One aliquot of dried glycans was 
redissolved in 200µl of DMSO and 250µl of freshly prepared reaction base was added to it. 
150µl of iodomethane was added to the mixture and sonicated for sharp 10mins. The reaction 
was stopped by adding 500µl of water in a dropwise manner. Then, the permethylated 
glycans were extracted twice with 400 μL DCM by liquid -liquid extraction. The mixture was 
vortexed well and centrifuged at10000rpm for 5mins.The supernatant was discarded and 
additionally 800µl of water was added and repeated the previous step. The washing was 
continued for additional 4 times and make sure that the supernatant is at pH 7. The bottom 
layer was transferred to a fresh tube and kept it open under the hood for 4 hrs. The dried 
glycans were resuspended in 20µl of 50% methanol for further MALDI analysis.  
2.5.2.3 Glycan permethylation (two steps method) 
The experiment was performed with previously published method with minute 
modification.90 A fraction of isolated glycan from plasma proteins was mixed with 25 μL of 
reaction mixture composed of 250 mM dimethylamine, 250 mM EDC and 500 mM HOBt in 
DMSO and incubated at 60 ºC for 1 h .The samples were kept in a speed Vac for additional 
20 mins at 60 ºC  for the removal of excess dimethylamine. The resulting sample was diluted 
with 200µl of DMSO and continued the permethylation process as described in 
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section2.5.2.2 The permethylated sample was dried and dissolved in 50% ACN/50% H2O for 
MALDI-TOF analysis. 
2.5.2.4 N-glycan analysis by MALDI-TOF-MS 
 One microliter of permethylated glycan was mixed to an equal volume of super-DHB 
(10 mg/mL in 50% ACN), 1 μL of the mixture was spotted on the target plate (Bruker 
Daltonics, MTP 384 polished steel) and allowed for crystallization. The samples were spotted 
in triplicate along with the permethylated dextran. The dextran serves as an external calibrant. 
We have used Ultra Flextreme MALDITOF-MS (Bruker Daltonics, Bremen, Germany) 
equipped with 1 kHz Smart beam-II laser operated by flex Control 3.4 software (Bruker 
Daltonics). The data was acquired in the reflector positive mode with accuracy up to 50 ppm. 
For each spot, the laser was shot up to 20,000 shots at a laser frequency of 666.7 Hz, using a 
complete-sample random walk with 2000 shots per raster spot. The mass range detection was 
1000- 5000 Da. The laser intensity was set based on the sample concentration, ionization of 
the glycan species, and depends on the instrument condition while the monoisotopic peak was 
still clearly defined for all detectable glycan masses. The m/z range was monitored from 1000 
to 5000. Tandem mass spectrometry (MALDI-MS/MS) was performed for the possible most 
intense glycoforms using CID.  
2.5.2.5 Data analysis using flex analysis v3.4 (Bruker daltonics) 
 
The glycoforms distribution in plasma and antibody was calculated independently. The 
details of data analysis include data acquisition, raw data, data clean up, including peak 
picking, baseline correction,  scaling, normalization, and quality assessment.192In details, the 
resultant MALDI-MS spectra were smoothed, and baseline-subtracted across all the m/z 
range and internally calibrated using a set of common complex glycan masses which is 
present in the human serum listed in appendix B table 1 . For the mice sample the 
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glycosylation variations are considered and spectra was calculated with the common 
glycoforms present in human plasma structures were listed in the same table . The glycan 
masses are in single charges in M+Na+ form. Masses were picked in the spectra using 
monoisotopic heights as intensity. The S/N intensity was set up to 10. The listed masses were 
assigned using a software, Glycoworkbench v.2 (http://www.eurocarbdb.org/applications/ms-
tools) to find the corresponding glycoforms and their compositions. The MS/MS was 
performed for the ambiguous structures, and the most probable structures were reconfirmed 
using the fragmentation pattern by the same software.  
The glycan masses were calculated as [M+Na] + precursor ions. The dextrin was used 
to calibrate the system. The known masses in the region of N-glycan mass 1500-5000 Da was 
also used for internal calibration in the flex analysis software. The calibrant list was given in 
the Appendix B table 1. Some of the common calibrant masses are  H5N2 (m/z 1579.7826), 
H3N4  (m/z 1661.8357),H6N2 (m/z 1783.8824), H4N4F1 (m/z 1835.9249), and  (m/z 
1906.9620) ,H4N4F1 (m/z 2040.0247), H3N5F1 (m/z 2081.0512),H4N5 (m/z 2111.0618), 
H5N4F1 (m/z 2244.1245), and H4N5F2 (m/z 2459.2402)). The sialylation samples were not 
considered due to their differences in sialylation in mice samples. The calibration performed 
with 50 ppm tolerance (H = Hexose, N = N-Acetyl hexosamine, and F = Fucose, G = N-
glycolyl neuraminic acid and A = N-acetyl neuraminic acid. The number of residues given 
after the letter). The intensity of each peak was calculated considering the monoisotopic ionic 
mass of each glycan. The fucosylation (mono, bi and multi), sialylation (mono, di and multi 
sialylation) were calculated by percentage calculation by adding the individual glycoforms 
with specification in total glycoforms intensities. Galactosylation index were calculated by 
the ratio calculation using the following formula.6  
𝐺𝐼 =
𝐺0𝑓




In which GI is galactosylation index, G0f represents non-galactosylated glycoforms, 
G1f represents mono-galactosylated glycoforms, and G2f represents di-galactosylated 
glycoforms. The data has been compiled together based on their structure specification as 
terminal galactosylation, and fucosylation. The plasma glycans are segregated based on their 
structural specification as in figure 2.8. The glycans were generally categorized into complex 
hybrid, high mannose and categorized based on their specific sugar which has functional 
impact like fucose and sialic acid. This segregation was again subdivided based on the 
number of fucose /sialic acid like total fucosylated / sialic acid containing species(total), 
mono, di and multi. The percentage calculation is done by taking the ratio of the sum of 
specific sugar intensities to the total identified sugar intensities.  Similarly, to the 
galactosylation index calculation, sialylation index can also be calculated using the similar 
formula based on 54000 (G2) glycoform. In addition to that, the linkage specificity was also 
calculated based on the two-steps permethylation data, using the formula  
SI=G2/G2S1+G2S2×2. In which SI is sialylation index, G2 represents non-sialylated 
glycoforms, G2S1 represents mono-sialylated glycoforms, and G2S2 represents di-sialylated 
glycoforms The sialylated species will vary based on the specific linkage calculation. The 
hybrid G2S2 structure (Which has both type of linkages) will be added to G2S1 as the 
specific sialic acid content was only one in the structure. The formula is adapted to mice SI 
calculation. 
2.5.2.6 Statistical analysis  
Before applying the statistics, the intensities across m/z range specific mass spectrum 
were smoothed and baseline subtracted. The relative intensities of each glycoforms were 
calculated using 5 4 1 0 0 (G2fS1, H5N4A1) as a reference peak. For the antibody 
glycosylation 4 4 0 0 1 (G1f, H4N4F1) is taken as the reference peak. The quality of  overall 
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signal intensity of each MADI-MS spectrum was confirmed by their individual peaks S/N 
and maintained minimum to 10. 
Differences in each type of hemophilia and control were analyzed across different 
glycoforms from the spectra and categorized based on their specifications, including 
glycoform structure, type, complexity, fucosylation, galactosylation, and sialylation. For that, 
all the glycoforms were summed together with their intensities in the spectra and the 
percentage were calculated with total glycoforms intensities. The statistical analyses were 
performed using GraphPad Prism version for Windows (GraphPad Software, La Jolla, 
California, USA). Statistical analysis was performed with the two-tailed student’s t-tests for 
unpaired data. The standard deviation, p value testing and graph visualization was performed 
using the same software. For the statistical testing, in which a p-value of < 0.05 was 
considered statistically significant. 
 




2.5.2.7 MALDI-MS method reliability study (spiking study) 
The MADI-based permethylated glycan analysis is already published as a reliable 
method with the biopharmaceuticals studies and  their accuracy , repeatability and intraday-
intra-day variability  and also showed the permethylated glycan by MALDI can be a  
potential application of glycosylation analysis for glycan biomarker studies combined with 
orthogonal methods.86 Here we took 8 µl of commercially available human serum (which 
contain approximately 1mg of protein calculated by Nanodrop). The N-glycans were 
separated as described in the section 2.5.2.1. The isolated glycans were equally split into 5 
vials (each contains glycans from approximately 200µg of proteins)50, 100, 150 and 200 
picomoles of 4 4 0 0 1 standard was spiked individually. The final tube was kept as a control 
baseline tube with no spiking. The tubes were continued for the further sample processing 
and data acquisition (Section 2.5.2.2, 2.5.2.4-2.5.2).Each sample was spotted in triplicate and 
the relative intensity of the standard 4 4 0 0 1 was calculated with the inherent glycoform 5 4 
1 0 0 in the serum sample. The linearity of 4 4 0 0 1 was also calculated with total intensity 
percentage. The standard deviation of the relative intensity and individual percentage at each 
point of 4 4 0 0 1 were calculated and plotted separately to calculate the %RSD and linear 
regression. 
2.5.3 Glycopeptide analysis and (Bottom-Up Identification) 
The glycopeptide level examination is additionally named as a bottom-up approach. 
We can recognize the glycoprotein using the sequence of the peptide and its identification by 
the database search. Likewise, we can get the site-specific glycan structure, percentage of 
occupancy along with the amino acid sequence analysis. Glycopeptide examination requires 
multi-step sample processing, which includes protein purification, trypsin (or endoprotease) 
digestion followed by glycopeptide enrichment together to determine the quality of spectra. 
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Separation and identification using adequate mass spectrometry methods and comprehending 
the complex data using adequate software are also essential for the precision of the analysis. 
2.5.3.1 Trypsin digestion of plasma protein 
 
The plasma protein concentration was determined by a nanodrop and approximately 1 
mg of total proteins from human or mouse plasma was subjected to FASP procedures.193The 
protein was denatured using the lysis buffer (4% SDS, 100 mM DTT, 20 mM Tris-HCl, pH 
7.6) at 95°C for 10 min. The denatured protein was diluted to 1 mL with UA1 buffer (8 M 
urea, 20 mM Tris-HCl, pH 8.5). The solution was transferred to a centrifugal 30kDa filter 
gradually buffer exchanged with UA1 for 3 times at 150000 rpm for 15 mins each time. The 
volume of the sample was maintained at 20µl and 100 μL of IAA solution (50 mM IAA in 
UA solution) was added to the filter and incubated for 30 min in the darkness. The mixture 
was centrifugated at 15,000 rpm for 10 min. and buffer exchanged with UA solution a 
followed by 200 μL of digestion buffer (100 μL of 50 mM NH4HCO3 each time). At last, 20 
μg of trypsin was added into the filter and the pH was adjusted to 8.0. The filter was 
incubated at 37 °C for 12 h. The digested tryptic peptides were collected from the filter by 
passing 100 μL of 50 mM NH4HCO3 through the filter for six times. The concentration of the 
collected peptides was measured at 280nm using a Nanodrop. The peptides were dried and 
reconstituted in 100µl of 80% ACN in 0.1% TFA/ water for glycopeptide enrichment. 
2.5.3.2 Enrichment of glycopeptides 
The glycopeptides enrichment was performed using an NP-HPLC with Bridge BEH 
Amide Column, 130Å, 5 µm 600 µL of 80% ACN containing 0.1% TFA. The column was 
equilibrated with 80% ACN containing 1% TFA. The glycopeptides was injected and 
allowed to separate on the column. The fractions of glycopeptides were collected from 66.5-
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40% of ACN.  The fractions were collected and dried using a centrifugal evaporator and 
injected to nano RP HPLC-MS for further analysis. 
2.5.3.3 Nano LC-MS/MS analysis 
The glycopeptide sample was injected into an LTQ-Orbitrap Elite mass spectrometer 
(Thermo Fisher) equipped with an EASY-spray source connected to nano-LC UltiMate 3000 
high-performance liquid chromatography system (Thermo Fisher). The mass spectra were 
recorded in a data-dependent mode in a full scan survey of m/z range 375 Da-2000Da. The 
fragmentation was undergone in higher-energy C trap dissociation (HCD) in orbitrap. The 
resolution at 400 m/z is 60,000 MS experiment and automatic gain control target, 1,000,000 
ions. The maximum accumulation time is 50 ms. The ten most intense ions were fragmented 
with optimized stepped collision energy (SCE) of 30 ± 15% NCE. The glycopeptides were 
separated on RP column at the flow rate of 300 nL/min, EASY-Spray pepmap C18 (75 μm × 
50 cm, 2 μm, Thermo Fisher, US) using a linear gradient of mobile phase 3% B to 40% B for 
120mins (MP A: 1.95% ACN, 97.95% H2O, 0.1% FA; MP B: 79.95% ACN, 19.95% H2O, 




Figure 2.6. The workflow for the site-specific identification and quantitation of glycopeptide/ glycoprotein by bottom 
up approach. 
 
2.5.3.4   Data analysis  
The data was analyzed using p Glyco 3.0 (an improved version of p Glyco 2.0 
software) was used to identify N-glycopeptides. In the glycan database, we have a code in a 
short form in the format “H N A G F’’. “H” is for galactose and mannose, “N” is for N-acetyl 
hexosamine, “A” for Neu5Ac and “G” for Neu5Gc and “F” is for fucose. The glycopeptides 
were assigned based on the UniProt-Swiss human protein database (20,417 reviewed entries 
on March 20, 2019) and the N-glycan database. Similarly, for the mice were assigned based 
on the UniProt-Swiss mouse database (17,032 reviewed entries on August 1,2019). The fixed 
modification was given as carbamidomethyl (Cys) and variable modifications are 
deamidation of N and Q and methionine oxidation. The trypsin digestion with maximum of 2 
missed cleavages were allowed for identification. The mass tolerance for the precursor ion 
was set to 10ppm and fragment ion was set to 20 ppm. The total false discovery rate (FDR) of 
1% was applied to the data. The identified glycoproteins were annotated using UniProt ID 
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mapping. The quantitation of the glycopeptides were performed using ‘PANDA’ which is 
annexure software of pGlyco. The PANDA search was performed using the pGlyco search 
result and the original raw data with allowed FDR of 1%. The intensity with respect to the 
scan number and retention time can be compared and manually annotated for the glycosite 
specific glycoform analysis of specific protein. The software extracted intensity of specific 
glycopeptide related to the antibody was used for calculating site-specific relative abundance 
(SRA) of each IgG subtypes with total relative abundance (TRA) of all N-glycoforms related 
to that site. For SRA, the glycopeptide intensity cutoff was set to 3(S:N>3). Then, the peak 
intensity of each glycoform was normalized to the total signal at each specific site. Similarly, 
the total glycoprotein composition within the sample was also calculated based on their 
glycopeptide intensities normalized to the total glycopeptide intensities within the plasma 
sample.  
2.6 Results 
The Antibody from the human plasma was successfully isolated and confirmed the 
enrichment by SDS-PAGE analysis. Whereas, we could not efficiently enrich the antibody 
from the mice sample. Hence, the IgG specific analysis was restricted to glycopeptide SRA. 
The N-glycosylation pattern was also compared with the normal patient to screen any 
possible differences. The HA without inhibitor development and with inhibitor development 
showed a remarkable difference in galactosylation especially in antibody galactosylation. The 
patients with lesser galactosylation showed an improvement in galactosylation percentage 
after treating with emicizumab. The trend was not shown in sample who has no differences in 
galactosylation. We additionally considered the plasma of two distinctive hemophilia A 
patients, one with and the other without inhibitor advancement, as the controls for this 
examination. We also analyzed the mice samples between BALB/c, SV129 and BL-6 CD54.1 
before and after inhibitor development, detailed in section 2.6.4 
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2.6.1  Antibody enrichment 
The antibody enrichment could get away many proteins from plasma and we can get a 
plasma cell specific glycosylation at the time of infection. As an underlying investigation, we 
efficiently separated the IgG from blood plasma by protein A/G conjugated magnetic beads 
using manufacture’s protocol with minute modifications. Further we confirmed the purity of 
isolated IgG using SDS-PAGE.  The results are shown in figure 2.7. The blood plasma 
sample was separated on 10% SDS gel and stained with Coomassie stain. 
 
Figure 2.7  SDS-PAGE separation of antibody and plasma 
The gel A corresponds to the antibody isolated from plasma. The 50kDa corresponds to the heavy chain and 
25kDa corresponds to the light chain. The additional band ~ 70kda band is the BSA in the binding buffer. The well 2 
corresponds to HA patient plasma. 3,4 corresponds to plasma with inhibitor development and 6 corresponds to the 
healthy individual. The gel B corresponds to plasma of different plasma sample the well 3 is BSA. The well 4 
corresponds to HA patient plasma. 5,6 corresponds to plasma with inhibitor development and 7 corresponds to the 
healthy individual. The inhibitor developed one are highlighted. 
 
We could not effectively enrich the mouse antibody from the plasma due to poor binding of 
mice antibody to protein A/G beads as well as some nonspecific binding. Hence, we limited 
the antibody enrichment study to only human samples. 
2.6.2 MALDI-MS method reliability study and standard spiking study 
     Reliable glycan analysis work flows should be having a fast  sample processing, reliability 
with , less sample to-sample variation, and increased speed and efficiency. MALDI-TOF-MS 
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is known to have high coefficients of variation (CVs) for quantification when compared to 
the commonly used UHPLC methods86. It was reported that the S/N ration of the individual 
should be maintained minimum limit of 10 which is considered as the limit of quantitation of 
the analytical instrument. The limit of quantitation of different analytical instrument may 
change due to their variation in sensitivity however when we perform the analysis we have to 
maintain the S/N 10 which is preferable for quantitation purposes. In all our current analysis 
we cross verified the individual glycoform which we took for quantitation and relative 
comparison were above S/N 10. The LOD and LOQ of the permethylated glycans were 
calculated previously from the lab by Kuan Jiang and detailed in previously published 
work.90The studied with permethylated glycan standard using the same MALDI, and 
standardized method proves that the glycan is detectable at as low as 50 fmol levels and 
showed a good signal-to-noise ratio ( >10).90 While checking the data quality during peak 
picking, it is essential to check the S/N ratio of each peak. This was just to get the clarity 
about instrument related sensitivity. Here  we performed the  spiking study was conducted 
with the common glycoform G1F standard (4 4 0 0 1) to the commercially available human 
serum. The human serum N-glycome which inherently having a small percentage of 4 4 0 0 1 
which we spiked to get the linearity. The relative intensity of the spiked standard was 
calculated with the 5 4 1 0 0 (G2S1), the inherent glycoform within the serum. The spiking 
study was showing linearity in their percentage calculation (considering the total glycan 
intensity). We have used RI calculation of the significant glycoforms concerning the most 
abundant 5 4 1 0 0 glycoform in the plasma. We adapted the RI calculation of the spiked 
standard for the common glycoform present in the human serum 5 4 1 0 0. The strength of the 
linear relation between the values were estimated using R-squared value, also called the 
coefficient of determination. For this case, in relative intensity of the standard was obtained 
with R-squared = 0.9761 (Appendix B F3 a1) and the percentage in total intensity was 
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obtained with R-squared = 0.9995(Appendix B F3 a2). So, we could conclude that the linear 
fitting is strong in this experiment. 200 picomole spike was out of linear range but considered 
for SD calculation (shown in the bar graph at APPENDIX BF6). All the acquisition was in 
triplicate trials, and %RSD was within 14% which in turn prove the method reliability for the 
current study. All the acquisition was in triplicate trials and %RSD was within 14%. The 
experiment is proving the consistency in individual measurements where absolute S/N 
depends on instruments/methods which is previously reported that less than 50 fmol90. Hence, 
it prove that the method is suitable to analyze the biological sample  
 
2.6.3 N-glycan analysis by MALDI-TOF-MS 
In the primary screening, we analyzed 11 healthy males varying in their age ethnicity 
and blood group. The antibody and plasma glycans were compared. Parallelly we have 
analyzed 4 HA patient with inhibitors and 2 without inhibitors. Three patients were showing 
with differences in the antibody galactosylation. The antibody galactosylation decreases in 
response to age and inhibitor development in most of the cases. We have identified around 82 
different glycosylation by plasma one-step permethylation in Appendix B. table 2. The 
glycoform mass and their intensity obtained through MALDI-MS spectra after smoothening 
the spectra and baseline is subtracted. The total glycan species intensity was also calculated 
from the all the glycoforms identified from the spectra. The percentage distribution was 
calculated by summing up each glycan species based on their structural specificity (Appendix 





 Figure 2.8 MALDI-MS profile of FC N-glycoforms derived from plasma and antibody 
◼ N-acetylglucosamine (GlcNAc), ◼ N-acetyl galactosamine (GalNAc), ⚫ mannose (Man), ⚫ Galactose (Gal),     
and ◆ N-acetylneuraminic acid (Neu5Ac). 
 
The major glycoforms were identified from the purified antibody is listed in 
(appendix B. table 3). The fucosylation (mono and multi) galactosylation and sialylation 
(mono, di and multi) percentages were calculated based on the structural specification 
identified by MALDI-MS and the peaks are assigned by Glycoworkbench software which is 
listed in appendix B table 1 and table 2. The major differences were observed in 
galactosylation. Hence the galactosylation index was calculated using a formula  
G0f/(G1f+G2f X 2)176 in which G0f is   3 4 0 0 1 and G1f is 4 4 0 0 1 and  G2f is  5 4 0 0 1. 
The ratio will give the conversion rate of the most abundant glycoform from its  
agalactosylated states to its possible galactosylated forms.176 If the ratio is higher, it indicates 
lower conversion rate of galactosylation hence an indication of aberrant glycan which can be 
a potential biomarker. The initial study was conducted with a patient with inhibitor and the 
same patient after treating with emicizumab within 4 years gap. The initial study proved that 
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as the age increases the galactosylation decreases in antibody. The galactosylation increased 
in response to the emicizumab treatment. The control plasma sample was selected from the 
HA patient within the age group of inhibitors developed sample. After emicizumab treatment, 
the sample was showing a significant increase in galactosylation, which is comparable to 
control value (Figure 2.9A). Due to the significant differences which we observed in this pair 
of samples, we further studied the additional analysis including NP-HPLC after treating the 
glycan with neuraminidase and derivatized with 2-AB. The increase in G2 peak was 
indicating the percentage of sialic acid-containing sugar in the real sample (Figure2.11 C), 
and the technique was complementing the MALDI-MS analysis. The two-step 
permethylation process was complementing the one-step result and separating the sialic acid 
containing sugars based on their linkage specificities (Figure2.11 D). Both α-2,3 and α-2,6 
sialylations were showing a significant decrease in the pretreatment stage when compared to 
post-treatment and control samples. All these results were complementing each other and 
showing a significant difference in the N-glycome of plasma at the pretreatment stage. The 
results also gave us the MALDI-MS method reliability to distinguish the differences between 
the samples.  
To confirm the observation, we increased the number of sample pairs and performed 
the antibody galactosylation index study. The results did not show consistent variation 
between pre and post treatment samples (Figure 2.9B). We could not conclude the results 
because each pair was varying in the inhibitor value. However, the inhibitor negative(control) 
samples never showed any changes in galactosylation values after treating with emicizumab. 
This observation was proving that the emicizumab treatment itself cannot have any effect on 
galactosylation improvement. We further arranged the data based on the inhibitor 
development and emicizumab treatment. We could see that half of the population with 
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inhibitor development showing higher galactosylation index whereas the inhibitor negative 
and emicizumab treated sample does not show this trend. 
 
Figure 2.9  Protein A/G enriched galactosylation index (G I) of the same person before and after 
emicizumab treatment. 
A) The Galactosylation Index of one patient with high proinflammatory signal with inhibitor development 
before and after emicizumab B) The study repeated with more pair of emicizumab treatment with varying inhibitor 
development and age. C) the galactosylation value arranged based on Inhibitor development and emicizumab 
treatment with a greater number of samples. 
 
2.6.4 Human plasma N- glycome analysis  
In this study, we categorized the relative intensity of the most intense 33 glycoforms, 
and their intensities were plotted using Graph Pad Prism 8.0 software. The data acquisitions 
were made in triplicate to confirm the repeatability of the spectra. The sample, which showed 
a significant increase in the antibody galactosylation index, was again showing a significant 
difference in plasma glycosylation profile. In the pretreatment stage, the glycoforms were less 
galactosylated and sialylated. After treating with emicizumab the glycosylation pattern was 
improved with higher galactosylation and sialylation and became comparable to the control 
sample. In the pretreatment stage, fucosylated glycoforms were higher in amount which get 
decreased after emicizumab treatment. We also observed less amount of complex multi-
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branched structures, which improved after post-treatment. Due to the significant differences 
which we observed in this pair of samples, we further studied the additional analysis 
including NP-HPLC after treating the glycan with neuraminidase and derivatized with 2-AB. 
The increase in G2 peak was indicating the percentage of sialic acid-containing sugar in the 
real sample (Figure2.11 C), and the technique was complementing the MALDI-MS analysis. 
The two-step permethylation process was complementing the one-step result and separating 
the linkage specific differences of sialylation (Figure2.11D). Both α-2,3 and α-2,6 
sialylations were showing a significant decrease in the pretreatment stage when compared to 
post-treatment and control samples. All these results were complementing each other and 
showing a significant difference in the N-glycome of plasma at the pretreatment stage. The 
results also gave us the MALDI-MS method reliability to distinguish the differences between 
the samples. However, we wanted to further confirm the reliability of the method with a 
spiking study using the commercially available serum. The 4 4 0 0 1 standard spiked study 
was showing linearity in their percentage calculation (considering the total glycan intensity) 
from 1800-4500 da mass range. We have used RI calculation of the significant glycoforms 
concerning the most abundant 5 4 1 0 0 glycoform in the plasma. We adapted the RI 
calculation of the spiked standard for the common glycoform present in the human serum 5 4 
1 0 0. The linearity of the percentage was obtained with an R2 value of 0.995. The Linearity 
of RI was obtained with an R2 value of 0.976. 200 picomole spike was out of linear range but 
considered for SD calculation (shown in the bar graph at APPENDIX BF6). All the 




Figure 2.10 MALDI-MS profile of FC N-glycoforms derived from plasma of the same patient before and 
















Figure 2.11The glycosylation pattern differences calculated by different analytical techniques using G2 
sialylation as an example. 
A)The plasma sialylation, identified based on the intensity of each glycoform obtained by permethylation analysis 
using MALDI-MS .B and D) linkage specificity of sialic acid by twostep method based on 54000  B indicate the SI 
value of each sample and D indicate the spectra showing differences in 1 step and 2 step permethylation differences  
wrf 54000 (G2) glycoform.  C) The sialylation percentage was also estimated with NP-HPLC by injecting each 
sample before and after neuraminidase digestion. The percentage of G2 peak was estimated after subtracting the 







Hence, we increased the sample number to relate the changes with inhibitor development. In 
contrast to the previous trial with one pair, the variations were insignificant in larger cohort 
(Figure 2.13) and individual dependent. Hence, we could not relate to the emicizumab 




The relative intensities of individual glycoform were calculated with the intensity of  
5 4 1 0 0 glycoform and compared the result before and after emicizumab treatment in 
inhibitor negative and positive cohort.  We additionally examined the glycoforms based on 
 
Figure 2.12 Changes of N-glycome composition human plasma from different HA patients based on the 
emicizumab treatment and inhibitor development.  
The most abundant 33 glycoforms are compared between different HA condition based on the Inhibitor 
treatment. The relative abundance was calculated with reference to G2S1(5 4 1 0 0). The patient with inhibitors is I+ and 
without inhibitors I-. The changes in glycoforms before and after the treatment is denoted as pretreatment(pre) and post 

































































































































































































































































































































































































































































































































































































































































































































































































































their structural specificity and then categorized each glycoform into the primary type like 
complex, hybrid, and high mannose. The glycoforms were further categorized based on their 
specific sugar composition and linkage. The main categories are based on fucosylation, 
sialylation, and their specificity in linkage as well as the number of existences. The specific 
sialic acid linkage was calculated based on G2 glycoform based analysis using the formula 
SI= G2/ G2S1+G2S2 X 2). The human categorization is listed based on the Appendix B 
table 4 and the statistical correlation is listed in figure 2.13. 
 
Figure 2.13Changes of N-glycome composition based on the types. 
 a) N-glycans based on their major three category complex, hybrid and high mannose. b) based on 
the fucosylation c) based on sialylation percentage d) plasma sialylation index calculated based on G2 
glycoform in plasma using the formula SI=G2/(G2S1+G1S2x2).  
 
2.6.5 Mouse plasma N- glycome analysis 
The plasma glycome analysis was identified similarly like in human and compiled in 
Appendix B table 10. We have identified around 89 different glycoforms by one-step 











varies in their percentage of composition between the stains. The glycoforms were also 
compiled based on the percentage of composition between the stains. We have identified the 
glycoforms similarly in all the three strains. However, the proportions were slightly varying. 
 
Figure 2.14 MALDI-MS profile of N-glycoforms of mouse plasma 
 
In this study, the spectra were more closely matching between their baseline-inhibitor 
development studies in comparison to human trials. The main differences between human 
and mice plasma N-glycome were the presence of α-gal and specific sialic acid, Neu5Gc, 
instead of Neu5Ac in the structure. The specific sugar compositions are also different 
between the species as the difference increases the glycoform signatures also changes 
Mainly, human glycoforms have a more non-fucosylated complex structure than in mice. 
However, we compared the glycoforms similarly as we strategized for human samples. 
The N-glycome pattern changes during inhibitor development and between the strains 
were monitored. The data acquisitions were made in triplicate to confirm the repeatability of 
the spectra. As a background analysis, we compared the HA wildtype mice sample with BL-6 
strain to confirm there is no variation in their plasma glycome during HA condition. Also, 11 
weeks and 15-weeks of HA mice plasma galactosylation were studied to confirm the age-
related and HA related ambiguity of the data. In both the cases of age and HA does not show 
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any significant differences in glycosylation (data is not shown).  In general, only a slight 
change was observed between the strains.  However, the existing differences were more 
evident in BALB/c mice strain than the other two mice strains (Appendix B F17, Figure 
2.15). The differences were not statistically significant (P value < 0.05). The galactosylation, 
fucosylation, and sialylation were also considered for the comparison. The mice sample also 
showed increased inhibitor development (Figure 2.15a). The fucosylation between the strains 
and during the inhibitor development was also monitored (Figure 2.15 b, c, d, e), which did 
not show any significant differences. However, we could see individual-based and strain-
based differences (Appendix B F7). Henceforth, the distinctions were not sufficiently able to 
relate with the inhibitor improvement. The sialylation, both of percentage and the linkage 





Figure 2.15  Mice plasma N-Glycan profile change compiled based on specific sugars 






Figure 2.16  Mice sialylation changes during inhibitor development. 






Figure 2.17  Sialic acid composition analysis between the strains during Inhibitor development 
a) Sialic acid linkage identification differences based on one step and two steps permethylation process labeled with G2S1 and G2S2 b) Sialic acid index calculated based 
on the equation G2/G2S1+G2S2*2 by one step equation in SV129 strain. c) Sialic acid index calculated based on the equation G2/G2S1+G2S2*2 by two steps 
permethylation to distinguish alpha 2,3 and alpha 2,6 linkage analysis in SV129 strain. d) Sialic acid index calculated based on the equation G2/G2S1+G2S2*2 by one step 
equation in BALB/c strain. c) Sialic acid index calculated based on the equation G2/G2S1+G2S2*2 by two steps permethylation to distinguish alpha 2,3 and alpha 2,6 




2.6.6 Human glycopeptide analysis and bottom-up approach 
Plasma glycoproteins were subjected to tryptic digestion by FASP. Then, the 
glycopeptides were enriched by HILIC chromatography and injected into orbitrap. The 
peptides are separated on an RP column prior to connecting to the orbitrap machine, and the 
spectra were further analyzed by peptide fragment fingerprinting (PFF) using pGlyco software 
using Uniprot human database. The identified peptides were quantitated using the PANDA 
software using the unique scan number and retention time differences. Hence we could 
semiquantitate the glycoprotein present in the sample based on the abundance of glycopeptide 






Figure 2.18 The glycoprotein profiling based on the bottom-up approach in each category of plasma protein 
analysis. 
a) inhibitor negative and emicizumab pre-treatment b) inhibitor negative and emicizumab post- treatment. c) 
inhibitor positive pre-treatment and inhibitor positive post-treatment 
 
2.6.7 Microheterogeneity identification at IgG subtyping level 
The site-specific glycan heterogeneity was performed through trypsin-proteolysis 
followed by offline HILIC-enrichment, leading to RP-HR-MS/MS through HCD 
fragmentation. The site-specific assignment of the glycan on the glycopeptide to segregate 
the changes in IgG subtype level, which may give more insight to the functional changes 
happening through the inhibitor development also during emicizumab treatment. The study 
was conducted to provide more insight into the initial observation received at glycan analysis 
during both the cases. The spectra were analyzed using pGlyco software, which detected the 
glycoproteins also provided the glycopeptides and their site specific microheterogeneity. The 
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Annexure Manual characterization was simultaneously carried out on N- and O-glycopeptide 
HCD spectra exhibiting signature fragments of oxonium ions. All observed N- and O-
glycoform compositions are summarized in Table 1. 
 
Figure 2.19 IgG subtyping expression and their microheterogeneity compilation  
a1-d1)The IgG subtyping  based on the bottom-up approach we compared IgG1,2 ,4 based on the 
glycopeptide composition in plasma .IgG3 was below LOD. IgM was also included based on their N-glycopeptide 
composition. a2-d2) The comparison of site-specific glycosylation differences of emicizumab treatment by 
comparing the glycosylation pattern in inhibitor negative samples. a3-d3) The comparison of site-specific 






Figure 2.20 HCD fragmentation pattern of the human IgG subtyping(IgG1,2,3 and 4) 




2.6.8 Mouse glycopeptide analysis (Bottom Up-Approach) 
Plasma glycoproteins were subjected to tryptic digestion by FASP. Then, the 
glycopeptides were enriched by HILIC chromatography and injected into orbitrap. The 
peptides are separated on an RP column prior connecting to the orbitrap machine, and the 
spectra were further analyzed by peptide fragment fingerprinting (PFF) using pGlyco 
software using UniProt human database. The identified peptides were quantitated using the 
PANDA software using the unique scan number and retention time differences. Hence we 
could semiquantitate the glycoprotein present in the sample based on the abundance of 
glycopeptide related to specific proteins in the sample.we could see a significant differences 




Figure 2.21The overall glycoprotein detection and quantitation based on bottom up approach. 
Here in both the strains there is an increase related to IgG and IgM. BL-6 did not the IgG1 expression in all the 




There is a strain-specific trend observed in BL6 and SV129. IgG1 was showing below 
the LOD level in BL6. BALB/c was showing significant improvement in the expression of 
the IgG and IgM. Hence we concentrated on BALB/c strain to study the microheterogeneity 
of the IgG subtypes, detailed in Figure 2.22 .  
 
Here the baseline/inhibitor negative (I-) samples are showing more sialylation, especially 
monosialylation in comparison to the inhibitor developed sample (I+). The result was 
constant in    IgG1,2B and 3 subtypes. The observation was matching with the human 
samples as sialylation and galactosylation are anti-inflammatory glycan relating to antibody. 





Figure 2.22 a1-d1) The IgG subtyping based on the bottom-up approach. 
we compared IgG1,2b,3 and IgM composition based on their N-glycopeptide composition in plasma. IgG3 was below LOD. IgM was also included based on their N-
glycopeptide composition. a2-d2) The comparison of site-specific glycosylation differences of emicizumab treatment by comparing the glycosylation pattern in inhibitor negative 





Figure 2.23 HCD fragmentation pattern of the mouse IgG subtyping. 
IgG1,2,3 and IgM identified based on their subtle differences in their peptide back bone. Here we selected a common glycoform 4 4 0 0 1 for showing similarity and differences in 






FVIII neutralizing antibodies, or inhibitors, happens to 25-30% of severe HA patients receiving 
rFVIII  replacement therapy. The inhibitor development against rFVIII is challenging in the 
treatment perspective, and the causes of inhibitor development is still unknown. It has been 
realized the distinctions in the glycomics can be a biomarker of the physiological changes 
occurring because of the disease progression and in light of the treatment. The recent 
development of understanding glycosylation reveals the importance of glycan in antigenicity 
immunogenicity, physiological changes, disease progression, and personalized medicine 
development. In order to investigate the effect of the host glyco environment on inhibitor 
development, based on our developed MS-based approach, glycosylation pattern of total 
immunoglobulins, and overall glycome changes of the host plasma environment was 
thoroughly characterized in a number of HA patients’ samples, .The advancement in the mass 
spectrometry analyzers, software, and databases helps glycobiologists analyze complex 
biological samples and understand the role of glycans in the natural system. The improvement 
in the analytical techniques, including sample preparation and separation technologies, help 
promote the application of glycobiology in prognostic and diagnostic aspects of diseases. All 
these help us understand the role of glycosylation changes during the inhibitor development 
and build up a corresponding structural library of glycoforms. Here, we identified plasma and 
antibody N-glycome of human HA patients who developed inhibitors and their negative control 
of the average HA population. We could not see any unusual glycoforms related to inhibitor 
development. Hence, we decided to relative quantitate the sugars with respect to the most 
intense glycoform G2S1(5 4 1 0 0 /H5N4A1) in plasma and G1f (4 4 0 0 1/H4N4F1) in the 
antibody. We checked the reliability of the MALDI-MS method by spiking the 4 4 0 0 1 
glycoform to human plasma and calculating the relative intensity with 5 4 1 0 0 glycoforms, 
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which already present in the serum. We also calculated the linearity of the percentage of spiked 
standards. After confirming the reliability of the method to semi-quantitate the glycoform in 
test plasma, we monitored the variability of most intense 33 glycoforms in the plasma. 
Additionally, we categorized the identified glycan based on their structural specificities, and 
their percentage was calculated by summing up the intensities of all the glycoforms within each 
category and divided it with total intensities and converting it to percentage. The sialic acid 
linkage specificities were also calculated with the conversion of G2 glycoform to its sialylated 
forms based on their linkage. We could see some individuals who developed inhibitor showed 
lesser galactosylation, especially reflected in antibody galactosylation index calculation. We 
conducted a background analysis to study the other factors which affect the glycosylation 
changes.  Factors like age, hemophilia A, inhibitor development, blood group, and ethnicity 
were tested to check the N-glycome change. The main elements which influenced the N-
glycome profile were age and inhibitor advancement. Both the cases indicated a huge in 
galactosylation and sialylation decrease of their antibody. Here, we noted the fact that the test 
study must be correlated with the individuals of similar age groups. We additionally analyzed 
the Plasma N-glycome of the inhibitor developed individual who showed a huge difference in 
the plasma and antibody glycosylation pattern at the pre-treatment and post-treatment stage of 
emicizumab treatment.  The examination indicated a momentous change in the glycosylation 
profile after emicizumab treatment and the profile was coordinating with the control HA patient 
with a similar age group and who is inhibitor negative. Hence, we developed the glycopeptide 
analysis strategy with the same patient who showed a huge difference in their IgG sub type-
expression and their site-specific glycosylation pattern (Appendix B F6).    The study was 
complementing with glycocentric results. It was showing a lower number of fucosylated 
glycopeptides and higher number of Sialylated glycopeptides after emicizumab treatment 
which was nearing to the range of control sample.  Subsequently, we broadened the data 
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analysis methodology with the assistance of PANDA software and quantitated the intensity of 
each glycopeptide within the sample, which initially identified with the assistance of pGlyco 
software. We merged both the results and compiled them to calculate the micro-heterogeneity 
at the N-glycosite of IgG’s based on their variability in the peptide sequences. The tandem 
mass spectrometry profile of human and mice IgG subtyping is illustrated with an example in 
figure   2.20 and figure 2.23, respectively.   The quantitation of glycoforms at each site 
demonstrated a noteworthy increment of galactosylation, which specifically happening at IgG1 
and IgG4 antibodies. Thus, the examination was supplementing the glycocentric investigation 
as well as giving an understanding of glycan variety at IgG subtyping level. The IgG specific 
glycosylation differences were also compared with the cytokine analysis of inhibitor developed 
sample, and indicated the over expression of pro-inflammatory cytokine IP-10 in the pre-
treatment stage. The difference is comparable to glycoform changes and reverse back after 
emicizumab treatment. Hence, we increased the number of samples for the analysis to confirm 
our observations.  
We analyzed additionally 6 pairs of HA plasma samples which contains with and without 
inhibitors at their pre and post treatment stages of emicizumab. We analyzed 11 samples of 
Inhibitor developed HA samples and 14 samples of inhibitor negative HA samples. Out of that, 
5 samples were treated with emicizumab in each category. The compiled results were showing 
that the patients who had developed inhibitors were susceptible to have a plasma N-glycome 
differences, especially a decrease in galactosylation at their antibody glycosylation but not 
necessarily reflected in all the cases. However, the patients with glycosylation pattern changes, 
is dynamic and positively responded to emicizumab treatment and became normal after treating 
with emicizumab. Since emicizumab itself is an antibody with glycosylation, we analyzed the 
drug glycosylation pattern to exclude the confusion about the emicizumab interference in the 
change at antibody level. The emicizumab showed a higher galactosylation index value (very 
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less amount of galactosylation) itself, which in turn prove that there is no interference of 
emicizumab in the plasma/antibody galactosylation index value. Hence, it is proving that the 
emicizumab administration is improving the immune aging profile of antibody isolated from 
the plasma of individuals with inhibitors with higher galactosylation index. However, the 
patients without a higher galactosylation index did not show any IgG glycan change relating to 
emicizumab treatment. 
We additionally performed the studies with mice model. Here, we analyzed three different 
strains of HA mice at its 11th week, followed by rFVIII injection to them to induce the inhibitor 
and further isolated the plasma at 15th week to identify the glycosylation changes specific to 
inhibitor development. By this study, we additionally analyzed the interstain glycome 
variations at baseline and inhibitor development stage. Also, we compared the plasma N-
glycome of mice with human by analyzing them using the same methodologies.  The N-
glycome results were showing the differences at individual level. The structural based 
glycoform pattern analysis showed a specific strain related variation are also seen in the plasma 
glycomics and glycoproteomics level. The changes related to inhibitor development were not 
significant. However, the inhibitor development related changes were more evident in BALB/c 
strain when compared to SV129 and BL-6 CD.45.1. in mice model, we could see an 
improvement in IgG and IgM production during inhibitor development. The distinctions were 
measurably critical. The site-specific glycan micro-heterogeneity indicated a decrease in 
sialylation (particularly mono sialylation) at the inhibitor advancement stage (figure2.22). The 
pattern was seen in all IgG subtypes identified (IgG1,2B and 3). 
Further we extended the study of glycocentric and glycopeptide data of human and mice model 
with statistical analysis. Both the results were complementing with each other. However, the 
human data were not statistically significant due to some cases who did not vary their glycome 
profile with inhibitor development. This also indicating how the glycomics and 
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immunogenicity of an individual varies. The observations related to this study was also giving 




3 CHAPTER 3 SITE-SPECIFIC N-GLYCOSYLATION ON THE AAV8 CAPSID 
PROTEIN 
3.1 Abstract 
Adeno associated virus (AAV) is a versatile gene delivery tool, which has been 
approved as a human gene therapy vector for combating genetic diseases. AAV capsid 
proteins are the major components that determine the tissue specificity, immunogenicity and 
in vivo transduction performance of the vector. In this study, the AAV8 capsid glycosylation 
profile was systemically analyzed by peptide mass fingerprinting utilizing high-resolution 
mass spectrometry to determine the presence of capsid glycosylation. We identified N-
glycosylation on the amino acid N499 of the capsid protein. We characterized the overall 
glycan profile for vector produced in 293 cells. Multiple N-glycosylated host-cell proteins 
(HCPs) copurified with AAV8 vectors and were identified by analyzing LC-MS data utilizing 
a human database and proteome discoverer search engine. The N-glycosylation analysis by 
MALDI-TOF MS, highlighted the probability of AAV8 interaction with terminal 
galactosylated N-glycans within the HCPs. 
3.2 Introduction 
Adeno associated virus (AAV) is a depend parvovirus that developed as a gene 
therapy vector for treating a variety of genetic disorders and acquired diseases. Lack of 
pathogenicity, low immunogenicity and differential tropism to multiple cell type make AAV 
a versatile gene delivery system194. Lack of pathogenicity, low immunogenicity and 
differential tropism to multiple cell type make AAV a versatile gene delivery system. This 
non-enveloped virus is approximately 25 nm in diameter and has a unique linear single-
stranded DNA genome195–197. It has a 4.8kilobase genome flanked with two copies of 145 bp 
inverted terminal repeats. The two AAV open reading frames comprised of rep and cap gene. 
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Rep gene encodes four different replicating proteins (Rep78, Rep 68, Rep 52 and Rep 40) and 
cap gene encodes the three VPs (VP1, VP2 and VP3) which are translated from different start 
codons at the same ORF198. AAP is also identified, which facilitate AAV packaging199,200. 
The three VPs are expressed from the same ORF region by alternating splicing of mRNA, 
hence contains a common C- terminal domain. In spite of the common region at C-terminal, 
VP1 contains extra N-terminal sequence contrasted with VP2 and the VP2 contains an extra 
amino acid sequence at its N-terminal, contrasted with VP3 201 . Capsid proteins of AAV 
assemble to form  a T1 icosahedral virion with sixty units of VP1, VP2  and VP3  in a ratio of 
1:1:10 202,203. The structural studies of the intact capsid with cryo-electron microscopy, X-ray 
crystallography and image reconstructions revealed that the N-terminal regions of VP1 and 
VP2 got enfold inside the capsid structure204,205 ; consequently, blocked off from their 
binding activities 206.Hence, the common C-terminal VP3 region(~530aa) determines the 
receptor binding of the virus. To date, around 13 distinct serotypes of AAV has been used 
widely for gene therapy207. AAV serotype display 55-99% sequence homology,208,209 
however, are different in their tissue tropism210–212. Amino acids in a particular serotype 
determines its tissue specificity213. AAV serotype 8 (AAV8) was isolated from rhesus 
monkey  widely  known for its high performance in  liver transduction205. It is a vector of 
choice for the treatment of genetic disorders utilizing hepatocytes as the target organ.195,214–
219. AAV8 is generally utilized in quality treatment research for the hemophilia A, hemophilia 
B, familial hypercholesterolemia and glycogen storage disease type II58,220–225.AAV8 
accounted for  crossing blood-cerebrum obstruction subsequently transferred the genes in 
cardiac and skeletal muscle in hamster and mice226. 
Typically, non-enveloped viruses are less commonly glycosylated. However, the 
capsid protein of hepatitis E, fiber protein of adenovirus-2 are glycosylated213,227. Such 
glycosylation has a drastic impact on viral properties especially regarding tropism. Moreover, 
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glycosylation may affect the immunogenicity of viruses if it is part of the capsid components. 
Site specific modifications of capsid proteins like tyrosine phosphorylation is reported to 
promote a ubiquitination and degradation of AAV2 capsid protein leading to decreased 
tropism228,229. Similarly, AAV tropism may have been varied by the presence of glycosylation 
on the capsid protein. To date, AAV has widely been deemed a non-glycosylated DNA virus. 
Here we presented direct evidence of N-glycosylation on the NNS499-501 AAV8. 
3.3 Experimental design 
AAV has a complicate capsid structure consisting of multiple units of VP1, VP2 and 
VP3.  Figure 3.1 showed the flowchart of our methodology for characterizing AAV capsid 
glycosylation. This comprehensive approach incorporates in purification of rAAV from 
media (as in a secreted form) and intracellular virus.  The purified virus were separated  on 
SDS-PAGE and differential glycoprotein staining technique used to identify the 
glycoproteins in the mixture. The purity of the mixture further checked by Coomassie 
staining. The differential fractions were taken for the N-glycan analysis using MALDI-MS. 
The viral proteins were used for site specific glycosylation analysis by HCD and CID after 
PNGase F mediated 18O labeling using CID analysis using HR-MS.  Both HCP and AAV 
capsid glycosylation are investigated by analyzing with AAV capsid proteome database 




Figure 3.1 The general workflow of deciphering the glycosylation identification in AAV8 sample. 
Intracellular or secreted AAV8 were processed parallelly and analyzed using multiple techniques. A) The 
glycoproteins are visualized on the SDS-PAGE gel by glycoprotein labeling. B) N-glycan analysis using MALDI-MS 
identifies the type of glycosylation. The peptides generated by Glu C or trypsin digestion were enriched using HILIC 
cartridges. The deglycosylation of enriched glycopeptide in the presence of H218O to label the glycosite with 18O.C) The 
samples are injected to LC-MS and using the database of AAV8 VPs, the N-glycosite was identified  D) The same data is 
searched against the human database to find out the HCPs interacted to AAV8 from host cell system. 
3.4 Materials and Methods 
The AAV8 vector was expressed using HEK 293 cell line and purified by density 
gradient centrifugation. Both secreted and intracellular AAV8 were purified from same AAV 
batch using differential purification from Sol Sherry Thrombosis Research Center (Temple 
university, Philadelphia, PA). The alkylating agent, iodoacetamide (IAM) and reducing agent 
DTT (dithio thritol) were purchased from Acros Organics (Morris Plains, NJ, USA).  30% 
acrylamide Bis -acrylamide solution obtained from Bio-Rad. Glycoprotein detection kit, BCA 
protein assay kit, and protein markers purchased from Thermo Fischer. Sequencing grade 
endoproteases trypsin and Glu C were purchased from Promega (Madison, WI, USA). 
Peptide-N-glycosidase F (PNGase F) bought from New England Biolabs (Ipswich, MA, 
USA). Absolute alcohol purchased from Decon Labs, Mass spec grade ACN was purchased 
from J.T Baker chemicals (Avantor Performance Materials, Inc., Center Valley, PA, USA). 
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Click Mal (5µ, 100 Å), the HILIC material is purchased from ACCHROM (Beijing, China). 
Microcon-10 kDa(YM-10,0.5ml) centrifugal filters obtained from Millipore. The 3M Empore 
C8 disk purchased from Bioanalytical Technologies (St. Paul, MN, USA). Urea, SDS, 
sodium cyanoborohydride, anthranilic acid (2AA), Tris base, tris HCl dihydrogen monoxide) 
and H2
18O (97% 18O) were purchased from sigma-Aldrich (St. Louis, MO). TEMED, 
ammonium persulphate, ethyl acetate, urea, sodium dodecyl sulfate (SDS) ammonium 
bicarbonate (ABC)and other reagents were also purchased from Sigma-Aldrich (St. Louis, 
MO). 
The samples were concentrated using speed vac to minimize the water content, and 
the proteins were precipitated using ice-cold ethanol. The protein pellet, dissolved in urea 
buffer (6M urea in 0.1 M Tris/HCl, pH 8.5) the concentration of the protein mixture was 
calculated using BCA protein detection kit according to the kit protocol using urea buffer as a 
blank. The protein mixture was denaturated by adding 1M DTT (100:1 v/v) in the reaction 
mixture and heated at 95 °C for five minutes and cooled and added around 1M IAM in the 
ratio 50:1, v/v at 37 °C for 1h. The reduced and alkylated samples desalted, and buffer 
exchanged using 50mM ammonium bicarbonate pH 8.0 buffer and aliquoted to three parts.   
SDS–PAGE and visualization of glycoprotein band and in-gel digestion. The capsid 
proteins of AAV8 particles were separated (around 10µg of protein) on 4- 12 % Bis-tris by 
SDS-PAGE. The glycoprotein detection kit purchased from thermo fischer scientific (catalog 
number:24562) was utilized to stain the glycoprotein band concretely on the SDS-PAGE gel. 
The glycoprotein staining was performed according to the manufacture’s protocol. In 
summary, When the protein gel treated with periodic acid (oxidizing reagent), glycols present 
in the sugar moieties of glycoproteins are oxidized to aldehydes. During this reaction, a 
magenta pink band is developed wherever the glycans are present. Rest of the protein remains 
invisible. The gel was further stained by Coomassie blue to visualize the protein bands. The 
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gels were stained exclusively with Coomassie blue, for the in-gel digestion and further mass 
spectrometric analysis. The corresponding bands identified from glycoprotein staining, was 
excised for in-gel digestion referred to pre-established protocol. The 10µg of PNGase F 
treated samples were loaded adjacently with the same amount of control samples to compare 
the protein profile and band shift after de-N- glycosylation230. 
3.4.1 N-glycan analysis 
 The intracellular and secreted AAV8 (~100µg each) were treated with ~50U of 
PNGase F. The sample was incubated at 37° C for 16. The released released N-glycans were 
separated by ethanol precipitation. The precipitated proteins were separated by centrifugation 
and the supernatant contains the released glycan. The N-glycans were dried using vacufuge 
and tagged with anthranilic acid according to the previously published protocol (30, 31). An 
excess of labeling agent got removed by ethyl acetate wash. The 2AA-labeled N-glycans 
were reconstituted in MS grade water and drop dialyzed on nitrocellulose membrane filter 
0.05µm VMWP in water for 30 mins. The dialyzed samples were concentrated to 1 µl in a 
Speed-Vac Vac and commixed with 1µl of a saturated solution of DHB matrix (70% ACN in 
dihydrogen monoxide). A 1µl of the sample spotted on the MALDI- plate and allowed to dry 
and form crystals. The plate is installed in the instrument, and the sample spot was 
bombarded with 32.5% high energy laser power utilizing a Bruker Daktronics MALDI-TOF-
MS (UltrafleXtreme, Bruker Daltonics; Bremen, Germany) system to acquire all the MS 
spectra. The data acquisition was in negative ionization using reflectron mode. The spectra 
were generated with the uniform signal intensity. The glycoworkbench 
(http://code.google.com/p/glycoworkbench/)was availed to annotate the m/z values in the 
spectra and give the structural identification cognate to the human system. The MS/ MS 
spectra of the major glycoforms, confirmed the structures. The tandem mass spectrometry 
was performed by ‘LIFT’ mode (negative ionization) bombarded with high energy laser. The 
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pattern of fragmentation was attesting the structure and composition of each oligosaccharide 
moiety. The relative intensity of the glycan masses calculated by Flex Analysis software 
(Bruker Daltonics) to produce the final spectra. 
3.4.2 Peptide mapping analysis 
 The third aliquot of the sample around 100µg was treated with sequencing grade 
trypsin in an enzyme protein ratio of 1:50 (w/w) and incubated at 37ºC for 16h. The reaction 
was ceased by keeping the tube in a boiling water bath for five mins. Approximately 50µg of 
the peptide was saved for further analysis and the other aliquot was digested with Glu C in an 
enzyme protein ratio of 1:50 (w/w) and incubated at 37ºC for overnight. These samples were 
further subjected to glycopeptide enrichment, HCD analysis, N-glycosite occupancy, and 
intact glycopeptide analysis. 
3.4.3 Glycopeptide enrichment 
The Click Mal, a HILIC media was used to enrich the glycopeptide from the virus 
sample according to previously published method with minute modifications231.An in-house 
HILIC-SPE column was prepared by inserting a small C8 disc into a 200 μL tip. Around 6 
mg of HILIC media was weighed out and washed with pure ACN and then transferred to the 
microtip to make the HILIC-SPE column. The column was then washed by passing with 100 
μL of 10% ACN containing 0.1% FA and then equilibrated with binding buffer (80% ACN 
containing 1.0% FA) for 3-5 times. The proteolytically (trypsin and trypsin followed by Glu 
C) digested peptides were dried and resuspended in 10μL of binding buffer and introduced to 
the microcolumn and allowed to bind to the column for 10 mins at room temperature. The 
unbounded peptides were washed off by passing 100µl of binding buffer and repeated the 
step for five times. The column bound glycopeptide were then eluted out utilizing 200μL of 
the elution buffer (EB; dihydrogen monoxide contacting 1.0% FA). The HILIC-enriched 
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glycopeptide were then dried using speed vac and resuspended in 5 μL of 2% ACN 
containing 0.1% FA in H2O and injected to the nano-LC orbitrap MS-system.  
3.4.4 N-glycosite detection (18 O labeling) 
 A fraction of (approximately 40µg) proteolytic enzymes treated intact peptides were 
subjected to glycosylation site identification.  The digest was thoroughly dried in a speed Vac 
and resuspended in 10µl of ABC buffer (ammonium bicarbonate prepared in H2
18O, pH 8.0). 
Asn linked N-glycans was removed by 1µl of PNGase F (50U), and the mixture was 
incubated at 37 °C for 16 h.  
3.4.5 Peptide analysis by LC−MS/MS 
The intact, enriched and 18O labeled peptides were dried and resolved in 2% ACN 
containing 0.1% FA. 5 μL of the intact glycopeptides or 3 μL of the 18O-labeled N-
deglycosylated peptides were injected to Dionex Ultimate 3000 RSLC nano System (Thermo 
Fisher, Waltham, MA, USA). The LC system has Nano Trap column packed with Acclaim 
Pep Map100 C18 (2 cm × 75 μm I.D, 3 μm). The flow rate was adjusted to 5 μL/min with 
mobile phase A (2% ACN, 0.1% FA) for 10 min for sample trapping, then washing and 
followed by the separation on C18 Column (15 cm × 75 μm I.D., 3 μm, 100 Å). The 
separation was accomplished by a 120 mins linear gradient (3 to 40% Mobile Phase B (80% 
ACN, 0.1% FA) at the flow rate of 300 nL/min. The column was washed for 10 min with 
99% B and reconditioned with 1.0% B for 5 mins for the next run232. 
 Elite mass spectrometer with the spray source(1.6kV) of (Thermo Fisher) LTQ-
Orbitrap is integrated with the LC system. The LTQ Orbitrap mass spectrometer was adjusted 
to data-dependent mode with an alternating MS1 and MS 2 acquisition. The Orbitrap mass 
analyser MS scan was performed with the mass range, m/z 400−1600; resolution at m/z 400, 
6×104; automatic gain control target (AGC), 106 ions; maximum ion accumulation time, 50 
ms. The MS1 ions of the ten most intense species, were subjected to MS/MS CID in the ion 
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trap analyser. The MS/MS scan model was performed in centroid scan model. CID-MS 
parameters were set by giving default charge state as 3, activation Q was 0.25 with an 
activation time 5.0 ms and isolation width was set to m/z 3.0. The normalized collision 
energy was set up to 35%. 
 For the HCD mode, orbitrap analyser was set at a resolution of 15,000 at m/z 400; 
AGC was 10,000 ions, and maximum ion accumulation time was increased to 200 ms. All the 
CID parameters were set remained same except the parameters of activation time which set 
upto 0.5 ms and the isolation width of m/z 2.0. The /MS parameter was performed at 27% 
NCE. MS/MS Data Interpretation For LC−CID−MS data analysis of deglycosylated peptides, 
pFind software 2.8 (http://pfind.ict.ac.cn)was used 233,65. FASTA sequence of AAV8 
sequence were created using the already published sequence of VP1, VP2 and VP3(13). 
Tolerance of peptide mass was set to 20 ppm, and the fragment ion tolerance was 0.5 Da. 
Since the proteins were reduced and alkylated the fixed modification was 
carboxyamidomethylation of cysteine (+57.021 Da), and the variable modifications were 
deamidation for N and Q (+0.984 Da) and oxidation of methionine (+15.995 Da). Two 
maximum missed cleavage sites were selected for trypsin (KR-C) and Glu C (DE). For the 
glycosite identification: CID−MS/MS data analysis of 18O- labeled de-N-glycosylated 
peptides were performed by setting the precursor ion mass between 350 and 6000 Da. Along 
with above described search parameters, we have included N-deamidated with 18O (+2.988 
Da) and specified as variable modifications with FDR < 0.1. The theoretical glycopeptide 
masses were obtained from the online server protein ExPAsy 
(http://web.expasy.org/peptide_mass)   and GlycoMod tool (http://web.expasy. 
org/glycomod) possibility of glycosylations and sites of glycosylation by consensus sequence 
predicted by NetNglyc (http://www.cbs.dtu.dk/services/NetNGlyc) were further related 
manually to the data which we obtained from N-glycan independent analysis234.   
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3.4.6 HCP identification by LC-MS/MS analysis 
 In the MS analysis of the peptide mapping data were sanctioned to detect the HCP 
glycoprotein present in the AAV 8 sample. The multiple protein identification in the sample 
was performed by Proteome DiscovererTM (Thermo Fischer Scientific). Human database was 
downloaded from UniProt (http://www. uniprot.org) which can also detect even the process 
induced, common contaminant proteins like keratin. The database was edited by adding 
AAV8 VP3 which is the most abundant protein in the sample. AAV 8 VP sequence was 
taken from a previously published article and fasta files were generated and uploaded to the 
search engine 231,235,236. The database was used to identify the other proteins apart from 
AAV8 in the sample especially host cell proteins (HCP) which is interacted to AAV 8. The 
precursor mass tolerance was set to 20 ppm and fragment mass tolerance was set to 0.8 Da. 
The data was generated from trypsin digested sample hence the enzyme entered used for the 
given search was trypsin. All the possible dynamic modifications like glutamine 
pyroglutamine conversion on any N- terminus(-17.027Da), methionine oxidation (+15.995 
Da), acetylation (K, +42.011 Da) and deamidation (N, Q/+0.984) were considered in the 
specification. Since we have performed 18O labeling, we included specific deamidation 
(N/+2.988 Da) also. Static modification is set to carbamidomethyl (C/+57.021 Da). Strict 
target false discovery rate was set to 0.01-0.05.  
3.5 Results: 
3.5.1 Detection of glycosylation by SDS-PAGE  
The AAV8 samples were denatured and separated on 12% SDS-PAGE. The capsid 
proteins, VP1,VP2, and VP3, are segregated in the region of 50-100kDa determined by the 
protein marker237,238 . We have identified magenta pink colored feeble bands in between the 
VP region indicated the VP glycosylation (figure 2 a). A dark magenta pink band was 
observed around 100kDa in the AAV8 secreted sample suggested the presence of host cell 
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glycoprotein in the sample. The VP glycosylation staining showed similar results in the 
region of VP2 and VP3. There was some additional glycoprotein band observed around 
100kDa in secreted AAV8. The gel was further stained by Coomassie brilliant blue to 
visualize the total protein profile on the SDS-PAGE (figure3.2 b). Side by side analysis of 
AAV8 secreted sample and AAV8(secreted) subjected to PNGase F digestion, confirmed the 
type of VP glycosylation on the capsid proteins (figure 3.2). We could likewise affirm some 
extra bands vanished in PNGase F digested sample compares to the host cell proteins 
promote validation of N- glycosylation in the given sample (figure 2C). The difference in 
glycoprotein bands from intracellular and secreted AAV8 can supplementally designate the 
different intermolecular interactions of VPs with various glycoprotein which may copurify 
with AAV particle in the purification procedures. We have seen multiple protein bands which 
are unrelated to the capsid proteins in protein profiling. Some of them are found to be heavily 
glycosylated and stained positively by glycoprotein staining procedure. The host cell proteins 
can copurify along with the VPs if they have a similar molecular weight which may lead to 
ambiguity in the analysis. Hence this technique has considered only for preliminary 
examination, and peptide mapping designates protein identity of the HCPs by high-resolution 
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LC-MS with the aid of database search.
 
Figure 3.2 AAV8 Glycosylation detection on SDS-PAGE by differential staining method. 
AAV8 derived from the cell(intracellular), and media (secreted) are separated on SDS-PAGE a) showed the 
protein bands visualized after glycoprotein staining. Glycosylated bands were observed near the VP region (55-100 kDa). 
The non-related VP bands (~200kDa, and 110kDa) can be an indicator of glycosylated HCP in the sample. Gel ‘b’ is 
identically tantamount gel stained with Coomassie brilliant blue to visualize the whole protein profile. c) is an independent 
gel running after de-N- glycosylation along with its reaction control. (+ and – betoken the addition of PNGase F). The loaded 
protein amount kept constant. The gel profile is after Coomassie staining. The glycosylated bands between the VPs have 
vanished after PNGase F treatment. Some weak bands in the VP regions in-between the main VP bands were mildly stained 
by the glycoprotein staining which may be cognate to VP glycosylation. 
3.5.2 The N-glycan profile of intracellular derived AAV8 and media derived 
AAV8 
 The intracellular and secreted AAV8 samples, parallelly treated with PNGase F for 
N-glycome analysis. The N-glycans of corresponding samples were isolated and tagged with 
2 Aminobenzoic acid (2-AA) and spotted on MALDI-plate to provide unique spectra of the 
N-glycan profile for corresponding samples.  The resulted spectra were smoothed, and 
baseline subtracted. The MS/MS of high-intensity peaks were performed in ‘Lift mode’ to 
confirm the monosaccharide composition. The peak annotation is done using the 
Glycoworkbench software after verified by CFG database (figure 3.3). Since the previous 
protein analysis suggested the presence of host cell glycoproteins in the sample, the N-
glycosylation profile of the secreted and intracellular AAV8 cannot be directly related to the 
98 
 
AAV8 capsid protein (VP). However, the high intensity of secreted AAV8 glycan spectra is 
correlating with the glycoprotein detection data and suggest the possibility of AAV8 
interaction with host cell glycans.  We could identify that the majority of the N-glycans in the 
sample were terminally galactosylated, indicating the capsid protein affinity to the terminally 
galactosylated HCPs. The glycoforms are identical in structure in both samples (Appendix C 
Table 1). The difference in proportion and intensity of each glycoform is noticeable 
(Figure3.1).
 
Figure 3.3 MALDI- MS spectra of 2-AA derived N-glycan in negative mode [M−H] −. 
a) the whole glycome profile of intracellular AAV8 b) The whole glycome analysis of secreted AAV8. The most 
intense peaks from both the spectra (m/z2110.234,1948.088 ,2401.633,1832.984 were further confirmed by MS/MS 
fragmentation spectra in MALDI-TOF MS in lift mode (supplemental figure 2). The uniform spectra were generated by 
keeping constant analytical parameters and sample amount. 
3.5.3 The glycosylation analysis in peptide level 
         The Peptide mass fingerprinting data by orbitrap was performed by multiple 
ways, including in-gel and in-solution digestion. In-gel digested data showed very less 
coverage (less than 10% sequence coverage). Hence, we tried to perform in-solution 
digestion which increased the coverage to 77-85%. The sequence search by the ‘GlycoMod’ 
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tool suggested that AAV8 has six putative sites for N- glycosylation; five are within the part 
of common region of VPs (NGT263-265, NLT338-340,NNS499-501 and NQS665-667 and an exclusive 
site near to the N- terminal (NLS 14-16) region of VP1 (figure 4). Hence, we focused the 
search of glycopeptide variants in HCD and CID spectra to find the glycosylated sites.  
 To characterize the N-glycosylation site of capsid proteins, we focused on HCD mass 
spectra of tryp/Glu C digested proteins of intracellular and secreted AAV8. The peptides 
were indicating N-glycosylation on multiple peptides at different retention time with the 
marker fragment ions in MS2 spectra (oxonium ions at m/z 366 (HexHexNAc1,1 +), m/z 292 
(Neu5Ac, 1+), m/z 204 (HexNAc, 1+), m/z 162 (Hex, 1+), and sub fragment ions at m/z 186 
(HexNAc- H2O, 1+), m/z 168 (HexNAc-2H2O, 1+), m/z 138 (HexNAc-2 H2O−CH3OH, 1+), 
m/z 126 (HexNAc-2H2O−CH3COH, 1+), and m/z 274 (Neu5Ac− H2O, 1+)).The analysis can 
also refer to O-glycosylation, but the spectra was not confirming any O-glycosylation. To 
enhance the intensity of detected glycopeptides, which is covalently linked to multiple 
glycoforms, the HILIC-enriched glycoptides were deglycosylated by PNGase F in the 
presence of 18 O water. Thus, the weak signals generated from scattering the peptides over the 
reverse phase column because of differential compositions of glycoforms covalently linked to 
the same peptide is eliminated. Furthermore, the signals from peptides derived from host cell 
proteins (HCPs) is hindering the glycopeptide signals. Therefore, we switched to CID 
analysis of the deglycosylated peptides, which have equal chance of vapour ionization in the 
mass analyser as non-glycosylated peptides. The shift of 2.988 Da (O18-deamidated Asn) in 
the MS spectrum clearly confirms to the glycosylation site.   
             We could withal confirm the glycosylation in capsid protein on N499, 
identified and attested by MS/MS analysis. Since the amount of glycosylated peptide was 
below the LOD, in normal enzymatic digest (trypsin and Glu C as well as trypsin alone) 
analysis, trypsin and Glu C trials were failed to pick up the glycopeptides; but improved the 
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coverage 77.0% to 81.38%. The glycopeptide was identified from media isolated AAV8 
sample, only after HILIC enrichment. The entire experiment was repeated with an 
independent batch of AAV8 and the result was reproducible (Appendix C F1). These sample 
showed the presence of glycosylated as well as non-glycosylated peptide. As enrichment 
process may cause the loss of non-glycosylated peptide, we could not quantitate the 
percentage of glycosylation. Repeatability of our results fortifies the current discovery.  
 
 
Figure 3.4: Glycosite identification on AAV 8 capsid protein. 
Two distinct tandem mass spectra of peptide sequence ‘VSTTTGQNNNSNFAWTAGTK’ of the AAV8 capsid 
protein (in the common region of VPs).  
Characterized CID spectra of glycopeptide after 18O mediated digestion. A) the position of de-N-glycosylated 
asparagine 499(18O-incorporated aspartic acid) was attested by mass increment of 2.8547 Da (theoretical mass difference 
2.98 Da) to the series of b and y ion (the precursor ion mass: m/z 2101.93193). B)  The position of Non glycosylated 
asparagine 499 in the sequence was confirmed by y12/b8 ions (the precursor ion mass: m/z 2099.0766 Da). The highlighted 
ions (marked with a star) shows the mass differences in both the spectra. y11+ (highlighted) ions are same in both the 
spectra. C) Capsid protein amino acid sequence and possible N-glycosylation sites predicted by NetNglyc software based on 
the consensus sequence (NXT/S, ‘X’ can be any amino acid except proline). Different N-terminal sequence of VP1, VP2 and 
VP3 are marked in the sequence. The glycosite peptide is marked on the sequence. 
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Consensus sequence search of N- glycosylation NXT/S through GlycoMod revealed 6 
possible glycosite; N14LS, N263GT, N338LT, N385GS, N499NS, and N665QS (figure 4C).  Aside 
from N14 every single other site is in the common capsid proteins. N14 , reported to be in the 
N-terminal domain and looped inside the capsid assembly206. Hence, the analysis for 
glycopeptide were mainly focused on VP3 because of the presence of all feasible 
glycosylation sites and abundance of peptide in the total sample.  
             We also identified various host cell glycoproteins in the sample that were 
copurified with AAV8. The virus vector isolated from the media and cells were analyzed 
utilizing proteome discover1.4 software. The search result was listed in Table3.1. We listed 
only the proteins showed more than 20% coverage. We could identify fifteen HCPs from 
intracellular AAV8 and thirteen HCPs from secreted AAV8 (Figure 3.5). Most of the 
proteins identified by the data search were heavily N-glycosylated. The presence of Lam R, 
G3BP (galectin 3 binding protein), fibronectin etc., are found to be the common proteins in 







Figure 3.5 HCPs identification in intracellular and secreted AAV8 using Proteome Discoverer1.4  
The protein indicated over 20% sequence coverage is recorded in Table 1 and compared between differentially 










Secreted AAV8 Intracellular AAV8 
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Table 3.1: HCP identification using Proteome Discoverer1.4 
UniProt 
Accession No 
 Protein identity  
Coverage% 
Intracellular Secreted 
P62158 Calmodulin (Human) 38.93 ND 
O60637-3 Tetraspanin-3 (Human) 34.39 ND 
P06748-3 Nucleophosmin (Human) 34.36 ND 
Q92542-2 Nicastrin (Human) 33.53 ND 
Q9BY67-2 






membrane glycoprotein 2 (Human) 
32.44 
ND 
Q5ZPR3-3 Isoform 3 of CD276 (Human) 29.61 ND 
P11279 
Lysosome-associated 




Lysosome membrane protein 
2  (Human) 
28.24 
ND 
Q13740 CD166 (Human) 27.1 ND 
















Q13162 Peroxiredoxin-4 (Human) 21.03 ND 
P12268 
Inosine-5'-monophosphate 
dehydrogenase 2 (Human) ND 
19.65 
P68363-2 Tubulin alpha-1B chain ND 41.49 
P01834 








Ig kappa chain V-III region 
(Human) ND 
31.19 
P23142-4 Isoform C of Fibulin-1 ND 30.75 
P23142 Fibulin-1 ND 30.3 
Q16222-2 
Isoform AGX1 of UDP-N-
acetyl hexosamine pyro phosphorylase ND 
29.31 
P07437 Tubulin beta chain ND 26.35 
P0CG48 Polyubiquitin-C ND 23.65 
Q04837 
Single-stranded DNA-binding 
protein, mitochondrial ND 
22.3 
P35556 Fibrillin-2 (Human) ND 20.81 




Host cell glycosylation plays significant roles in AAV viral entry, tissue selection, and 
infectivity. These roles are partly documented by identified AAV receptors, which are often 
glycans. Heparin sulphate, N-glycans terminated with galactose, and sialic acid are the well-
known primary receptors of various AAV serotypes.212  The essential receptor for AAV2 and 
3 is Heparan Sulphate Proteoglycan (HSPG). AAV1 and 5 utilize N-linked sialic acid cell 
surface receptors for the viral entry while AAV9 utilizes N-linked galactose.224 The essential 
receptor of AAV4 is known to be O-linked sialic acid in the host cell surface.225 Likewise, 
AAV6 uses N-linked sialic acid and HSPG. The secondary receptor of AAV8 is a laminin 
receptor (Lam R), a host cell surface glycoprotein.239  
However, AAV glycosylation status is still unclear. The initial study of AAV 
prototypes was based on AAV serotype 2, which was not perceived to have any glycosylation 
even though the primary sequences of capsid proteins suggest presumptive glycosylation sites 
on capsid protein.237Since there are many AAV serotypes that have been identified and 
characterized, some AAV serotypes have notable differences in terms of in vivo 
performances and secretion efficiency, which are characteristic feature that may have been 
influenced by glycosylation.  Here we utilized the high-resolution mass spectrometry with 
well-designed sample preparation to explore potential glycosylation in AAV8 capsid protein. 
We designed this study to enrich the glycosylated AAV from both intracellular and 
secreted AAV8. It is anticipated that AAV8 may be glycosylated in the secretion pathway by 
the glycosylation machinery.  The SDS-PAGE specific staining (figure 2a) indicated to 
glycoproteins in the AAV8 capsid proteins. The capsid proteins VP1,VP2 and VP3 have 
molecular weights around 87 kDa,73 kDa and  60 kDa, respectively213. The darkly stained 
glycoprotein bands around 100 kDa in the profile was suggesting the presence of copurified 
host cell glycoprotein in the secreted AAV8 sample. There are feeble glycoprotein bands in 
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the capsid protein region(55-100kDa) indicated capsid protein glycosylation.  The PNGase F 
treated sample did not demonstrate any glycoprotein in the protein profile, which affirm the 
presence of N-glycosylation in the capsid proteins.  
The N-glycome analysis of intracellular and secreted vectors confirmed the presence 
of N-glycosylation in the overall viral sample. Even though the examination intended to 
separate and characterize the N-glycans derived from purified capsid proteins, the parallel 
analyses confirmed the presence of host cell glycoproteins in both samples and diverted the 
outcome significantly connecting to the HCP glycosylation. The N- glycan profile of 
differentially purified sample demonstrates the distinction in extents and limit of 
glycosylation. Although the method is not an absolute quantitative technique yet, the N-
glycosylation pattern in terms of proportion and MS profile is unique for each differentially 
purified virus and showed the presence of high amount of N-glycoforms in secreted AAV 
virus. The result correlated to SDS-PAGE gel examination for glycoprotein detection. The 
glycoform analysis indicates that both the AAV samples contain high galactosylated species 
as the major sugar. The protein ID verified the presence of G3BP (Galectin 3-binding 
protein), a heavily galactosylated glycoprotein backup the affinity of AAV8 to the galactose 
sugar, which is reflected in the N-glycan analysis. The interaction of G3BP with AAV-6 has 
been reported earlier.229 This galactose binding protein was eluted at the same region of 
darkly stained glycoproteins in the SDS-PAGE gel. Both AAV samples showed different 
glycosylation profiles that may arise due to the variation in the host cell glycoprotein present 
in each sample. 
 
 The peptide level investigation of virus samples utilizing high resolution mass 
spectrometry confirms the previously mentioned observations. The HCD information of in-
gel processed 70 kDa band (which can be a glycosylated VP3) demonstrated signature 
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masses of carbohydrate moieties covalently linked to AAV peptides. However, HCD spectra 
alone was plausible, and the sequence coverage was very less for further investigation (data 
not given)228. To enhance the coverage, as well as the signal intensity of glycopeptide, we 
performed in-solution digestion followed by HILIC enrichment of glycosylated peptides. The 
HCD spectra of HILIC-enriched samples were suggesting many glycopeptides with signature 
fragments with enhanced signal intensities. Although HILIC enrichment increases the 
probability of fishing glycosylated peptides and thus enhance the glycopeptide detection, the 
intensity of a glycopeptide is far low compared to non-glycosylated peptide. Also, HCD 
experiments showed the presence of many unrelated glycopeptides. Thus, to overcome the 
analytical challenge of detecting the viral peptides and avoid the column-based segregation of 
modest glycopeptides related to the capsid proteins, the N-glycan release was performed in 
the presence of H218O, by which the glycosylated site is labeled and localized easily.  
The glycosylation was found on the overlapping peptide of trypsin and double 
digested sample, VSTTTGQNNNSNFAWTAGTK at NNS499-501 of AAV8 capsid proteins. 
The amide (CO-NH2) group of N-glycan linked N499 is deamidated to carboxylic group (CO-
OH) thus to D499 with 
18O atom in H218O media. This replacement causes an increment of 
+2.98 Da, which is easily identified by mass spectrometry.  The mass differences of 2.8547 
Da from y12+-y17+ ions in the MS/MS spectra (figure 4) clearly distinguished the glycosylated 
peptide from the most abundant non-glycosylated peptide. The experiment was repeated with 
another batch of AAV8 and CID spectra showed a reproducible spectrum with the mass 
difference of 3.03 Da from y12+-y17+ ions in the MS/MS spectra (figure S1). The 
fragmentation pattern of non-glycosylated peptide does not show any mass differences in 
y12+-y17+ ions as shown in the deglycosylated peptide tandem MS spectrum. The CID 
fragmentation has confirmed the presence of negligible amount of glycosylated variant of 
AAV8. The enormous amount of non-glycosylated peptide substantiates the majority 
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population of AAV8 are non-glycosylated virus. The superlative method of glycopeptide 
enrichment and analytical strategy could identify the inadequate glycosylated variants of the 
capsid protein, indicating the minor population of glycosylated AAV8. Repeatability of our 
results fortifies the current discovery. Since glycosylation has the essential biological 
functions such as cell recognition, ingression, and immunogenicity, this discovery is 
significant for studying the effect of AAV8 N-glycosylation for manipulating their 
therapeutic application in various monogenic disorders. From here, further research focus is 
in need.  
The enormous glycopeptides present in the peptide mapping data was unrelated to 
virus capsid protein. The component proteins apart from major VPs detected in current 
samples were also a censorious subject to be considered. Since the expression system was 
HEK-293 cells, we searched the generated CID spectra of AAV8 peptides against combined 
fasta files of the human protein database and AAV8 VP3. In summary, the LC-MS/MS 
peptide map fingerprinting recognizes the best matching protein belongs to the human 
database or AAV8 VP3. We have reported only the recommended protein which showed 
more than 20% coverage for better reliability. Since many non-glycosylated peptides were 
lost through HILIC enrichment, expecting 100% coverage of a glycoprotein is unrealistic. 
Majority of the reported proteins are glycosylated. The presence of G3BP emphasis the 
galactose binding properties of AAV8. The interaction of the galactose binding protein with 
AAV-6 has been reported earlier and found to be segregated between 75-100 kDa on SDS-
PAGE227. Detection of Lam R, a secondary receptor of AAV8, also confirms the close 
associations of reported HCPs with AAV8 vector and may explain the copurification.  
 In summary, we studied different aspects of N-glycosylation in AAV8 recombinant 
vector and confirmed the presence of N-glycans on N499 on 
'VSTTTGQNNNSNFAWTAGTK' peptide, localized on the common region of AAV8 capsid 
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protein. The glycosylated peptide and non-glycosylated variant coexisted in the AAV 
preparations suggest that the existence of multiple pathway for AAV8 maturation post AAV 
packaging.  It would be important to study how glycosylation of AAV and its copurified 
proteins would affect the neutralizing AAV antibody and in vivo performance. The close 
interaction of AAV8 with different host cell glycoprotein also suggest providing addition clue 






















4 CONCLUSIONS  
Life is comprised of four significant classifications of molecules, including nucleic 
acid, protein, lipids, and carbohydrates. Be that as it may, the significance of glycans is an 
understudied field. The detailed analysis of protein glycosylation can connect numerous 
fields of biological science to see how a protein changes its functions during various 
physiological conditions utilizing a dynamic glycan arm. The glycosylation can get altered by 
genetic, environmental, epigenetic factors of an  individual. Hence, the altered glycoforms 
may result in malfunctioning due to protein misfolding due to micro and macro heterogeneity 
of their oligosaccharide part. Therefore, the host N-glycome can influence its immune system 
on disease progression. The changes can also revert during the treatment. Hence, the 
glycosylation  can be potential candidate for altering the biological specificity between the 
molecule and alter between healthy and disease state of the body  . 
The glycosylation is an essential field in gene therapy-based vector designing. The 
glycan may increase tropism and create a specific channel of gene-delivery to the host cell. 
Glycan can be used as a unique key for delivering the gene into a distinctive tissue type based 
on their special receptors on their cell surface. Nevertheless, the glycosylation analysis is still 
challenging for a novice because of the diversities of analytical methods available in the field 
and the limitations of each method. However, glycan analysis methods evolve rapidly from 
simple monosaccharide analysis strategy, which provides only compositional information for 
intact glycoproteins and glycopeptides, and gynocentric analysis strategies that provide 
structural, compositional, isomeric, and linkage specific information. The latest developments 
in mass spectrometry and its complementary analytical techniques help to advance the 
glycoprotein interpretation efficiently. The advancement in the mass spectrometry analyzers, 
software, and databases helps glycobiologists analyze complex biological samples and 
understand the role of glycans in the biological system. The advancement in the analytical 
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techniques, including sample preparation and separation technologies, helps promote the 
application of glycobiology in prognostic and diagnostic aspects of diseases. In Chapter 1, we 
tried to give an overview of the standard techniques and method for characterizing the protein 
glycosylation, which commonly used for the project. All these techniques help us understand 
the role of glycosylation changes during a specific biological condition and build up a 
corresponding structural library of glycoforms. The recent developments in mass-
spectrometry-based glycoprotein characterization are providing an enormous scope of 
glycobiology applications in clinical and research aspects. 
In Chapter 2, we tried to build up the knowledge of the mass spectrometry-based 
glycoprotein analysis to elucidate the biomarker discovery relating to inhibitor development 
against rFVIII.  Here we analyzed the plasma and antibody N-glycome change during 
inhibitor improvement, taking HA-mice and HA-human as an investigation model. The 
glycosylation can change from according to the biological organization and hence vary from 
human to mouse model. However, we assumed a trend that can be correlated related to 
inhibitor development. We addressed the complexity of glycan analysis by approaching the 
study using multilevel by different mass spectrometry-based methods primarily as a released 
N-Glycan analysis(glycocentric) and glycopeptide analysis(bottom-up).  
The released N-glycan analysis was conducted in two levels by one-step and two 
steps permethylation followed by MALDI-MS based data acquisition. In humans, we could 
successfully enrich the antibody from plasma. Whereas in mouse, we could not enrich the 
antibody; hence, the glycan analysis was limited to plasma N-glycome. Eventhough, we 
considered three different strains of HA-mice and the induced for inhibitor development by 
treating with rFVIII. The plasma was taken before and after the rFVIII treatment and 
inhibitor development. At the pretreatment stage, the mice were at 11 th week, and inhibitor 
developed stage the mice were at 15th week. We did a background study to see the variation 
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between 11th and 15-week mice. Additionally, we analyzed HA and wild type mice to 
confirm there is no interference of age and HA in the N-glycome analysis of the current 
cohorts. For the human sample, we did a preliminary analysis to see the difference in the 
plasma N-glycome of individuals who vary in their age, HA condition, blood group, and 
ethnicity. Since HA is an X-linked recessive disorder, we considered only male candidates 
for the study. We noted that the galactosylation and sialylation change in plasma, mainly in 
the antibody, as the age increases. The changes were noted in two categories, in response to 
age and inhibitor development. In both cases, galactosylation and sialylation decreased as the 
value increases. Hence, we concluded that we must conduct the study within the same age 
group. However, considering the fact that unknown factors like diet, health, other diseases, 
and the physiological difference can also alter the glycosylationprofile240,241 we assumed 
inter-species that comparison could fortify our study.  
In the next level, we reconfirmed the observation with an individual with inhibitor 
development and the same individual after treating with emicizumab, which is the functional 
analog of rFVIII. The study was conducted to see how dynamic the N-glycome profile and 
how it changes by just a treatment protocol. Here we could see a drastic change in both 
plasma and IgG glycome profile. We could see a significant improvement in sialylation (in 
both the linkages), galactosylation, and complex multi antennary glycoform formation, in 
response to emicizumab treatment. The post-treatment profile was positively correlated to the 
range of the analytical control sample. The control sample was the plasma taken from the HA 
individual from the same age group but without inhibitor development. By one-step analysis, 
we identified 80-90 glycoforms in different human and mice samples. There were no specific 
sugar structures identified with inhibitor development. But the discussed differences were 
calculated based on their relative intensity-based glycan profiling. By the two-step 
permethylation analysis, we could further divide the sialylated glycoforms based on their 
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linkages. Here we calculated the difference based on the conversion of 5 4 0 0 0 glycoforms 
(di- galactosylated biantennary non-fucosylated complex sugar, H5N4) to its sialylated 
glycoform 5 4  1 0 0 and 5 4 2 0 0 by calculating the sialylation index. The approach was 
decided to discriminate the linkage specific sialylated glycoforms from the one-step study, 
which in turn confirms the variabilities related to the individual profile. The glycocentric 
analysis can provide better structural elucidation, linkage analysis, and relative quantitation 
of glycan profiling. The permethylated glycoforms are analyzed using the glycoworkbench 
software, which in turn linked with glycan databases (CFG, Carbbank, Glycome DB, and 
Glycosciences). We extended our study to glycopeptide analysis, where we could identify the 
glycoproteins by a bottom-up approach using pGlyco software. We additionally, semi 
quantitated the microheterogeneity of the site-specific glycan related to IgG subtyping. We 
could see that IgG productions are higher in inhibitor developed plasma in comparison to the 
negative inhibitor cohort. We could also see a decrease in IgG galactosylation at IgG subtype 
level. According to our result, the significant decline in galactosylation is happening at IgG1 
and 4, whereas the differences are negligible at IgG2. According to the glycocentric analysis, 
the plasma sialylation was also less at pre-treatment and increased after emicizumab 
treatment, which again in the range of control sample. Here we could see a more significant 
number of sialylated glycopeptides in the post-treatment stage and HA control sample 
compared to the pre-treatment stage. The glycocentric analysis also showed a substantial 
increase in fucosylated glycoforms at the pre-treatment stage, which reduced after post-
treatment and matched to the control result. The glycopeptide analysis again fortifies this 
observation. All the mentioned results were complementing between the glycocentric and 
glycopeptide analysis. Hence, we set our analytical strategies, and we extended our studies 
with a higher number of emicizumab treatment sample pairs and inhibitor-positive samples to 
confirm our results. Here the differences were not very significant in response to inhibitor 
112 
 
development in both glycocentric and glycopeptide analysis. However, the number of 
patients who showed lesser antibody galactosylation was all from the inhibitor developed set. 
We also observed that the changes get vanished, and galactosylation improved after treating 
these individuals with emicizumab. Those were showing negligible changes were not 
showing any differences after treating with emicizumab. The human-based analysis was also 
giving an insight into the importance of personalized medicine and how glycosylation plays 
an essential role in individual-based treatment strategies.241 
Additionally, from our study, we could see the species level distinction between the 
human and mice plasma glycome. The variability in the percentage of glycoforms was also 
noted at different strains of HA mice sample. However, we could not enrich the antibody 
from mice plasma. Therefore, the analysis was limited at plasma glycome level. Here the 
differences between the individual were higher, so we could not correlate the change specific 
to inhibitor development. Nevertheless, there was a slight decrease in plasma galactosylation, 
noted after inhibitor development. To get a more precise result, we analyzed the plasma 
glycopeptide analysis using orbitrap-MS with HCD- based fragmentation. The bottom-up 
approach results were showing a statistically significant increase in the expression level of 
IgGs and IgM. The site-specific heterogeneity showed that there is a slight decrease in 
monosialylation, responding to the inhibitor development at all the IgG subtype level.  
Both the models are showing a difference at their IgG glycosylation. Both their trends 
were matching, primarily by reducing sialylation/ galactosylation in response to inhibitor 
development. The decrease in IgG galactosylation/ sialylation indicates a pro-inflammatory 
response, whereas the increase in galactosylation/ sialylation is indicating the anti-
inflammatory response of the same antibody. Hence it is clear that patient who develops 
inhibitors are containing pro-inflammatory antibodies whereas the inhibitor negative 
individuals containing anti-inflammatory antibody in their blood. We also observed that the 
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emicizumab treatment could convert the immunological status of an individual from pro-
inflammatory -to anti-inflammatory at a personalized level. 
 In chapter 3, we used the advanced mass spectrometric techniques to identify the 
glycosylated variants of a gene therapy vector which in turn will be useful in the field of 
capsid engineering. The challenge and new aspect of the study was the identification of a 
very small variant of glycoprotein from a complex protein mixture using different mass 
spectrometric techniques. Adeno Associated virus plays a significant role as a gene therapy 
vector to treat multiple genetic disorders. In the present study, the scope of AAV8 capsid 
glycosylation was systemically examined using high-resolution mass spectrometry and 
confirm the N-glycosylation site of the capsid protein at N499. We analyzed the overall sugar 
profile of purified vector produced in 293 cells, using MALDI-TOF-MS and correlated with 
proceeding results. We also identified the presence of co-purified host cell glycoproteins in 
differentially purified AAV8 vectors, highlighted the probability of AAV8 interaction with 
terminal galactosylated N-glycans within the HCPs. 
The viral samples were expressed in HEK-293 cell line and purified separately as 
secreted and intra cellular fraction using density gradient centrifugation. The glycoprotein 
profiling was carried out by SDS-PAGE and differentially stained using pierce glycoprotein 
staining kit. The PNGase F treated sample was run as a negative control to confirm the N-
glycosylation. The overall protein profile and purity of the viral protein were determined by 
Coomassie staining. The N-glycan profile by 2AA-labelling and MALDI-MS analysis 
identified from the differentially purified samples. The glycopeptides were enriched from the 
samples and analyzed using orbitrap-MS. The site of N-glycosylation was confirmed by 
labelling it with 18O. The co-purified host cell glycoproteins were identified analyzing the 
peptide map data using proteome discoverer search engine and human database.  
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Virus capsid glycosylation is a potential PTM which may influence the vector 
immunogenicity, intracellular trafficking, host tissue specificity, and tissue tropism. The post-
translational modification of AAV capsid protein is an underserved area. Here we identified 
the existence of natural N-glycosylation on the AAV8 capsid protein. The protein profiling 
by SDS-PAGE, indicated the glycosylated variants of capsid protein in a feeble amount in the 
AAV8 sample. We identified the presence of other glycoproteins which possibly from the 
host cell protein interaction, which further confirmed by peptide mass fingerprinting. PNGase 
F digested capsid proteins were analyzed side by side on the same gel also indicated the 
presence of heavy molecular weight variants of VP1, VP2, and VP3 in the control samples. 
To confirm the glycosylation, we performed peptide mass fingerprinting after enriching the 
glycosylated peptides.  We also performed the PNGase F mediated deglycosylation in 18O 
water, which specifically deamidate the N-glycan linked Asn to Asp labeled with 18O  and 
verified by the mass addition of 2.98 Da The peptide mass fingerprinting and tandem mass 
spectrometry of 18O labeled glycopeptides confirmed the presence of N-linked glycan at 
N499 in “VSTTTGQNNNSNFAWTAGTK” peptide, localized in the common region of 
AAV8 capsid proteins. We also identified nonglycosylated version in ample amount implies 
the existence of multiple pathways for AAV8 maturation and packaging. The total protein 
identifications in AAV8 sample indicated the presence of different glycoproteins from host 
cell through AAV8-host cell interactions. The N-glycan analysis of the differentially purified 
AAV8 samples was performed independently to monitor the structural features of glycan 
present in the sample. The isolated N-glycans were labelled with 2 aminobenzoic acid and 
analyzed using MALDI-MS. Each glycoform was well characterized by tandem mass 
spectrometry and further confirmed by Glycoworkbench analysis tool. The high amount of 
terminally galactosylated glycoforms and presence of galectin binding proteins pointing out 
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the high affinity of AAV8 to the terminal galactose containing glycoforms. These results 
provide new insights into AAV8 vector production and capsid engineering process. 
In summary, by using the advanced techniques of mass spectrometry and sample 
preparation, we could explore the field of glycobiology to study the significance of protein N-
glycome in biomarker discovery and gene therapy using Hemophilia A inhibitor development 
and rAAV8 as study models. 
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Appendix A F.2: The fluorescent property of 2HQ 
Labeled dextrin separated on Amide column using the FLD detector with excitation wave length λex=280nm and emission 
wavelength λ em=335nm compared with conventional 2AB labeled dextrin separated with the same method but FD 
parameter was set at λex=330nm  and λem was set at λ em=420 n
141 
 
A)                                                                                                                                                           B) 
                                          
C)                                                                                                                                       D 
  
 
Appendix A F.3: The optimization parameters with triplicate analysis. 




















































































Appendix A F.5: The MALDI-MS profile comparison with reductive amination,2HQ labelling and untagged sugars acquired in MALDI-MS . 
 
The results showed that using the same method and their intensities were compared.it showed that 2HQ can give similar ionization with reductive amination and 3 





Appendix B Table 1 Internal calibration mass list used for MALDI-TOF-MS 





signal   
Tolerance 
(ppm) 
  calibrant 
(m/z) 
1  33000  1416.7094  50  
2  34001 
 1835.924  50  
3  44001 
 2040.0247  50  
4  54001  2244.1245  50  
5  54101  2605.2981  50  
6  54201  2966.4718  50  
                 
 
Appendix B Table 2 The glycoforms detected from human plasma 















3 3 0 0 0      1416.709 1416.682 -19.34 Hybrid Non- Fucose/agalactosylated/ 
2 
 




3 3 3 0 0 1 1590.799 1590.784 -9.18 Hybrid Core-fucose/agalactosylated 
4 
 
4 3 0 0 0 1620.809 1620.798 -6.84 Hybrid Non- Fucose/galactosylated 
5 
 
3 4 0 0 0 1661.836 1661.832 -2.23 Complex Non- Fucose/agalactosylated 
6 
 
3 3 0 0 2 1764.888 1763.867 -578.72 complex Multifucosylated/galactosylated 
7 
 
3 3 1 0 0 1777.883 1777.822 -34.31 complex Non- Fucose/Mono sialylated 
8 
 




                     
 
                                                                                                          …. Continues 
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No. Structure Gly ID 
  Theoretical 
m/z 
(M+Na+) 










4 3 0 0 1 1794.8984 1793.879 -568.27 Hybrid Core-Fucose/galactosylated 
10 
 
5 3 0 0 0 1824.9089 1824.893 -8.71 Hybrid Non- Fucose/galactosylated 
11 
 
3 4 0 0 1 1835.9249 1835.933 4.41 Complex Core-Fucose/agalactosylated 
12 
 
4 4 0 0 0 1865.9355 1865.939 1.875 Complex Non- Fucose/galactosylated 
13 
 
3 5 0 0 0 1906.962 1906.961 -0.52 Complex Non- Fucose/agalactosylated 
14 
 
4 3 0 0 2 1968.9876 1967.97 30      -515.56 Complex Multifucosylated/galactosylated 
15 
 
4 3 1 0 0 1981.9828 1981.974 -4.44 Hybrid Non-fucosylated/Mono sialic 
16 
 
4 4 0 0 1 2040.0247 2040.023 -0.83 Complex Core-Fucose/galactosylated 
17 
 
5 4 0 0 0 2070.0352 2070.036 0.39 Complex Non- Fucose/galactosylated 
18 
 
3 5 0 0 1 2081.0521 2081.06 3.8 Complex Core-Fucose/agalactosylated 
19 
 
4 5 0 0 0 2111.0618 2111.059 -1.33 Complex Non- Fucose/galactosylated 
20 
 
3 6 0 0 0 2154.06 2154.062 0.93 Complex Non- Fucose/agalactosylated 
21 
 
5 3 0 0 2 2173.0873 2172.066 -470.2 Hybrid Multifucosylated/galactosylated 
22 
 
5 3 1 0 0 2186.0826 2186.068 -6.68 Hybrid Non-fucosylated/Mono sialylated 
23 
 





























4 4 0 0 2 2214.1139 2213.084 -465.37 Complex Multifucosylated/galactosylated 
25 
 
4 4 1 0 0 2227.1091 2227.094 -6.78 Complex Non-fucosylated/Mono sial 
26 
 
5 4 0 0 1 2244.1245 2244.115 -4.23 Complex Core-fucose/galactosylated 
27 4 4 0 1 0 2257.1197 2257.109 -4.74 Complex Non fucosylated/Mono sial/NGNA 
28 
 
4 5 0 0 1 2285.151 2285.143 -3.5 Complex Core-fucosylated/galactosylated 
29 
 
5 5 0 0 0 2315.1616 2315.135 -11.49 Complex Non-fucosylated/galactosylated 
30 
 
6 3 1 0 0 2390.1824 2390.163 -8.12 Hybrid Non fucosylated/Mono sial 
31 
 






4 4 1 0 1 2401.1983 2401.149 -20.53 Complex Core-fucosylated/mono sial 
33 
 
5 4 0 0 2 2418.2137 2417.17 -431.79 Complex Multifucosylated/galactosylated 
34 
 
5 4 1 0 0 2431.2089 2431.215 2.51 Complex Non-fucosylated/mono sial/galactosylated 
35 
 





4 5 1 0 0          2472.2355 2472.246 4.25 Complex Non-fucosylated/mono sialylated 
                                                                                                                                 …. continues 
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5 5 0 0 1 2489.2508 2489.252 0.48 Complex Core-fucosylated/galactosylaated 
38 
 
6 5 0 0 0 2519.2613 2519.269 3.06 Complex Non-fucosylated/galactosylated 
39 
 






5 3 2 0 0 2547.2563 2547.242 -5.61 Hybrid Non-fucosylated/disial 
41 
 






5 4 1 0 1 2605.2981 2605.282 -6.18 Complex Core-fucosylated/monosial/gal 
43 
 





4 5 1 0 1 2646.3246 2646.28 -16.85 Complex Core-fucosylated/monosial 
45 
 
5 5 0 0 2 2663.314 2663.306 -3 Complex Multifucosylated/agalactosylated 
46 
 





6 5 0 0 1 2693.3506 2693.31 -15.07 Complex Core-fucosylated/galactosylated 
48 
 
5 6 0 0 1 2734.3117 2736.305 728.46 Complex Core-fucosylated/galactosylated 
49 
 






4 4 2 0 1 2762.372 2762.308 -23.17 Complex Core-fucosylated/disial 





















4 7 0 0 1 2775.4056 2776.32 329.36 Complex Core-fucosylated/galactosylated 
52 
 
5 4 2 0 0 2792.3862 2792.385 -0.43 Complex Non-fucosylated/disialylated 
53 
 
5 7 0 0 0 2805.4142 2806.393 348.78 Complex Non-fucosylated/galactosylated 
54 
 
5 4 1 1 0 2822.3942 2822.427 11.62 Complex Non-fucosylated/disial/NGNA 
55 
 
5 5 0 0 3 2837.4232 2836.435 -348.4 Complex Multifucosylated/galactosylated 
56 
 
5 5 1 0 1 2850.4244 2850.457 11.44 Complex Core-fucosylated/monosial 
57 
 
6 5 1 0 0 2880.435 2880.456 7.29 Complex Non-fucosylaated/monosial 
58 
 
5 4 2 0 1 2966.4718 2966.485 4.45 Complex Core-fucosylated/ disial 
59 5 4 1 1 1 2996.4824 2996.5 5.87 Complex Core-fucosylated/ disial/NGNA 
60 
 






5 5 2 0 0 3037.5089 3037.477 -10.5 Complex Non fucosylaated/disial 
62 6 5 1 0 1 3054.5242 3054.533 2.88 Complex Core-fucosylated/monosial 
63 5 5 2 0 1 3211.5981 3211.594 -1.28 Complex Core-fucosylated/disial 
64 
 
5 8 0 0 1 3224.6297 3226.555 596.7 Complex 
Core- fucosylated/ 
galactosylated 





                                                                                                                      …. Continue 
 
 







































































































































Appendix B Table 3 The glycoforms detected from Protein A/G enriched IgG fraction 




( M+Na+) Error in ppm 
1 
 
3 3 0 0 0  1416.7094 1416.75 28.7 
2 
 
5 2 0 0 0  1578.7826 1578.83 30.0 
3 
 
3 3 0 0 1 1590.7986 1590.844 28.5 
4 
 
4 3 0 0 0 1620.8091 1620.854 27.7 
5 
 
3 4 0 0 0 1661.8357 1661.881 27.3 
6 
 





6 2 0 0 0 1783.8824 1783.934 28.9 
8 
 
4 3 0 0 1 1794.8984 1794.95 28.7 
9  5 3 0 0 0 1824.9089 1824.959 27.5 
10 
 
3 4 0 0 1 1835.9249 1835.973 26.2 
11 
 
4 4 0 0 0 1865.9355 1865.988 28.1 
12 
 
3 5 0 0 0 1906.9620 1905.993 -508.4 
13 
 
6 2 0 0 1 1957.9716 1957.035 -478.6 
14 
 
7 2 0 0 0  1987.9821 1988.035 26.6 
15 
 
4 4 0 0 1 2040.0247 2040.073 23.7 
16 
 
5 4 0 0 0 2070.0352 2070.09 26.5 
17 
 
3 5 0 0 1 2081.0521 2081.104 24.9 
18  4 5 0 0 0 2111.0618 2111.107 21.4 
19 
 





5 3 1 0 0 2186.0826 2185.127 -437.3 
21 8 2 0 0 0  2192.0819 2192.137 25.1 
22 
 
6 3 0 0 1 2203.0971 2202.157 -426.9 
23 
 
4 4 0 0 2 2214.1139 2213.121 -448.6 
24 
 
4 4 1 0 0 2227.1091 2227.132 10.3 
25 
 
5 4 0 0 1 2244.1245 2244.177 23.4 
26 
 
4 4 0 1 0 2257.1197 2258.172 466.0 
27 
 
4 5 0 0 1 2285.151 2285.205 23.6 
28 
 
5 5 0 0 0 2315.1616 2315.202 17.4 
29 
 
3 6 0 0 1 2326.1176 2326.794 290.7 
30 
 
9 2 0 0 0 2396.1817 2396.235 22.2 
31  4 4 1 0 1 2401.1983 2401.254 23.2 
32  5 4 0 0 2 2418.2137 2417.228 -407.8 
33 
 
5 4 1 0 0 2431.2089 2431.267 23.9 





5 5 0 0 1 2489.2508 2489.307 22.6 
36  6 5 0 0 0 2519.2613 2518.293 -384.5 
37 
 
5 3 1 0 2 2534.261 2533.302 -378.6 
38 
 
6 3 1 0 1 2564.2716 2563.322 -370.5 
39 
 
5 4 0 0 3 2592.3029 2591.339 -372.0 
40 
 
5 4 1 0 1 2605.2981 2605.36 23.8 
41 
 
6 4 1 0 0 2635.3087 2635.362 20.2 
42 
 
4 5 1 0 1 2646.3246 2646.385 22.8 
43 
 
5 5 1 0 0  2676.3352 2676.394 22.0 
44  3 6 1 0 1 2687.3512 2686.927 -157.9 
45 
 
7 5 0 0 0 2723.3611 2722.392 -356.0 
46 
 





5 5 0 0 3 2837.4232 2836.478 -333.2 
48 
 
5 5 1 0 1 2850.4244 2850.501 26.9 
49 
 
6 5 1 0 0 2880.435 2880.502 23.3 
50 
 
5 4 2 0 1 2966.4718 2966.562 30.4 
51 
 
5 5 2 0 0 3037.5087 3037.142 -120.7 
52 
 
3 6 2 0 1 3048.5247 3048.08 -145.9 
53 
 
6 5 1 0 1 3054.5242 3054.619 31.0 
54 
 
5 5 2 0 1 3211.5981 3211.722 38.6 
55 
 
6 5 2 0 0 3241.6087 3241.6087 0.0 
56 
 
6 5 2 0 1 3415.6979 3416.866 341.9 
57 
 


















Sialic acid% Fucosylation% Galactosylation % Gal Index 
Sample I(BU) Age Total Mono  Di  Multi Total Mono  Multi   G0f/(G1f+G2f*2)  
B01 11 62  58.9 22.8 32.2 3.9 45.3 37.8 7.5 44.8 0.02 
B04 43 65 64.1 22.2 39.0 2.9 43.4 33.3 10.1 46.9 0.02 
B05 <0.6 34  56.0 22.8 30.0 3.2 51.7 43.1 8.6 52.0 0.02 
B06 <0.6 18  57.9 22.2 33.1 2.6 49.1 40.0 9.2 51.1 0.02 
B07** <0.6  27 21.3 19.4 1.9 0.0 51.6 47.5 4.1 73.5 1.12 
B08** <0.6 31 52.0 31.8 19.5 0.6 41.2 35.6 5.6 59.9 0.14 
B09 <0.6  25 70.7 39.2 30.9 0.5 26.1 21.4 4.7 59.9 0.07 
B10-1 <0.6 31 64.1 27.9 33.5 2.8 39.6 29.3 10.4 48.7 0.02 
B10-2 past 25 54.7 26.2 26.0 2.5 49.5 40.5 9.0 56.2 0.04 
B13 <0.6 34 63.7 28.2 33.4 2.0 46.1 33.5 12.6 50.6 0.03 
B17-1 <0.6 49 60.9 24.6 33.6 2.7 45.6 36.1 9.5 51.6 0.03 
B17-2 <0.6 58 71.6 26.7 42.4 2.4 39.1 29.8 9.3 45.2 0.01 
B18-1 6 19 63.7 24.5 36.5 2.7 39.4 28.8 10.6 46.2 0.02 
B18-2 <0.6 34 68.4 27.0 37.6 3.7 38.2 26.8 11.3 47.7 0.02 
B19-2 36 5 70.9 27.6 40.0 3.3 35.5 25.6 9.9 45.3 0.01 
b11-2 3 21 61.6 27.6 31.2 2.8 47.0 34.3 12.7 52.0 0.03 
b12-2 3 20 68.2 25.0 39.6 3.7 39.8 27.2 12.5 46.6 0.02 
b20-1 <0.6 35 67.1 37.9 27.5 1.6 33.2 25.7 7.4 62.8 0.10 
b20-2 <0.6 37 74.2 21.1 46.3 6.8 35.1 28.1 7.0 39.0 0.01 
 
 














b21-1 <0.6 27 73.3 24.4 45.3 3.6 36.2 28.3 7.9 42 0.01 







b15-2 11 38 63.1 28.2 31.4 3.5 46.8 35.3 11.5 54 0.04 
b22-1 <0.6 22 71.8 22 46.8 3 34.9 24.3 10.6 40.6 0.01 
b16-1 <0.6 23 71.7 25.3 43.1 3.2 38.5 28.8 9.7 44 0.01 




*Patient with acquired inhibitor, that is he did not have inherited hemophilia, but late in life 
developed an antibody to FVIII 
**These are on the same individual pre (B07) and post (B08) emicizumab.  He had a history 
of a high titre inhibitor but did not have recent FVIII exposure at the time of these lab draws and did 
not have a measurable inhibitor.  He was later given FVIII and his inhibitor titre peaked at 50 BU one 
month after the B08 specimen was drawn.    
*** This specimen was drawn prior to a FVIII infusion that showed that the FVIII half-life 
was decreased.  So he has a functional inhibitor below the level of detection.  He has a history of a 






Appendix B F2 Glycan profile of emicizumab 




a1)                                                                                                                     a2) 
 
b1)                                                                                       b2) 
Appendix B F3 Method reliability analysis of MALDI MS by standard spiking. 
Glycan isolated from 8µl of human serum was aliquoted equally to 5 tubes equally and 50,100,150 and 200 picomoles of 4 4 0 0 1(H4N4F1 or G1f) was added to them individually 
and the last one was kept as control tube without spiking. The relative intensity of the spiked standard was calculated with the 5 4 1 0 0 (G2S1) inherent glycoform within the serum (a1 and b1). 
The percentage of intensity of the spiked standard at each point (a2 and b2) were calculated. The linearity was calculated even after reducing the intensity from the no spike sample(a2, orange 
spots).  The SD with triplicate values  was plotted in bar graph at b1 and b2 for the spiking study at different points . 200 picomole spike was out of linear range but considered for SD 
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Appendix B F4 Effect of emicizumab on the patient with HA individual patient compilation 




























































































































































































































































































































































































































































































Appendix B F5 Comparison of the most different glycoforms between I+ and I- sets with p values. 
The most varied glycoforms from I+ and I- HA were compiled and unpaired t test were performed. The p values of total sialylation and fucosylation were calculated between the inhibitor 





Appendix B F6 Site-specific glycan subtyping of a single batch showed maximum differences in antibody glycan index 
and its improvement after emicizumab treatment. 
The study was conducted in comparison with the normal HA patient (I-)from the same age group. a) bottom-up approach 
study and most abundant glycoprotein profiling and comparison between control, pre-treatment and post-treatment samples. 
b) fucosylated glycopeptides comparison between samples and their percentage calculated with total number of glycopeptide 
detected c) sialylated glycopeptides comparison between the samples and their percentage calculated with total number of 
glycopeptide detected d) the glycoprotein profiling of most abundant glycoproteins in the sample calculated with their 
percentage of composition calculated with their intensities  e) IgG subtyping -N-glycosite microheterogeneity calculated 
based on the structural categorization of glycan.  
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Appendix B Table 5  The most abundant glycoproteins identified in human plasma sample by bottom up approach 
Uniprot id common Protein identified in human plasma 
P0DOX5 Immunoglobulin gamma-1 heavy chain 
P01859 Immunoglobulin heavy constant gamma 2 
P01861 Immunoglobulin heavy constant gamma 4 
P01024 Complement C3 
P02679 Fibrinogen gamma chain 
P02675 Fibrinogen beta chain 
P0C0L4 Complement C4-A 
P02751 Fibronectin 
P02748 Complement component C9 
P04114 Apolipoprotein B-100 
P04004 Vitronectin 
Q96PD5 N-acetylmuramoyl-L-alanine amidase 
P01591 Immunoglobulin J chain 
P05155 Plasma protease C1 inhibitor 
P02750 Leucine-rich alpha-2-glycoprotein 





P00748 Coagulation factor XII 
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 
P01871 Immunoglobulin heavy constant mu 
P02790 Hemopexin 
P00450 Ceruloplasmin 
P00751 Complement factor B 
P05546 Heparin cofactor 2 
 P10909 Clusterin 
P02787 Serotransferrin 
P13671 Complement component C6 
O75882 Attractin 
P03952 Plasma kallikrein 
P02749 Beta-2-glycoprotein 1 
P02765 Alpha-2-HS-glycoprotein 
P22792 Carboxypeptidase N subunit 2 
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 




P08603 Complement factor H 
P06681 Complement C2 
P01042 Kininogen-1 
Q92954 Proteoglycan 4 
P08185 Corticosteroid-binding globulin 
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 
P01031 Complement C5 
P04196 Histidine-rich glycoprotein 
P01023 Alpha-2-macroglobulin 
P01876 Immunoglobulin heavy constant alpha 1 
P27169 Serum paraoxonase/arylesterase 1 
P04217 Alpha-1B-glycoprotein 
P01011 Alpha-1-antichymotrypsin 
P02743 Serum amyloid P-component 
P05156 Complement factor I 
P01880 Immunoglobulin heavy constant delta 
Q96IV0 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase 
P04278 Sex hormone-binding globulin 
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Appendix B Table 6 Site specific microheterogeneity of IgG1 compiled based on specific sugar percentage of existence 
IgG1 specific glycan Pre-I+ Post I- Pre-I- Post I+ 
 B01 B02 B04 B07 B10_1 B18.1 B19 B10_2 B17.2 B18.2 B20.2 B21.2 B05 B06 B09 B13 B16.1 B17.1 B20.1 B21.1 B22.1 B08 B11_2 B12_2 B15.2 B16.2 
Sial% 0.1 8.9 5.5 2.7 0.2 5.6 3.1 3.09 5.18 5.62 1.29 2.26 3.5 2.3 0.2 9.6 11.8 2.9 1.5 0.4 4.0 5.12 1.73 11.82 8.48 12.44 
terminal gal% 39.9 46.1 30.5 44.2 32.3 40.2 30.0 54.02 52.23 40.21 40.58 33.76 55.0 46.5 32.3 49.1 35.3 55.9 40.2 22.8 36.0 30.50 46.91 43.38 59.57 24.92 
Fucosylation 85.7 95.8 96.4 89.6 91.2 88.4 96.7 86.36 68.13 88.38 84.81 86.89 96.4 93.1 91.2 87.2 92.7 67.4 88.2 89.7 69.8 39.29 92.93 94.22 81.63 92.66 
bisecting 5.0 3.3 4.1 7.2 13.5 3.4 2.9 0.80 3.17 7.64 10.46 4.38 1.63 4.29 2.88 4.78 3.77 10.27 5.01 3.26 0.00 29.9 1.8 4.7 4.4 17.4 
Hybrid high mannose 29.0 26.6 37.7 38.9 43.5 45.2 48.5 25.8 33.0 38.9 48.4 61.0 31.7 34.8 50.6 29.3 31.1 40.9 45.0 57.3 43.7 44.0 36.2 31.9 13.5 18.9 
Appendix B Table 7 Site specific microheterogeneity of IgG2 compiled based on specific sugar percentage of existence 
Microheterogeneity 
of IgG2 
Pre I+ Post I- Pre I- Post I+ 
B01 B02 B04 B07 B10_1 B18.1 B19 B10_2 B17.2 B18.2 B20.2 B21.2 B05 B06 B09 B13 B16.1 B17.1 B20.1 B21.1 B22.1 B08 B11_2 B12_2 B15.2 B16.2 
Sial% 0.8 9.6 11.7 0.3 7.4 4.2 2.7 3.0 0.6 1.7 3.6 0.7 3.2 1.9 2.5 4.3 4.8 0.6 6.1 0.9 33.5 2.2 4.4 3.5 3.9 1.5 
Gal% 15.5 29.9 52.3 8.2 42.0 11.1 19.5 13.1 24.4 17.9 30.6 40.1 20.2 14.8 26.7 25.4 17.7 24.4 44.4 54.4 76.4 12.8 18.2 19.2 22.8 18.3 
Fuc% 85.0 98.6 86.5 98.1 98.2 98.9 98.3 98.0 90.1 92.0 94.0 80.3 97.3 93.4 96.9 92.5 97.3 90.1 84.5 84.1 100.0 94.6 96.9 96.9 94.5 97.0 
Bisecting 1.1 1.1 0.9 4.1 5.9 1.5 5.1 2.5 3.2 2.4 5.3 0.3 2.4 4.5 6.0 2.5 1.8 5.2 6.5 11.2 13.0 3.4 6.9 3.4 4.3 5.3 
high mannose hybrid 38.5 33.2 44.0 46.9 36.2 35.3 34.7 31.1 28.8 48.0 68.8 68.2 50.7 41.9 38.8 24.2 38.3 39.9 52.8 46.4 18.9 47.6 42.9 24.1 37.5 37.3 
 
 
Appendix B Table 8 Site specific microheterogeneity of IgG4 compiled based on specific sugar percentage of existence 
Microheterogeneity of IgG4 
Pre I+ Post I- Pre I- Post I+ 
B01 B02 B04 B07 B10_1 B19 B10_2 B17.2 B18.2 B20.2 B21.2 B05 B06 B09 B13 B16.1 B17.1 B20.1 B21.1 B22.1 B08 B11_2 B12_2 B15.2 B16.2 
Sial% 0.0 10.6 3.9 3.2 9.4 15.6 14.3 24.7 10.6 3.8 26.3 3.8 2.6 7.3 14.4 16.3 2.9 1.8 21.8 5.6 21.8 22.9 36.7 5.8 20.5 
Gal% 18.6 73.2 18.2 23.5 54.1 34.3 56.9 69.6 51.5 29.5 55.0 37.2 41.1 30.3 54.3 41.7 69.0 28.7 82.9 59.5 44.8 44.1 28.2 47.5 32.9 
Fuc% 84.8 100.0 83.8 100.0 97.1 71.1 100.0 100.0 59.0 82.3 90.6 98.7 96.2 100.0 100.0 91.7 33.7 70.3 91.5 94.0 100.0 100.0 100.0 82.2 73.8 
Bisecting GlcNac 2.2 1.8 0.3 1.4 0.0 0.0 0.0 0.0 3.0 4.9 0.0 0.0 2.1 1.1 1.1 0.0 0.7 3.2 0.0 0.9 0.0 1.6 0.0 0.0 23.4 





Appendix B Table 9 Site specific microheterogeneity of IgM compiled based on specific sugar percentage of existence 
 
Microheterogeneity at IgM glycopeptide 
Pre I+ Post I- Pre I- Post I+ 
B01 B02 B04 B07 B10_1 B19 B10_2 B17.2 B18.2 B20.2 B21.2 B05 B06 B09 B13 B16.1 B17.1 B20.1 B21.1 B22.1 B08 B11_2 B12_2 B15.2 
Sial % 66 77 60.2 75.4 62.5 68.2 72.7 69.8 80.9 48.7 29.6 79.9 75.5 53.9 67.2 82 78 38.3 32.9 42.1 75.5 65.3 92.8 85.3 
Gal % 74.7 75.5 73.6 67.9 71.2 49.1 79.1 63 54.8 52.4 79.6 83.6 61.4 52.2 72.7 83.3 84 62.2 76.1 48.1 62 67.9 91.3 89.8 
Fucosylation 67.1 42.5 71 51.2 65.2 34.1 40.5 45.7 66.8 46.6 65.8 49.3 56.4 69.1 74.9 43.9 28.9 68.1 54.8 49.5 44.8 43.3 28.2 45.7 
Bisecting GlcNac 37.5 20.1 35.6 23.1 29.5 31.5 12.2 21.9 13.7 11.7 23.9 25.1 25.5 19.4 41.1 22.2 10.7 14.5 13.3 6.9 16.7 15.7 17.5 30.1 







Appendix B Table 10 Site specific microheterogeneity in N- glycosite relating to major immunoglobulins 
No 
 
Structures identified  Gly ID(H,N,A,G,F) IgG1 IgG2 IgG4 IgM 
1 
  




















3 5 0 0 0  Yes Yes no no 
 
  
     
7   3 5 0 0 1  Yes Yes Yes Yes 
8 
 
 4 2 0 0 0  no no no yes 
9 
  
4 2 0 0 1  no no no no 
10 
  
4 3 0 0 0  Yes Yes Yes Yes 
11 
  
















4 4 0 0 0  Yes Yes Yes Yes 
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No Structures identified  Gly ID(H,N,A,G,F) IgG1 IgG2 IgG4 IgM 
16 
 
4 4 0 0 1  Yes Yes Yes Yes 
17 
 
4 4 0 0 2  Yes No No No 
18 
 
4 4 1 0 0  Yes Yes Yes No 
19 
 
4 4 1 0 1  Yes Yes Yes Yes 
20  4 5 0 0 0  Yes Yes No Yes 
21 4 5 0 0 1  Yes Yes Yes Yes 
22 
 
4 5 0 0 3  Yes No No No 
23 
 
4 5 1 0 1  Yes No No No 
24 
 
5 2 0 0 0  Yes Yes No yes 
25 5 2 0 0 1  No No No yes 
26 5 4 0 0 2  No yes No No 
27 
 
5 3 0 0 1  Yes Yes No Yes 
28 
 
5 3 1 0 0  No No No yes 
29 5 3 1 0 1  Yes Yes No Yes 
30 
 
5 4 0 0 0  Yes Yes Yes Yes 






No Structures identified  Gly ID(H,N,A,G,F) IgG1 IgG2 IgG4 IgM 
31 
 
5 4 0 0 1  Yes Yes Yes Yes 
32 5 4 1 0 0  Yes Yes yes yes 
33 
 
5 4 1 0 1  Yes yes yes yes 
34 5 4 1 0 2  No No No yes 
35 5 4 2 0 1  Yes yes yes yes 
36 
 
5 5 0 0 0  No No No yes 
37 5 5 0 0 1  Yes yes No yes 
38 
 
5 5 1 0 0  No No No yes 
39 5 5 1 0 1  Yes Yes No yes 
40 5 5 1 0 2  No No No yes 
41 
 
6 2 0 0 0  Yes yes No yes 
                                                                                                                                                                                           ….. continues 
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No Structures identified  Gly ID(H,N,A,G,F) IgG1 IgG2 IgG4 IgM 
42 
 
6 3 0 0 0  No No No yes 
43 
 
6 3 1 0 0  No No No yes 
44 
 
6 3 1 0 1  Yes No No yes 
45 
 
6 4 0 0 0  No yes No yes 
46 
 
6 4 0 0 1 No No No yes 
47  6 4 1 0 0  No No No yes 
48 
 
6 4 1 0 1 No yes No yes 
49  6 5 1 0 1 No No No yes 
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Appendix B Table 11 Mouse plasma glycome detected by one-step permethylation 
No Structure Gly ID Theoretical Mass (Na+) Experimental mass(Na+) Glycan main type Subtype 
1 
 
3 3 0 0 0 
1416.709 1416.701 Complex Non- Fucose/agalactosylated/ 
2 
 
       5 2 0 0 0 
1579.783 1579.794 
High mannose High mannose 
3 
 
4 3 0 0 0 
1620.809 1620.826 
Hybrid Non- Fucose/galactosylated 
4 
 
6 2 0 0 0 
1783.8824 1783.907 
High mannose High mannose 
5 
 





3 3 0 1 0 
1807.8936 1807.92 complex Non- Fucose/Mono sial 
7 
 
5 3 0 0 0 
1824.9098 1824.9370 
Hybrid Non- Fucose/galactosylated 
8 
3 4 0 0 1 
1835.9249 1835.949 Complex Core-Fucose/agalactosylated 
9 
 4 4 0 0 0 
1865.9355 1865.964 
Complex Non- Fucose/galactosylated 
10 
 
7 2 0 0 0 
1987.9821 1988.011 
High mannose High mannose 
11 
 5 3 0 0 1 
1998.9981 1998.006 
Hybrid Fucosylated /galactosylated 
12 
 
4 3 0 1 0 
2011.995 2012.017 
complex Non- Fucose/Mono sial 
13 
 
6 3 0 0 0  




4 4 0 0 1 




5 4 0 0 0 
2070.0352 2070.06 Complex 
Non- Fucose/galactosylated 
16  





5 4 0 0 1 
2244.1245 2244.144 
complex galactosylated/ core-fucosylated 
18 
 
4 4 0  1 0 
2257.1197 2257.146 





    
  
No Structure  Theoretical Mass (Na+) Experimental mass(Na+) Glycan main type Subtype 
19 
 
6 4 0 0 0 
2274.135 2274.15 complex Non- Fucose/galactosylated/alpha-gal 
20 
 






5 3 0 1 1 
2490.1824 2390.184 
Hybrid Non-fucosylated/ monosial/core-fucose 
22 
 
      9 2 0 0 0  
           2396.1817 2396.193 
High mannose High mannose 
23 
 6 3 0 1 0 
2420.1929 2420.203 Hybrid Non-fucosylated/ Monosial/NGNA 
24 
 4 4 0 1 1  
2431.2089 2431.2 Complex Core-fucosylated/ monosial 
25 
 
6 4 0 0 1 
2448.2242 2447.207 Complex galactosylated/ core-fucosylated/alpha-gal 
26 
 
5 4 0 1 0 
           2461.2195 2461.224 Complex Non-fucosylated/ monosial/NGNA 
27 
 
7 4 0 0 0 2478.2378 2477.228 Complex Non-fucosylated/ galactosylated/alpha-gal 
28 
 
5 5 0 0 1 
2489.2508 2491.263 Complex core-fucosylated/galactosylated 
29 
 
6 5 0 0 0 
2519.2613 2519.289 Complex Non-fucosylated/ galactosylated 
30 
 
5 3 0 2 0 
2607.2774 2607.297 Hybrid Non-fucosylated/ Disialylated 
31 
 
5 4 0 1 1 




6 4 0 1 0 





6 5 0 0 1 




5 5 0 1 0 
2706.3456 2706.353 Complex 
Non-fucosylated/ galactosylated/mono-sial 
35 
7 5 0 0 0 












6 4 0 0 3 2796.4026 2795.372 Complex 
 





No Structure  Theoretical Mass (Na+) Experimental mass(Na+) Glycan main type Subtype 
38 
 
5 4 0 1 2 
           2809.3979 2808.367 Complex multi fucosylated/galactosylated/ monosial 
39 
 
 5 4 1 1 0  





6 4 0 1 1 





 5 4 0 2 0 
2852.4037 2852.389 Complex Non-fucosylated/disial 
42 
 
6 5 0 0 2 
2867.4398 2866.407 Complex multi-fucosylated/galactosylated 
43 
 
7 4 0 1 0 




5 5 0 1 1 
2880.435 2882.423 Complex 
core-fucosylated/ galactosylated/ mono sial 
45 
 
7 5 0 0 1 










8 5 0 0 0 




5 4 0 0 5 




5 4 1 0 3 










6 4 0 1 2 
3013.4917 3012.468 Hybrid 
multi-fucosylated/monosial 
52 
 5 4 0 2 1 




6 5 0 0 3 




5 5 0 1 2 




6 5 0 1 1 





Gly ID Theoretical 































5 4 0 3 0 3743.5879 3243.572 Complex 
non-fucosylated/multi-sial 
     62 
 
6 5 0 1 2 3258.624 3257.582 Complex 
Multi-fucosylated/galactosylated/mono-sial 
       63 
 
 
5 5 0 2 1   






6 6 0 0 3 




6 5 0 2 0 











6 6 0 1 1 






8 6 0 0 1 





7 6 0 1 0 3359.6717 3359.657 complex 














5 4 0 4 0 






Gly Id Theoretical 




6 5 0 2 2 
3649.8082 3648.737 complex 




5 5 0 3 1 
3662.8035 3662.764 complex 
core-fucosylated/ multi sialylated 
75 
 7 5 0 2 1 





6 5 0 3 0 
3692.814 3692.787 complex 
Non-fucosylated/ multi sialylated 
77 
 
7 6 1 1 0 
3720.8453 3722.812 complex 
Non-fucosylated/ multi sialylated 
78 
7 6 0 2 0 
3750.8559 3751.839 complex 
Non-fucosylated/ multi sialylated 
79 
 
6 5 0 3 1 
3866.9032 3866.856 complex 
core-fucosylated/ multi sialylated 
80 
 
7 5 0 2 1 
3924.9451 3924.89 complex 





7 6 1 1 2 4069.0238 4069.949 complex 




6 5 0 4 0 4083.9983 4083.976 complex 




7 6 0 2 2 
4099.0343 4097.973 complex 




6 6 0 3 1  4112.0296 4113.008 complex 




7 4 0 2 1 4129.0449 4127.985 complex 















7 6 0 4 0 4533.2244 4533.294 complex 
 
Non-fucosylated/ multi sialylated 
89 
 
7 6 0 5 0 
4924.4086 4925.465 complex 
 
 








Appendix B F7 Changes of N-glycome composition based on the major 28 glycoforms in mice plasma from different HA patients based on the inhibitor development. 
The most abundant 33 glycoforms are compared between different HA mice strains. a) SV129 baseline plasma analysis b) SV129 Inhibitor development c) BALB/c baseline 


































































































Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Prothrombin Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Nil Yes Nil Nil 
Histidine-rich 
glycoprotein 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes 
Murinoglobulin-1 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Fibronectin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Alpha-1-
antitrypsin 1-2 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Nil Yes Yes Nil 
Immunoglobulin 
heavy constant mu 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Complement C4-B Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Vitamin D-
binding protein 




Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Haptoglobin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Yes Yes Yes Nil 
Ig gamma-2B 
chain C  
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Apolipoprotein C-
IV 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Nil Nil Nil 
Vitronectin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Yes 
Carboxypeptidase 
N subunit 2 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Nil Nil Nil 
Ig gamma-3 chain 
C region 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Complement 
component C9 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Yes Nil Nil 
Pregnancy zone 
protein 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Transthyretin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Heparin cofactor 2 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Nil Nil Nil Nil 
Hemopexin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes Nil Nil Nil Yes Yes Yes 




Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Epidermal growth 
factor receptor 






























































Leukemia inhibitory factor 
receptor 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Kininogen-1 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Antithrombin-III Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Yes Yes Yes Nil 
Afamin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Clusterin Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Nil Nil Yes Nil Nil Yes Nil 
Complement C5 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Yes Yes Yes Yes Yes Yes Yes 
Serotransferrin Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Alpha-1-acid glycoprotein 1 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Plasma kallikrein Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes 
Fibrinogen beta chain Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Nil 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Complement factor H Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Carboxylesterase 1C Yes Yes Yes Yes Yes Nil Nil Yes Nil Yes Yes Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil 
Serum 
paraoxonase/arylesterase 1 
Yes Nil Nil Yes Nil Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Nil Nil Nil 
Protein Z-dependent protease 
inhibitor 
Yes Nil Nil Yes Nil Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes 
Complement factor I Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Immunoglobulin J chain Yes Nil Nil Yes Nil Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes 
Carboxypeptidase B2 Yes Nil Yes Nil Nil Nil Nil Yes Nil Yes Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil 
Apolipoprotein B-100 Yes Nil Yes Yes Yes Yes Nil Yes Yes Yes Yes Nil Yes Yes Yes Nil Nil Nil Nil Nil Nil 
C4b-binding protein Nil Nil Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Fetuin-B Nil Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Nil Nil Nil 
Alpha-2-HS-glycoprotein Nil Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Interleukin-1 receptor 
accessory protein 




































































Serum amyloid P-component Nil Yes Yes Yes Nil Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil 
Sulfhydryl oxidase 1 Nil Nil Nil Yes Nil Yes Yes Yes Nil Nil Yes Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil 
Sulfhydryl oxidase 2 Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Beta-2-glycoprotein 1 Nil Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Nil Nil Nil Nil Nil Nil 
Complement component C8 
beta chain 
Nil Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Nil Nil Nil Nil Nil Nil 
Serine protease inhibitor A3M Nil Nil Yes Nil Nil Yes Yes Yes Yes Yes Yes Yes Nil Yes Nil Yes Nil Nil Nil Yes Nil 
Inter alpha-trypsin inhibitor, 
heavy chain 4 
Nil Nil Yes Yes 
Ye
s 
Yes Yes Yes Yes Yes Yes Nil Nil Yes Yes Yes Nil Yes Nil Yes Nil 
Hepatocyte growth factor 
activator 
Nil Nil Yes Nil Nil Nil Nil Yes Nil Yes Yes Nil Nil Yes Yes Nil Nil Nil Nil Nil Yes 
Phosphatidylcholine-sterol 
acyltransferase 
Nil Nil Yes Nil Nil Nil Nil Yes Nil Yes Nil Nil Yes Yes Yes Nil Yes Nil Yes Nil Yes 
Coagulation factor XIII B 
chain 
Nil Nil Yes Nil Nil Nil Nil Yes Nil Yes Yes Nil Nil Yes Nil Yes Yes Yes Yes Yes Nil 
Microfibril-associated 
glycoprotein 4 
Nil Nil Yes Nil Nil Nil Nil Yes Nil Yes Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Killer cell lectin-like receptor 4 Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Ceruloplasmin Nil Nil Yes Nil Nil Yes Nil Yes Yes Yes Yes Nil Nil Yes Nil Yes Yes Yes Yes Yes Nil 
Complement component C8 
gamma chain 
Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Yes Nil Nil Yes 
Zinc-alpha-2-glycoprotein Nil Nil Yes Nil Nil Nil Nil Yes Nil Yes Yes Yes Nil Yes Yes Nil Nil Nil Nil Nil Nil 
Odorant-binding protein 1a Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Cellulose synthase-like protein 
D2 
Nil Yes Yes Nil Nil Yes Yes Yes Nil Yes Yes Yes Nil Yes Yes Nil Yes Yes Yes Yes Yes 
G2 and S phase-expressed 
protein 1 
Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Yes Nil Nil Nil Nil Nil Nil 
Mannan-binding lectin serine 
protease 1 
Nil Nil Nil Yes 
Ye
s 
Yes Yes Yes Nil Yes Yes Nil Nil Nil Nil Yes Yes Yes Yes Yes Nil 
Pentatricopeptide repeat-
containing protein At2g32630 
Nil Nil Nil Yes Nil Nil Nil Nil Nil Yes Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil 
Proteoglycan 4 Nil Nil Nil Yes 
Ye
s 
Nil Nil Yes Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Acyl-CoA-binding domain-
containing protein 1 
Nil Nil Nil Yes Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Periostin Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 





























































Lumican Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Carboxypeptidase N catalytic 
chain 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Yes Nil Nil Yes Nil Nil Nil Nil Nil Nil 
Ig gamma-1 chain C region 
secreted form 
Nil Nil Nil Nil Nil Yes Yes Yes Yes Yes Yes Yes Nil Yes Yes Yes Yes Yes Yes Yes Yes 
Platelet glycoprotein V Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Thrombospondin-1 Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Nil Yes Yes Nil Nil Yes Nil Yes Yes Nil 
Serum albumin Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil 
Zinc finger protein 638 Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Beta-taxilin Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil 
Coagulation factor IX Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Alpha-1-acid glycoprotein 
1(Mus caroli (Ryukyu 
mouse(Mus caroli (Ryukyu 
mouse) 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Yes Nil Yes Nil Yes Nil Nil Yes Yes Nil 
Insulin-like growth factor-
binding protein complex acid 
labile subunit 
Nil Nil Nil Nil Nil Nil Yes Yes Nil Yes Yes Nil Nil Yes Nil Nil Nil Nil Yes Nil Nil 
Ig heavy chain V region AC38 
15.3 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Complement factor B Nil Nil Nil Nil Nil Yes Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Corticosteroid-binding globulin Nil Nil Nil Nil Nil Yes Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Plasma protease C1 inhibitor Nil Nil Nil Nil Nil Yes Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Testis-expressed protein 15 Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Kinesin-like protein KIN-14Q Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Zinc finger and BTB domain-
containing protein 8A 
Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil 
Prenylcysteine oxidase Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Zinc finger protein 
ENHYDROUS 
Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Armadillo repeat protein 
deleted in velo-cardio-facial 
syndrome homolog 
Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Two-component response 
regulator-like APRR2 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
LON peptidase N-terminal 
domain and RING finger 
protein 3 






























































Complement C1q subcomponent 
subunit A 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil 
Gamma-tubulin complex component 
4 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil 
Transcription initiation factor TFIID 
subunit 6 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil 
DDT domain-containing protein 
DDR4 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Complement C1s-A subcomponent Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Ankyrin repeat and EF-hand 
domain-containing protein 1 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Inhibitor of carbonic anhydrase Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Dedicator of cytokinesis protein 5 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil 
Coagulation factor V Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Yes Nil Nil Yes Nil 
Collagen alpha-1(III) chain Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Yes Nil Nil 
N-acetylmuramoyl-L-alanine 
amidase 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Nil Nil Nil Nil Nil Nil Nil 
Dynein heavy chain 8, axonemal Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil 
Apolipoprotein D Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil 
Integrin beta-2-like protein Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil 
Coagulation factor XII Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Yes Nil Nil 
DUF724 domain-containing protein 2 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil 
Protein AMBP Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Yes Nil Nil Nil 
Cartilage oligomeric matrix protein Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil 
Fibrinogen gamma chain Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Yes Nil Yes Yes 
Ig heavy chain V region MC101 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil 
Complement C1r-A 
subcomponent 
Nil Nil Nil Nil Nil Nil Nil Yes Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Totally identified 42 45 58 54 44 56 57 81 51 71 66 53 50 71 56 40 40 42 47 48 34 





Appendix B Table 13 Mouse IgG subtyping site specific microheterogeneity arranged bases on BALB/c data  
Trial No Glycan Id (HNAGF) Cartoon structure IgG1 IgG2B IgG3 
1 
3 3 0 0 0  
 
yes yes yes 
2 
3 3 0 0 1  
 
yes yes yes 
3 
3 4 0 0 0  
 
yes yes yes 
4 
3 4 0 0 1  
 
yes yes yes 
5 
3 5 0 0 1  
 
yes no no 
6 
4 3 0 0 0  
 
yes no no 
7 
4 3 0 0 1  
 
yes yes yes 
8 
4 3 0 1 1  
 
yes yes yes 
9 
4 4 0 0 0  
 
yes yes no 
10 
4 4 0 0 1  
 
yes yes yes 
11 
4 4 0 1 0  
 
yes no no 
12 
4 4 0 1 1  
 
yes yes yes 
13 
5 2 0 0 0  
 
yes no no 
14 
 
15 5 3 0 1 1  
  














16 5 4 0 0 0 
 








18 5 4 0 1 1  yes yes yes 
 
 








      21 
6 4 0 0 2  
 




22 6 3 0 1 1  
 








24 6 4 0 1 2  
 
yes yes no 
 








Appendix C F1 Re-confirmation of N-glycosite identification on AAV8 glycopeptide by MS/MS. 
The batch is expressed purified, processed and analysed independently from the previous analysis. a) CID spectra 




















Appendix C Table 1  The Major glycoforms AAV8 samples. 




Experimental    m/z Theoretical 
m/z) 
Structure Composition Type 
No Secreted Intracellular 
1 1354.510 1354.458 1354.4789 
 
H5N2 High mannose 
2 1436.532 1436.587 1436.532 
 
H3N4 Complex 
3 1516.606 1516.618 1516.5317 
 
H6N2 High mannose 
4 1541.654 1541.576 1541.5631 
 
H4N3F1 Complex 
5 1558.431 1557.538 1557.5873 
 
H5N3 Hybrid 
6 1582.710 1582.658 1582.5872 
 
H3N4F1 Complex 
7 1597.537 1597.438 1598.5848 
 
H4N4 Complex 
8 1678.516 1679.583 1678.5846 
 
H7N2 High mannose 
9 ND 1686.738 1686.6009 
 
H4N3S1 complex 
10 1719.742 ND 1719.611 
 
H6N3 Hybrid 
11 1745.000 1744.814 1744.6427 
 
H3N4F1 Complex 
12 1760.959 1760.903 1760.6377 
 
H4N4 Complex 
13 1785.973 1785.924 1785.669 
 
H3N5F1 Complex 
14 1801.938 1801.882 1801.6642 
 
H4N5 Complex 
15 1833.035 1832.984 1832.5688 
 
H4N3S1F1 Complex 
16 1841.019 1841.849 1840.6304 
 
H8N2 High mannose 
17 1848.866 1848.956 1848.6537 
 
H5N3S1 Hybrid 
18 1865.875 ND 1865.669 
 
H6N3F1 Hybrid 
19 1881.924 ND 1881.664 
 
H7N3 Hybrid 





21 1907.067 1907.089 1906.696 
 
H5N4F1 Complex 
22 1948.124 1948.080 1947.722 
 
H4N5F1 Complex 
23 1989.172 1989.183 1988.749 
 
H3N6F1 Complex 
24 2003.070 2003.139 2002.690 
 
H9N2 High mannose 
25 2028.055 2027.958 2027.722 
 
H7N3F1 Hybrid 
26 2052.218 2053.157 2051.733 
 
H5N4S1 Complex 
27 2069.126 2069.191 2068.748 
 
H6N4F1 Complex 
28 2092.760 2094.338 2092.760 
 
H4N5S1 Complex 
29 2110.275 2110.234 2109.775 
 
H5N5F1 Complex 
30 2198.400 2198.377 2197.791 
 
H5N4S1F1 Complex 
31 2313.471 2313.569 2312.854 
 
H5N6F1 Complex 
32 2401.631 2401.603 2400.870 
 
H5N5S1F1 Complex 
33 2475.764 2475.78 2474.907 
 
H6N6F1 Complex 
34 2489.599 2489.867 2488.886 
 
H5N4S2F1 Complex 
35 2530.676 2530.964 2529.913 
 
H4N5S2F1 Complex 
36 2563.931 2563.828 2562.923 
 
H6N5S1F1 Complex 
37 2604.750 2604.881 2603.950 
 
H5N6S1F1 Complex 
38 2691.961 2693.006 2691.966 
 
H5N5S2F1 Complex 
39 2750.676 ND 2748.987 
 
H5N6S2 Complex 
40 2767.100 2767.024 2766.002 
 
H6N6F1S1 Complex 
41 2842.087 ND 2840.039 
 
H7N7F1 Complex 
42 2894.984 2895.584 2895.045 
 
H5N6S2F1  Complex 
190 
 
43 2930.047 2930.072 2928.055 
 
H7N6S1F1 Complex 
44 3098.125 3097.795 3098.124 
 
H5N7S2F1 Complex 
45 3132.698 3132.202 3131.132 
 
H7N7S1F1 Complex 
46 3185.324 3186.702 3186.141 
 
H5N6S3F1 Complex 
 
 
 
 
 
 
 
 
 
